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Abstract 
 
Background: 
Nutritional supplements are used by competitive and recreational athletes of all 
ages. As a consequence the supplement industry has grown to meet the increasing 
demand.  The regulation of the supplement industry is unrefined, which increases 
the risk of the nutritional supplements being contaminated.  Contamination may 
be intentional, where the companies “spike” their products with an ergogenic aid, 
or unintentional. A consequence of contamination is that an athlete may fail a drug 
test after ingesting a contaminated supplement or there may be negative health 
consequences. Without adequate legislation it is difficult to control the industry 
and reduce the risk of contamination in the supplement.  
Objectives: 
To investigate the industry associated with commercially available nutritional and 
traditional supplements. These are  in the  five specific areas; (i) to review the 
regulations and legislations, and labelling and claims associated with nutritional 
products in the USA, European Union and South Africa, (ii) to assess the labelling 
and claims information on nutritional supplement products imported into and 
manufactured or assembled in South Africa, (iii) to assess using a survey 
questionnaire the container labelling and other sources of information that assist 
consumers of nutritional products in their purchasing decisions, (iv) to assess 
traditional commercial supplements for contamination and consistency of trace 
elements and heavy metals using Inductively Coupled Plasma-Mass Spectrometry, 
and (v) to assess the content of nutritional commercial supplements for steroids, 
stimulants and other compounds of interest using Tandem Liquid 
Chromatography-Mass Spectrometry. 
Methods:  
The thesis is divided into 6 Chapters. Chapter 1 describes the background to the 
problem and Chapter 2 reviews the existing legislation. In Chapter 3 the labelling 
and claims information on 40 nutritional supplements products are analysed, and 
the self-administered questionnaire determined what product label and other 
information influences consumers of nutritional supplements in their purchasing 
decisions. In Chapter 4 the consistency of trace elements and heavy metals are 
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analysed in selected nutritional supplements using Inductively Coupled Plasma 
Mass Spectrometry. In Chapter 5 selected nutritional supplements are analysed for 
steroids, stimulants and other compounds using Tandem Liquid Chromatography 
Mass Spectrometry.  All the data of these sections are summarised in Chapter 6.    
Results and conclusions: 
The study identified shortcomings in the current South African regulations and 
legislation, labelling and claims, which detract from maintaining safety, quality, 
efficacy and enforcement of nutritional supplement products in the market place. 
Furthermore, there is a need to have statements such as “exclusion of use, and not 
a cure for disease”, and the “presence of banned substances in the supplements” 
on the label. The self-administered questionnaire findings show the information 
that is pertinent for people who purchase nutritional supplements. The findings 
also show that trace element and heavy metals can be used as product specific 
markers to identify contamination, and product intra-and-inter-batch consistency, 
based on “finger-print” profiling, bar charts, and visual radar plots. The steroid 
and stimulant analysis findings reflect a high proportion of “positive” nutritional 
supplements, and provide sufficient evidence to emphasize the importance of 
regulation, monitoring and enforcement on an ongoing basis. However, the 
findings need to be verified, by re-extraction and analysis of identified “positives”, 
to provide confirmation of results. 
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Chapter 1 
 Introduction 
 
1.1 Introduction 
 
There is increased use of nutritional supplements by athletes in competitive and 
recreational sport. There is also increased awareness of illegal substances used, 
and as such athletes have come under much media and public scrutiny, due to the 
increase in positive doping tests worldwide [1]. The situation is further 
exacerbated by the general pressure placed on certain groups to use supplements. 
For example, young sports participants who are engaged in developmental and 
competitive phases of sport, encounter peer pressure to use supplements [3].  
 
Based on the World Anti-Doping Agency (WADA) Adverse Analytical Findings 
and Atypical Findings  report (2009) from accredited  laboratories for  both 
Olympic and Non-Olympic Sport, there was an increase in number of samples 
analysed. For example, in 2003 there were 151 210 samples analysed, in 2008, 
274 615 samples were analysed, and in 2009, 277 928 samples were analysed. The 
report shows a slight increase in Adverse Analytical Findings (AAFs) and 
Atypical Findings (AFs) from 1.84% (2008) to 2.02% (2009) [2]. 
 
Further, it has been suggested that the increase in positive tests is also due to 
unintentional exposure of athletes taking nutritional supplements which are 
contaminated or adulterated with performance enhancing compounds on the 
WADA list. These undeclared constituents may also have harmful short - and 
long-term health consequences. While some athletes have been guilty of deliberate 
misuse of banned substances, a growing number of bona fide athletes have blamed 
nutritional supplements as the primary cause of their positive doping test 
outcomes [4,5,6]. This has brought uncertainty to the minds of well-intentioned 
athletes, and has also compromised the development of the legitimate nutritional 
supplement industry.  
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1.2 History of Performance-Enhancing Substances   
 
Through history, performance-enhancing substances have been part of competitive 
sport. As far back as 300 BC, athletes were disqualified from competing at the 
Olympics because they ingested mushroom or animal proteins which were banned 
at the time [7]. During the late 1900’s the emphasis was placed on mainly using of 
steroids and amphetamines as ergogenic aids [7]. These agents were subsequently 
banned and athletes and scientists started searching for legal substances that would 
provide the competitive edge [7-10]. Whilst the general public has been targeted 
by the supplement industry for many years, as their big market, the shift in trend 
now in the marketing strategy has been to also target recreational athletes and 
children using the profile of athletes to increase sales. 
 
During the late 1900s there was a large market focus on the role of nutrition in 
exercise and the use of “normal” dietary or nutritional supplements to enhance 
performance in competition and training [11]. However, now the emphasis has 
shifted and the use of sports nutritional supplements are no longer restricted to 
elite athletes, but are increasingly being used by recreational as well as 
professional   athletes and children [12,13]. Consequently, the nutritional 
supplement industry has grown significantly, due to an increased trend to launch 
new supplement products that have a high level of “sports image” linked to 
increasing demand and market size. Further, in most countries there is not a clear 
distinction between  “normal“ and “sports” nutritional supplements, with many 
products and  “small” players  having their own sales channels. This approach 
leads to problems of controllability in the sector [14-16].    
 
Global sporting organizations and anti-doping agencies, such as the World Anti-
Doping Agency (WADA) often advise athletes to abstain from using supplements 
[2]. The South Africa Rugby Union, via there BokSmart programme 
(www.boksmart.com), makes a strong case against the use of supplements. Their  
recommendation  states that  supplements  should  not  be used  where  nutrient  
needs  can  be met  by  normal foods and that nutritional  supplements  cannot  
compensate  for poor dietary  choices [17,18]. 
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 WADA’s concern is that in many countries the manufacturing and labelling of 
supplements may not follow strict rules, which may lead to a supplement 
containing an undeclared substance that is prohibited under anti-doping 
regulations [2]. They have made it clear that failing a drug test as result of a poorly 
labelled dietary supplement product is not an adequate defense in a doping hearing 
[2]. 
 
It is therefore imperative, if the goal is to limit the risk of unintentional intake of 
forbidden substances, to have in place the relevant methods of assay analysis for 
supplement testing, verification and statistical evaluation [19, 20]. It is further 
important  that research and testing  should not  be restricted  to  the prohibited  
substances, but that  potential  precursors of  these  prohibited  substances should 
also be investigated  in nutritional supplements and traditional  indigenous food 
and medicine practices [21-27].  
 
The media often raise the awareness to the general public about elite athletes who 
test positive in an anti-doping test. However the negative consequences of 
adulterated supplements should be of equal concern for the potential negative 
health ramifications of the broader general public who consume nutritional 
supplements in an unregulated environment. [28-30]. A doping problem in the 
context of sport performance can be defined as the knowing use and/or abuse of 
prohibited substance(s), or products that may contain these substances, that if 
consumed is not in the interest of fair play or the physical and mental health of the 
athlete. Instead it is to gain a competitive advantage over others due to 
performance-enhancing properties of the substance(s) [29]. A health problem, in 
the context of the broader general public, is the unknowing consumption of 
prohibited substance(s) in contaminated nutritional supplement products. 
Consuming these substances could cause both short and long term medical 
conditions [29].   
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1.3 Nutritional Supplement Industry 
 
In  the USA, the annual  retail supplement sales  increased  from $8.8 billion in 
1994 to $18.8  billion  in 2003, an increase  of 115%, with a sizable proportion  
that is spent  on “sports  supplements” [31].  A Global Industry Analysts Inc. 
report  indicates that  the  herbal supplement market did not decline during the 
worldwide recession, but in fact exhibited  steady growth over the period 2008 to  
2009 [32]. It is anticipated that the market will reach US$93.15 billion by the year 
2015. Also, the sales of vitamins and supplements at the retail level recorded a 
significant increase of more than 10 % in 2008, as compared to the previous year 
[32]. Further, the Nutrition Business Journal (NBJ) estimated in its Global 
Supplement & Nutrition Industry Report of February 2010 that the total global 
nutrition industry sales had increased by 8% to $270 billion in 2008. The 
definition includes dietary supplements, natural and organic foods and beverages, 
functional foods and beverages, and Natural and Organic Personal Care and 
Household Products (N&OPC) [32].   
 
In the context of South Africa, the local turnover for nutritional supplements was 
estimated at R1.5 billion per year (Health Product Association survey 1998-2000) 
and has grown rapidly since then. In 2007 the estimates by the Health Product 
Association of Southern Africa was an average of  R78.5 million for 39 
companies,  many  with double digit  growth rate  in 1 year [33]. 
  
Drinks which provide energy form a large part of the supplement industry.  There 
is a general belief that ingesting drinks containing electrolytes and carbohydrates 
before, during and after exercise has an ergogenic effect [33-38]. This however is 
a relatively new practice. For example, athletes, prior to 1969 were advised to 
avoid drinking during exercise, however by 1996 all athletes were advised to drink 
“as much as tolerable” to insure that they did not lose any weight during exercise – 
the “zero percent dehydration” doctrine [39]. The changing advice was met by a 
proliferation of products designed to accommodate the recommendations.  
 
Publicly listed companies in the sports drink industry in the United States are 
required by law, to show a return on investment for any monies granted 
“altruistically”. This requirement showed a financial return for the US sports drink 
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industry in an annual turnover from $217 million in 1985 to $2.69 billion in 2003. 
Thus encouraging the “staying ahead of thirst” concept implies that athletes would 
potentially increase consumption of sports energy drinks [39]. 
 
1.4 Use of Nutritional Supplement - Beliefs and Studies 
Dietary supplements have been widely used by elite athletes who are convinced 
that these substances boost their physical and psychological abilities [29, 40]. The 
belief is fuelled by the supplement industry which markets their products in such a 
way as to create the impression that the ingestion of nutritional supplements is an 
essential prerequisite for optimal performance and rapid recovery from the rigors 
of competition and training [29]. The mechanisms underlying the proposed 
beneficial effects of these products are not clearly understood [8, 41-44]. Further, 
the issue is compounded by the fact that the nutritional supplements may be 
deliberately tainted with banned substances that are not listed in the ingredients 
advertised on the label. Furthermore, the supplements may be contaminated with 
traces of banned substances from lack of sterilisation or sanitation between batch 
preparations that could lead to adverse analytical finding [29, 45]. It has become 
common practice among elite athletes to request certification of batch purity and 
acceptance of liability from the nutritional supplement company in an attempt to 
decrease the risk of testing positive from contaminated supplements [29].  
 
Several studies have also surveyed supplement use among athletes in general, or 
within specific types of sports. In these studies the use of supplements varied from 
50-100% across most sports disciplines [15, 45, 46]. The studies showed that the 
most frequently used sources of information about supplements were from health 
care professionals, the internet, followed by magazines [15]. 
 
There is also concern among sports scientists and nutritionists that athletes and 
consumers make uninformed choices about sport and food supplements. Current 
literature suggests that information about supplements are obtained  from coaches,  
parents, health store clerks, fitness clubs, books and magazines, and that this 
source of information may lack appropriate knowledge and accuracy [47-58].  
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1.5 Nutritional Supplements in health care 
Nutritional supplements are also used, as example, to manage obesity. In South 
Africa, 30% of women are obese [59, 60]. Supplements are also used, as example 
to manage obesity, and in an unregulated environment, could however have large-
scale disastrous consequences if contaminants are present that could adversely 
affect the initial treatment care and health management objectives [61-67]. 
 
Nutritional supplements are also used to treat deficiencies in nutrient intake in 
both the clinical and health promotion settings.  There is global recognition that 
the environmental and climate changes may impact negatively on the 
sustainability of harvested products and natural indigenous food resources. 
Therefore, in response it makes nutritional supplement programmes attractive in 
particular regions where there is a need to overcome nutritional deficiencies [68, 
69]. However, such good intentions could be compromised by the presence of 
contaminants in the nutritional supplement. The contaminants could be present in 
the nutritional supplement product unbeknown to the prescriber and/or patients 
due to lack of verifiable evidence of nutritional product quality [70-75]. 
 
1.6 Nutritional Supplement Contamination 
Some nutritional supplements may exert their ergogenic effect as a result of 
contaminants such as steroids or other banned ergogenic substances which have 
been added intentionally by the manufacturers. In other cases the contaminants are 
added inadvertently.  Research conducted in 2002 and 2004 identified that some 
supplements contained sufficiently high amounts of anabolic steroids to cause a 
positive drug test. Examples were 19-nor-4-androstenedione and 4-androstene-
3,17, dione [76]. Some nutritional supplement products also contained hormones 
or prohormones not claimed on the label, and also contained substances other than 
those indicated by the manufacturer. In particular, nandrolone prohormones 
resulted in positive doping results for norandrosterone for several hours after 
ingestion [7, 76, 78].  
 
Further, trace elements and heavy metals also forms part of the composition of 
nutritional supplement products, and might not be displayed on the product label. 
The trace elements and heavy metals could thus also be implicit in causing or 
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contributing to adverse reaction events [127]. Commercially available plant and 
nutritional supplement products are used extensively in self-medication, 
complementary and alternative medicine practices, and primary healthcare. 
Therefore, such products should be subject to rigorous routine quality control and 
scientific screening methods to verify their safety, quality and efficacy [142]. 
The book, “The Coming of China Wars” by Peter Navarro provides good insight 
into possibilities for contamination of supplement products [35]. This book 
explains that contamination can occur intentionally or inadvertently via the  
following marketing strategies, viz., (a) buyers market, (b) the underground   
market, (c) mislabelling market, (d) world-wide web marketing or a combination 
of stipulated marketing approaches [35].   
 
1.7 Nutritional Supplements and Nanotechnology   
The advent and widely acclaimed potential of nanotechnology has paved the way 
for innovation of nanoparticle usage in the nutritional supplement industry.  This 
approach could have possible implications for nutritional supplement product 
formulations and nutrient content delivery systems and, consequently, may affect 
human metabolism and health.  Thus, the great promise of nanoparticles could 
also be a peril, especially if contaminants cause undetermined or undesired 
adverse events and pathogenic effects.  Therefore, the general use and application 
of nanotechnology in the nutritional supplement sector need to be carefully 
monitored within a legislative framework that specifies all the safety precautions 
and risks applicable to toxic and dangerous substances [92]. 
1.8 Laboratory Testing 
The ideal situation for laboratory screen testing of   nutritional supplements for 
contaminants requires simple, robust, sensitive and selective screening methods.  
These methods have to be established and/or modified from existing methods, but 
should also consider detecting a possible changing composition of the supplement 
on an ongoing basis. The analytical laboratory for testing and/or screening for drug 
analysis has evolved over time from High Performance Liquid Chromatography 
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(HPLC), Gas Chromatography-Mass Spectrometry (GC-MS), to Liquid 
Chromatography-Tandem Mass Spectrometry (LC-MS/MS) [79-81]. 
 
Furthermore the issue is compounded  by the fact  that the nutritional  
supplements  may  be deliberately  tainted  with banned substances, that are not 
listed  in the ingredients advertised  on the label, or contaminated with traces of 
banned substances from lack of sterilisation or sanitation  between  batch 
preparations that could lead to adverse analytical  finding. In targeted testing,  the 
aim is to confirm compounds  that  are declared on the product  label, and in 
untargeted  testing the laboratory  screen seeks to identify  compounds  that  are 
not declared  on the  product label [29, 45]. Further, analysing supplement 
products with varying ingredients also presents potential pitfalls, due to potential 
matrix effects that could negatively contribute to a confirmatory qualitative 
determination.   
 
1.9 Summary  
While the media often raise the awareness of the public when an elite athlete tests 
positive for a banned substance, the negative consequences of adulterated 
supplements should be of equal concern for the broader general public who 
consume nutritional supplements in an unregulated environment [28-30]. To limit 
the risk of unintentional intake of forbidden substances it is imperative to have the 
relevant methods of assay analysis for supplement testing, verification and 
statistical evaluation [19, 20]. It is further important  that research and testing  
should not  pertain  to  the prohibited  substances as defined only, but that  
potential  precursors of  these  prohibited  substances should also be investigated  
in nutritional supplements and traditional  indigenous food and medicine practices 
[21-27]. In parallel to this there is a growing responsibility for health professionals 
and scientists to generate and circulate factual, evidence-based and practical 
advice about nutritional supplements [82-85].  
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1.10 Purpose of Research Study 
This study seeks to evaluate the content and safety of commercially available 
nutritional and traditional supplements.  
 
The key questions to be addressed are:  
 
• What information is presented on the container labels of nutritional 
and traditional supplement products?  
• What container labelling and other sources of information assist the 
consumers of nutritional supplement products in their purchasing 
decisions? 
• How consistent is the batch-to-batch trace element and heavy metal 
composition of commercial traditional supplement products?  
• Do nutritional and traditional supplement products contain 
undeclared contaminants and/or adult rants, such as steroids and 
stimulants that could compromise nutritional and traditional 
supplement usage and safety? 
 
Scope of study 
 
Aim 
 
To firstly scrutinize popular commercially available traditional supplements for 
trace element and heavy metal consistency and safety. Secondly, to detect the 
presence of steroids, stimulants and other compounds of interest in nutritional 
supplements using qualitative and semi-qualitative techniques. 
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Objectives 
 
1. To review regulations and legislation, and labelling and claims associated 
with nutritional supplement products in the USA, European Union and 
South Africa (Chapter 2). 
2. To assess the labelling and claims information on nutritional supplement 
products imported into/and manufactured or assembled in South African 
(Chapter 3).    
3. To assess using a survey questionnaire the container labelling and other 
sources of information that assist consumers of nutritional products in their 
purchasing decisions (Chapter 3).   
4. To assess traditional commercial supplements for contamination and 
consistency of trace elements and heavy metals using Inductively Coupled 
Plasma-Mass Spectrometry (Chapter 4). 
5. To assess the content of nutritional commercial supplements for steroids, 
stimulants and other compounds of interest using Tandem Liquid 
Chromatography-Mass Spectrometry (Chapter 5). 
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Chapter 2 
Regulations and Legislation, Labelling and Claims 
 
2.1 Introduction 
The nutritional supplements (nutraceuticals) sector is generally encumbered with 
statutory laws in two extremes. Notably, those that govern medicines and those 
that govern foods. Legislation (statutory laws) is law promulgated by a legislature 
or a governing body for several purposes, including, to regulate, to sanction, and 
to declare or restrict. Regulations on the other hand are measures to control human 
or societal behaviour by rules or restrictions. These regulations, can take the form 
of legal restrictions or self-regulation. As such, medicine and food production, 
processing, distribution, retail, packaging and labelling in general is a multifaceted 
industry often governed by several laws, regulations, codes of practice and 
guidance, in different countries. This makes this a complex subject.  
The nutritional supplement industry annual  retail sales in the United States of 
America increased  from $8.8 billion in 1994 to $18.8  billion  in 2003, an 
increase of 115% of which a sizable proportion was spent on “sports  
supplements” [31,55].  In South Africa, the local turnover was estimated at R1.5 
billion per year (Health Product Association survey 1998-2000) and has grown 
rapidly, if not exponentially since [9]. The increase in supplement sales can likely 
be attributed to aggressive marketing by manufacturers, rather than the 
development of more effective nutritional supplements [17]. As a result of the 
complex legislation governing supplements in most countries, including South 
Africa, the companies can make unsubstantiated claims about the efficacy of the 
supplement [83]. Furthermore, the accuracy of the labelling often goes 
unchallenged, therefore any effects of the supplement may be due to contaminants 
or adulterants such  as 19-nor-4-androstenedione and androsten -3,17-dione in 
these products not reflected on the label [76,78, 86, 87]. The way in which the 
supplement industry is managed is in stark contrast to the drug industry which has 
strict legislation and control. Divergence between food and drug laws has 
generated “grey” areas with regard to the “voluntary” declaration of “all” content 
in a specific nutritional supplement product, making the product manufacture 
chain difficult to deal with or even subject to appropriate law enforcement. 
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Although some Consumer Protection and Anti-Doping Agencies have requested 
stricter report requirements for supplement manufactures and tougher penalties for 
repeat offenders, legislation remains unchanged in most countries [87]. 
In an attempt to heighten awareness about the lack of control in the supplement 
industry, this chapter will, (i) assess current peer-review literature with respect to 
nutritional supplements, (ii) provide examples of spurious claims and labelling 
practices as published in magazines aimed at the general population,  
and (iii) assess the regulation, legislation and consumer forums in the USA, the 
European Union of Nations and South Africa, pertaining to the nutritional 
supplement industry. This will facilitate, identify and expose current practice in 
the nutritional supplement sector. Improved processes and practices can as a result 
be formulated and enabled in the best interest of the consumer. 
2.2 Current Issues in the Scientific Literature 
2.2.1 Energy Drinks Claims and Negative Health Effects   
Many energy drinks, are also considered as functional foods when they contain 
fortified ingredients that aid specific bodily functions. These energy drinks are 
marketed aggressively without always providing information about the type and 
quantity of ingredients on their labels. Some energy drinks promote the inclusion 
of natural ingredients which purport to supply energy, improve alertness and 
athletic performance. However, these claims are not always supported by 
published peer-review evidence [17]. Also there are concerns about the negative 
health effects associated with these products [37].    
2.2.2 Health Claims on Nutritional Supplements 
Nutritional supplements have received attention both from producers as a means 
of marketing the added value to health, and from consumers in terms of 
awareness, education and improved health. The nutritional supplements regulatory 
framework should thus be compatible with public health and safety, protect the 
consumer, promote fair trade, and encourage innovation [88-90]. 
The desired goal is for better control, for the claims on nutritional supplements in   
the same way that claims about medicines are controlled. At present 
unsubstantiated claims are often believed by the general public and vulnerable 
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groups of patients who are promised recovery or reduction in symptoms, despite 
the fact that there is no scientific basis for most of the claims [91]. 
Some of the marketing about the efficacy of nutritional supplements are not 
always supported by published peer-review evidence. This often leaves the general 
public confused as they are not able to distinguish between correct or false claims 
[10]. Another factor adding to the confusion is that the labelling on the containers 
does not always accurately reflect the contents [17]. This poses health concerns 
and also the risk of a competitive athlete failing a drug test, if a contaminant in the 
supplement is on the banned list. Indeed, there are examples in South Africa of 
nutritional supplements containing banned substances which would have resulted 
in a positive doping test [76]. Examples of spurious claims and labelling, 
published in magazines aimed at the general population are shown in Table 1. 
These examples are selected from popular magazines, such as, The South African 
Journal of Natural Medicine, Men’s Health, Runners World, Bicycling, Muscle 
and Fitness and Iron Man. Examples have been selected which use 
pseudoscientific terminology designed to create an elevated impression about the 
product that is being advertised.  
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Table 1. Examples of claims about effects and contents of supplements made in 
adverts published in popular magazines aimed at the general public. 
 
 Natural Medicine  August 2010 Page Comment 
1. Manufactured to international 
pharmaceutical quality standards 
9 The quality of the raw materials 
however could be tainted. 
2. Product manufactured under GMP 
conditions in an approved facility 
24 GMP or an approved facility 
does not necessary imply a 
quality untainted product. 
3. Organic and 100% natural  66 This implies that the product is 
contaminant free. 
4. Where science and nature meets the effective 
natural way 
83 The use of the words “science” 
and “nature” implies quality 
validation. “Science” is used in 
a misleading way.  
 Men’s Health  August 2010   
5. Has been scientifically formulated  35 The product could still be 
contaminated. “Scientifically 
formulated” is a misleading 
term. 
6. Advanced Nutrition  93 The product could still be 
tainted. 
 Runners World September 2010   
7. Originated from Nature. Perfected by Science 33 The use of the words science 
and nature may imply quality 
validation. 
 Bicycling 2008   
8. Scientifically Formulated 22 The product could still be 
tainted. “Scientifically 
formulated” is a misleading 
term. 
9. Supports Muscle Growth 18 The product could still be 
tainted. What is the evidence to 
support these claims? 
10. Stimulant  Free 
 
 
22 What are the guarantees that the 
product is not contaminated?  
 Muscle and Fitness 2010   
11. Based on University Research 13 This is simplistic – University 
research does not automatically 
translate into believable valid 
research.   
12. Natures ultimate lean Muscle Formula 45 Use of the word “nature” may 
imply quality validation. 
13. For faster muscle building and definition 55 The product could still be 
tainted. 
14. Powerful Anabolic Catalyst 
 
 
 
241 The “catalyst” could be a 
prohibited substance. Many 
anabolic substances are on the 
prohibited list. 
 Ironman 2010   
15. Messenger Hormone Amplifiers 33 The “messenger” could be a 
prohibited substance.  This is 
cagey language designed to 
impress. 
16. Professional  Strength Anabolic Complex 53 The “complex” could be a 
prohibited substance. Many 
anabolic substances are on the 
prohibited list and the language 
uses pseudoscience terminology. 
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2.3 Assessment of Legislation  
Regulation of nutritional supplements in most countries, including South Africa, 
are usually embedded in other forms of legislation, in comparison to those 
governing and acted upon for medicine [93, 94]. The regulation and legislation of 
the nutritional supplement industry in the USA, the European Union of Nations 
and South Africa are used as examples of such legislation. 
 
2.3.1 United States of America  
The USA constitutes one of the world's most comprehensive and effective 
networks of public health and consumer protections, having a population of 305 
million people. The Federal Food, Drug, and Cosmetic Act (FDC) of 1938 was 
passed after a legally marketed toxic elixir, killed 107 people, including many 
children [95]. The FDC Act completely overhauled the public health system in the 
USA at that time. Among other provisions, the law authorized the Food and Drug 
Administration (FDA) to demand evidence of safety for new drugs, issue 
standards for food, and conduct factory inspections. It was the vigilance of the 
FDA that prevented thalidomide being marketed in the USA after the tragedy of 
side-effects of the drug in Europe [95]. This strengthened the rules for drug safety, 
and required manufacturers to prove the effectiveness of their drugs.  
 
The specific section of the USA FDC Act related to food and medicine (drugs) are 
(i) Chapter IV (Section 401-417) which covers food aspects in particular, and, (ii) 
Chapter V (Section 501-523) covers medicine (drugs) [95]. Both these sections of 
legislation may have aspects which apply to nutritional supplement products.  
Further, the Dietary Supplement Health and Education Act of 1994 (DSHEA) 
placed the responsibility on the manufacturer, to ensure that the dietary 
(nutritional) supplement is safe before marketing [95]. Prior to this act, dietary 
supplements were under the same regulatory requirement category as food. 
The FDA thus ensures that products are honestly, accurately and informatively 
presented to the public. Some of the agency’s specific responsibilities that may 
also include nutritional supplement products are; Manufacturing Licensing and 
Standards, Testing Methods, Labelling, and Product Safety, not necessary as 
individual segments, but as overlapping roles.  It is a requirement for domestic and 
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foreign suppliers to register their manufacture facilities with the FDA; however 
these manufactures and distributors are not required to register their products with 
the FDA where existing ingredients in the market are used. The exception is in the 
case of a new dietary ingredient, where pre-market review for safety data and 
other information are required by law [95].     
In 2007 comprehensive regulations were published by the FDA for those 
companies which manufacture, package and hold dietary supplement products. 
The goal of these regulations was to ensure the identity, purity, quality, strength 
and composition of products [95].  
According to these regulations any claims made about a product needs to be 
substantiated by adequate evidence. Manufacturers are allowed to make three 
types of claims for their dietary supplement products, (i) health, (ii) nutrient 
content claims, and (iii) structure/function claim, that also require a “disclaimer” 
indicating that the statement has not been evaluated by the FDA. The 
manufacturer is also required to provide label information that is “truthful” and 
not “misleading”.  To ensure that  consumers are informed  prior  to purchasing  of 
dietary products the FDA has developed a website 
(http://www.fda.gov/food/dietarysupplements)  that provides tips to the consumer 
about making  informed  decisions and evaluating  information  provided by 
companies, and claims  that can be made  for  conventional food  and  dietary  
supplements. 
 
The FDA only acts on voluntary reporting where consumers may have identified 
or experienced adverse events.  The responsibility of the FDA in such cases 
includes claims about product information, labelling, package inserts, and   
accompanying literature. Consumer nutritional supplement concerns and reporting 
needs to be dealt with and lodged to the specific manufacturing companies, in the 
first instance, and not to the FDA.   
 
The FDA’s Centre for Food Safety and Applied Nutrition (CFSAN), that has been 
in existence since 1906, has oversight for dietary supplements, and also ensures 
the monitoring in the market place for potential illegal products [95]. CFSAN also 
gathers information about products from agency inspectors, the dietary 
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supplement manufacturers and distributors, the internet, consumers and trade 
complaints. Laboratory analyses are done occasionally of selected products, in 
particular those associated with adverse events.  
 
Due to limited resources the FDA has enforcement priorities that are only applied  
to  products  thought  to be unsafe, have caused injury or illness, and are 
fraudulent or in violation  of  the law. The FDA’s remaining funds are applied to 
the routine monitoring of products, based on it’s own assessment or as the FDA 
determines. Consumers who would want to know or verify content of dietary 
supplements would need to engage the manufacturer directly and arrange for the 
analysis to be done in a commercial laboratory.  
 
Although certain levels of legislation are in place in the USA to control the 
supplement industry, consumers are also often left confused about which 
regulatory agency is the most appropriate.  
 
The alternate approaches  for consumer concerns in the  USA, is to solicit   
support via the American Consumer Council (ACC), which is dedicated to 
consumer education, awareness, and has an interest in quality products and 
services, and The Council for Responsible Nutrition (CRN) association 
representing dietary supplement manufacturers and ingredient suppliers[96,97]. 
2.3.2 Summary of the USA System  
The FDA is by far the most comprehensive federal agency responsible for food 
and related products consumption and safety in the world today. The FDA’s 
function is underpinned by the FDC Act that was promulgated as a direct result of 
proactive legislative requirement, in the context of the marketing of a toxic elixir 
and the thalidomide tragedy at the time. Whilst the regulation and laws have been 
developed, good proactive consumer activism has been thwarted by confusion 
when the need for engagement was required to debate the cross-cutting 
responsibility, authority and priorities of respective agencies in the area of 
nutritional (dietary) supplements. This perplexity was compounded, in particular 
by resource constraints that limited enforcement approaches and priorities. To 
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relieve the aspect of such constraints, the FDA has created guidance 
communications to the industry that does not confer rights to any party. 
2.3.3 European Union   
The European Union (EU) of Nations represents a population of 500 million 
people. It is a relatively recent development (1993), and has had to develop 
synergy across member nations to establish new legislation with reference to 
nutritional (food) supplements. This was accomplished via the European 
Community Treaties, which sets the EU constitutional basis for nations whom 
previously had their own legislative provisions as sovereign states. The Food and 
Veterinary Office (FVO) is the commission in the treaties that has as its primary 
responsibility the implementation of the legislation on food safety, animal health, 
plant health and animal welfare [98].  
 
The current focus in the EU, as provided by the European Advisory Services on 
food and nutritional supplements relates to, (a) maximum levels of vitamins and 
minerals, (b) actions on “other ingredients”, (c) providing information to the 
consumer about labelling, (d) nutritional and health claims regulations, and (e) 
revision of novel food regulation [99]. The Directive 2002/46/EC of the European 
Parliament and Council of 10 June 2002 on the approximation of the laws of 
Member States relating to food supplements established harmonized rules for the 
labelling of food supplements, and introduced specific rules on vitamins and 
minerals in food supplements. 
 
Food contamination generally has a negative impact on quality, and may imply a 
risk to human health. The EU has therefore taken measures to minimise 
contaminants in foodstuffs, by having the European Commission (EC) publish a 
fact sheet on food contaminants [100]. The European Commission regulates all 
nutritional and health claims on the product pack as well as all other 
communication materials intended for all consumers (promotions, advertising, 
leaflets). To assist the implementation of the necessary legislation and actions 
the European Food Safety Authority (EFSA) agency manages relations to ensure 
science-based risk management. 
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The alternate approach for consumer concerns in the European Union is via the 
European Consumer Centres Network (ECC-Net) [101]. This is designed to 
promote consumer confidence by advising on consumer rights, and ensuring easy 
access to redress with respect to cross-border information and assistance to 
individual member states who form part of the EU.  
 
2.3.4 Summary of the European Union System 
The development and formation of the EU of nations as a new phenomenon has 
implied that ideas and concepts for the provision of laws and regulations and the 
application thereof, and with specific reference to nutritional (food) supplements 
has been more current and relevant, although complex.  This essentially meant that 
nations who now form part of the EU have to find synergy and collective 
harmonization of processes and requirements. Countries in the EU at the forefront 
of developments pertaining to adulteration and contamination of nutritional 
supplements are Germany, Belgium, The Netherlands, Austria and the UK.   
Much of the work currently performed by the EU is covered and done in the form 
of Laws, Councils, Directives and Commissions, with the aim to have an 
integrated approach with adequate monitoring whilst ensuring effective 
functioning of the internal market of the EU.  Whilst steady progress has been 
made in some areas, the initial time-lines by the EU in terms of firm accepted 
proposals and adoption of an implementation strategy are proving too complex to 
put into action [99].  
2.3.5 South Africa  
South Africa, with a population estimated at 49 million people has a constitution 
regarded as one of the most progressive in the world and enjoys high acclaim 
internationally [102].  There is a provision in the preamble of the constitution that 
states, “Improve the quality of life of all citizens and free the potential of each 
person”. Implicit in this statement is the assurance of improving quality of 
wellness and health of the nation. This has direct bearing on the topic of 
legislation of the nutritional supplementation industry where the risk of 
contamination of the products may impose health risks.  
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In South Africa the constitution has provided several acts which are associated 
with governance, in part, of nutritional supplements;  (i) The Consumer Protection 
Act, (ii) The National Health Act, (iii) The Medicines and Related Substance and 
Amendment Act, (iv) The South African Institute for Drug-Free Sport and 
Amendment Act,  and (v) The Medical Research Council Act [102].  
 
The Consumer Protection Act, which is intended to serve the consumer, should 
have become operational incrementally on the 30th October 2010, but the 
implementation of the Act was postponed until April 2011. 
This Act introduces consumer courts as a means of achieving protection and 
speedy enforcement of consumers rights. Consumer courts will however have 
limiting powers, and subservient to the Common Law Court, with respect to 
interpretation, ambiguity and the best spirit, that promotes the Consumer Act 
[103]. 
Within the context of the Act, in the event of harm (no-fault liability) being 
suffered as a result of the supply of any unsafe goods, product failure or 
inadequate instructions or warnings pertaining to hazardous use of any goods, the 
producer/importer/distributor or retailer is liable, irrespective of whether there was 
any negligence on the part of any of those persons [104,103]. This is in particular 
with respect to the manufacturer of medical products such pharmaceuticals. There 
will however be no-liability on unreasonable grounds, on the part of a distributor 
or retailer if they discover an unsafe product, and they did not form part of 
marketing of such products. Whilst the Consumer Protection Act is intended to 
serve the interest of the consumer it’s intention will only become meaningful 
when challenges are lodged to the courts [103,104].   
The National Health Act incorporates, The Medicine Control Council (MCC) who 
is charged with ensuring the safety, quality and effectiveness of medicines, and 
matters related. This requirement has however experienced difficulty considering 
that the MCC has registered less than half of the medicine applications to it, over 
the past 7 years [105]. This situation has become a life-threatening risk to patients 
and is now under legal threat from stake holders who claim it to be dysfunctional 
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[105]. Pharmaceutical companies and activist have also expressed “intense 
frustration“with the current process [105]. A problem is that the MCC is grossly 
understaffed resulting in inefficiency and the lack of appropriate delivery of 
requirement. The law enforcement division has also come under sustained fire, for 
failing to stem the flood of unscrupulous practices [105]. This point is further 
supported when one considers nutritional supplements may be tainted with 
conventional drugs (medicines) as in the case of the recently claimed natural 
supplement product Simply Slim, which was found to contain the prescription 
substance sibutramine [106]. This reinforces the concern that prohibited 
substances and stimulants may be embedded in nutritional supplements. 
The Medicines and Related Substance and Amendment Act in part is to ensure the 
provision of registration of medicines intended for human or animal use, and 
providing licences to persons whom wish to compound and dispense, manufacture 
or act as a wholesaler or distributor for medicines. The South African Institute for 
Drug-Free Sport and Amendment Act ensures in part independent sample 
collection and testing programme, which may subject any sportsperson 
specifically to dope testing. The provision is thus specifically testing of the 
athletes and does not concern itself with the monitoring of nutritional supplements 
for tainted or contaminants that may affect the population adversely. The Medical 
Research Council Act makes provision for the establishment of the Medical 
Research Council (MRC) which has a mandate to promote the improvement of the 
health and quality of life of South Africans.   
Further, providing safe food (nutritional supplements) to the consumer remains in 
part also the responsibility of the service provider. So whilst the Hazard Analysis 
Critical Control Point (HACCP) system for “food safety” has been gazetted as part 
of the South African Foodstuff, Cosmetics and Disinfectants Act, no sector to date 
has been obliged by law to introduce a functioning system or similar for 
nutritional supplements based on the principles of the HACCP [107]. 
The alternate approaches for consumer concerns in South Africa are to solicit   
support via National Consumer Forum (NCF), and the South African National 
Consumer Union (SANCU). These two leading consumer organisations should 
ensure in the interest of consumers, to (i) a wholesome environment, (ii) a 
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fundamental quality of life, and, (iii) good quality in the goods (including products 
such as nutritional supplements) and services provided by the private and public 
sectors alike [108,109]. 
The South African system of Acts and Bills  have  similarity to that of the USA 
with reference to Medicine and Food Law, maybe with the same intention, but not 
necessary the same intensity, rigour and enforcement as the FDC Act of the USA 
[110]. The lack of specificity pertaining to nutritional supplements may 
compromise enforcement, accountability and responsibility by respective 
authorities [88-90]. The content of nutritional supplement products in the market 
may also therefore, compromise the health of consumers, due to potential 
contamination and lack of appropriate labelling of products [37].  
 
2.3.6 Summary of the South Africa System 
South Africa’s constitution embodies the principle of improving the quality of life, 
wellness and health of all it’s citizens.  In South African Law there are itemized 
sections in respective Acts and regulations that cover medicine and food that 
potentially relates to nutritional supplements and as indicated, closely resemble 
those of the USA.  However, currently South Africa has no formalized guidance 
documentation on nutritional supplements and the industry, and many aspects of 
this sector are self-regulated. This applies to contamination or adulterated 
substances that may be present in nutritional supplements as well as provisions 
and requirements of labeling and respective claims. 
Many of the Acts ensure compartmentalization of function, but are not necessarily 
directly related to nutritional supplements. However the link can be inferred. 
Although many aspects can be covered by this approach, in an environment of 
limited resources scant regard is often given to matters if they are not specifically 
defined. This creates “grey areas” for those who should take accountability and 
responsibility for appropriate enforcement. This also points to a lack of capacity 
that needs to be developed. These combination of factors, together with the 
increase in economy of scales and utilization of nutritional supplements in the 
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market, makes South Africa vulnerable for the download of goods from countries 
or regions where laws and regulations may have become more stringent.   
2.4 Concluding Summary  
A synopsis of the regulatory and legislation, claims and labelling provisions of the 
management of nutritional supplement products was described for the USA, the 
European Union and South Africa. The assessment has shown shortcomings 
across all the regions investigated, with inadequate provision to enforce legislation 
appropriately.    
It is pivotal in the development of a sound nutritional supplement management 
system that consumer structures will have to play a greater role. This to ensure that 
quality products are maintained and knowledge awareness is created. Consumer 
forums will also need to contribute to ensuring appropriate legislation and 
regulation comes into place, that can appropriately be enforced where needed. 
 
For South Africa it may be necessary to engage current Consumer Forums, and 
have them expand on their current objectives, to enable a more  in-depth  and 
ongoing scrutiny of nutritional supplement products in the best interest of 
consumers.  There is also a need in South Africa to have an appropriate specific 
agency or intensified enforcement to monitor the quality of nutritional supplement 
products. This in the best interest of the consumer, considering that there is 
increased use of nutritional supplements that are being produced in a self-
regulatory environment. 
General observations also point to, (i) the need for synergy across sovereign 
regions with respect to regulatory and legislative frameworks, (ii) the need for 
clear and specific regulation and legislation for nutritional supplement sector 
without ambiguity, that is not embedded in legislation and regulations that may 
facilitate “grey” areas in interpretation and application, (iii) more attention to 
facilitate required resources needed to give effect to greater levels of policy 
development, enforcement and vigilance, and  the need for a functional  HACCP 
for nutritional supplements. 
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Chapter 3  
Label content and information factors influencing consumers 
 
This chapter consist of two sections. Section 1 focusses on the content on 
nutritional supplement product labels, and Section 2 focusses on what product 
label and other information influences consumers of nutritional supplement 
products in their purchasing decisions. Each of the sections has its own    
introduction, methodology, results, discussion, conclusion and recommendations. 
Section 1 
Nutritional supplement product labels 
3.1 Introduction 
 
Nutritional supplements have received attention both from manufacturers of food, 
as a means of marketing the added value to health, and from consumers in terms 
of awareness, education and improved health. The regulatory framework of 
nutritional supplements should thus be compatible with public health and safety, 
protect the consumer, promote fair trade, and encourage innovation [88-90]. 
 
To assist this process, it is important to have specific knowledge and 
understanding on the claims and labelling on nutritional supplements products 
used for general, and more specifically sports consumers. In particular, labelling 
information, including warnings, claims, disclaimers as well as proposed 
mechanisms of action need to be documented. All this information is needed for 
practical intervention, policy development, and possible appropriate legislation 
and regulation.  Such information may also further provide and facilitate the 
design of guidelines on how nutritional supplement products may be marketed in 
future, and ensure that the consumer makes informed choices.  In accordance with 
these points, the aim of this study was to select a group of nutritional products 
either imported into, or manufactured in South Africa and quantify the labelling 
and claims information on the labels.  
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3.2 Methodology  
 
Nutritional supplement products were purchased at Century City Dischem 
Pharmacy in Canal Walk, Cape Town, Western Cape, South Africa. They 
consisted of internationally imported, and locally manufactured or assembled 
products, based on the list of top sellers as determined by purchased sales at the 
Dischem store, and within the available budget for the project. 
 
Labelling information and claims made on the containers were assessed according 
to specific predetermined categories [48-50,110-114,125,126]. The categories 
included claims made on containers, general information, disclaimers, warnings, 
quality assurance, scientific pledge, and consumer/public relations categories, 
respectively. For the  study, (i) a disclaimer was defined as any statement intended 
to specify or delimit the scope of rights and obligations that may be exercised and 
enforced by parties in a legally-recognized relationship, (ii) a warning is a caution 
to the consumer, (iii) quality assurance  refers  to the superiority of the  product  as 
stated by the  manufacture, (iv) scientific pledge refers to the manufacturer’s 
undertaking/guarantee of product, and (v) consumer/public relations refers to  the 
facilitation of further  contact  between the consumer and the 
manufacturer/distributor. Figure 1 provides an illustration of product package 
content. 
   
 
Figure 1. Illustration of product package label content 
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The supplements were assessed for each category and the information transcribed 
into a Widows-based Microsoft ® Office Excel 2003 SP 1 (Excel © 1985-2003 
Microsoft Corporation) spreadsheet, for each of the nutritional supplement 
product labels, respectively. The statements were then captured as “yes” or “no” 
statements.  The Excel file was imported to Statistica Version 10 (Stat Soft Inc. © 
1984-2011 Stat Soft Inc.) to determine the percentages in the respective categories 
investigated. 
 
3.3 Results 
 
Forty products were selected for analysis of which, 21 (53%) were locally 
assembled or manufactured products, and 19 (48%) were international imported 
products. The formulations consisted of powders 16 (40%), capsules 13 (33%), 
tablets 8 (20%), and tablets and liquid in capsules 3 (8%). Only 4 (10%) of the 
product labels cited a literature reference, and of these 3 (75%) cited studies done 
in humans, and 12 (30%) of products had a statement  on the labels indicating that 
the product  was  “contaminant free”. 
 
Thirty-eight  (95%) of the nutritional supplements referred to a website on their 
labels. All the products provided information with the directions for use. 38 (95%) 
had a “best before” date and expiry date for the consumption of the specific 
product and 38 (95%) had batch numbers on the nutritional supplement labels.  
The mean number of ingredients/compounds described on each label was 28, with 
a range of 1 to 88. There was an average of 5 colours (range 3 to 9) on each label.  
 
Thirty-eight (95%) of the products had some form of warning statement(s) on the 
label. The number of warnings ranged from no warnings, to 14 warnings per 
product, with a mean of 5 warnings. The warning categories assessed from the 
nutritional supplement label in this study are shown in Table 2. To give an 
illustration of how the various statements were collapsed for the warning 
description, the example, “Keep product out of reach of children” implies that the 
product is for adult consumption, and warns of the possible harm that may be 
incurred, if children were to consume product.  
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 3 Label content and information factors influencing consumers 
  
27
27
Table 2. The 17 warning categories assessed on the product labels (n=40)   
 
  
Total Percentage  
of total 
% 
 Warning  Descriptions    
 Keep product out of reach of  children 27 68 
 Importance of adherence to  storage details 23 57 
 Use during pregnancy and lactation 17 43 
 Exceeding recommended dose  17 43 
 Importance of consultation with health care professionals 17 43 
 Age categories for consumption 12 30 
 Lower dose when experiencing adverse events  10 25 
 That nutritional supplements should not replace dietary requirements 10 25 
 Potentiate and suppress effect of drugs 10 25 
 Certain medical conditions and the use of supplements 10 25 
 Importance of staying hydrated  8 20 
 Time restriction consideration  when consuming product 4 10 
 Maximum dose “dangers” 4 10 
 Presence of banned substances in the supplements 2 5 
 Presence of food items associated with allergies/intolerance 2 5 
 Product is gender specific 1 2 
 Exclusion of use, and not cure for disease states. 1 2 
 
 
Thirty-four (85%) of the nutritional supplement products had a disclaimer on the 
label. Table 3 represents the disclaimers observed on the product labels in this 
study. To give an illustration of how the  various statement were collapsed for  the 
disclaimer descriptions, the example , “The product does not cure illness”, implies 
that the product is not intended  to treat illness and the disclaimer covers  the 
manufacture  in a broad context.  
 
Table 3. Disclaimers on product labels (n=40) 
  
Total Percentage  
of total 
% 
 Disclaimer  Descriptions   
 The product does not cure illness 21 52 
 The product  is free of stimulants, colourants, flavourant and/or  
preservatives 
16 40 
 The  product, or claim made by the product,  has not been evaluated 
by the FDA 
12 30 
 The product should not replace medication 7 18 
 
Thirty-two (98%) of the nutritional supplement products labels had some claim on 
the label. The different categories and numbers of supplements within each 
category are shown in Table 4. To give an illustration of how the  various 
statement were collapsed for specific claims descriptions, the example , “Quality 
of the product emphasized ”, implies that the manufacture wants  to ensure the 
consumer of  superiority of the  product. 
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Table 4. Description of the specific claims on the product labels (n=40) 
 
 
Total Percentage 
of total 
(%) 
Claims Descriptions   
Quality of the product emphasized 22 45 
Muscle  mass changes 19 47 
Provides  increased  energy 17 43 
Use of pseudo–scientific  terms 15 38 
Will increase physical performance 15 37 
Provides increased strength 13 33 
Improves  recovery 13 32 
Supports general  metabolism 12 30 
Supports  fat metabolism 7 18 
Can have an effect on mood changes 7 18 
Outrageous  claims 7 17 
Supports cognitive function   6 15 
Serves as a weight  loss/management product 5 12 
Removal of metabolic  by-products 5 12 
Serves as an appetite suppressant 4 10 
Supports glucose  metabolism 4 10 
Supports  testosterone  metabolism 4 10 
Gives support  to the immune  system 4 10 
Provides anti-oxidant properties 4 10 
Research  supporting evidence  4 10 
Serves as a meal replacement 2 5 
Relieves stress  2 5 
Could alter libido 2 5 
 
 
All the nutritional supplement products labels 40 (100%), presented some 
scientific indication and/or pledge, and 24 (60%) of the nutritional supplements 
had scientific and/or research claims on the labels. There was no evidence on the 
label that the claims made were peer-reviewed.  
 
Sixteen (40%) of the supplements had pledges and/or indication of commitment to 
the nutritional supplements assessed and 14 (35%) made some pronouncement 
about a specific technology and/or specific patent used in the manufacture of the 
nutritional supplement. 13 (33%) of the nutritional supplement products had 
advertising on the label and 3 (8%) of the nutritional supplement products 
provided a linkage to social networks (eg. facebook, twitter). 
 
Table 5 provides examples of selected categories as determined and assessed.  
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Table 5. Examples of selected categories  
 
Examples  
Outrageous claims (i) Instant muscle gratification, (ii) no loading, no cycling, no side 
effects, and (iii) the "last word" in ultra-enhancing sports 
supplements. 
 
Pseudo Science (i) Activates metabolism and shreds fat, (ii)  
ignites intense workouts, (iii) triggers anabolism and builds 
muscle, and (iv) natural thyroid support complex supports and 
enhanced metabolism. 
 
Scientific, Research and Pledge 
terminology 
(i) Scientifically formulated, (ii) Scientifically formulated for 
professional athletes, (iii) National Academy of Sciences, and (iv) 
New formula with the latest clinically researched ingredients. 
 
Strong  terminology (i) Anabolic Hormone Enhancer, (ii) High Potency, and (iii) the 
Power of Science. 
 
Specific technology and/or 
specific  patent 
(i) Advanced liquid delivery technology maximizes 
bioavailability, and (ii) Patent-pending Nano - Diffuse technology, 
and Patent creatine stabilization technology. 
 
Claims 
 
(i) Improves  glucose  metabolism, Lipotropic  agent,  Red blood 
cell and oxygen booster, (ii) we only use superior ingredients, 
sourced from international raw material suppliers, and (iii) to take 
your physical performance to the  next level.  
   
Disclaimers (i) This product does not intend  to prevent or cure any form of 
illness or disease and should  not replace  any medication, (ii) 
these statements have not been evaluated by the Food and Drug 
Administration, and (iii) the capsules contain no banned 
substances, illegal stimulants, caffeine, gluten, preservatives, 
colouring agents, yeast or lactose.  
 
Indication of commitment (i) With formulation based in the latest scientific research 
available our aim is to ensure that our products are unsurpassed in 
quality, potency and efficacy, (ii) copy of laboratories certificate 
of analysis for each lot can be supplied, and (iii) we make an 
unconditional pledge to you, our valued customer to continually 
supply you with products of highest quality and purity. 
 
Advertising (i) “Learn about our products, get diets and chat with members 
you can also win great prizes”, (ii) It is foundational, "core" 
nutrition that provides the basic nutritional framework for any 
lifter serious about iron warfare, and (iii) “If this product doesn’t 
meet with your standards for any reason, take the remainder back 
with your receipt to where you bought it for a full refund or 
exchange - No questions asked.” 
 
Warnings (i) Maximum dose “dangers”, (ii) keep product out of reach of 
children, and (iii) the importance of adherence to storage details. 
 
Contaminant Free (i) Stimulant free, (ii) ephedrine free, (iii) no artificial flavours, 
(iv) no artificial colourants, (v) no preservatives, and (vi) 
ingredients free of all impurities and by-products. 
 
3.4 Discussion  
 
This chapter has provided diverse examples of labelling of nutritional 
supplements. A limitation in this study is the sample selection that was based on 
the top nutritional supplement sellers at the time of purchase, and within the 
financial constraints of the study. This was done with specific reference to the 
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impact on elite athletes/consumers, and the impact the research outcome would 
have to educate, bring about awareness and advocacy.   
The 40 nutritional supplement products assessed as part of this study yielded the 
following; 
Twenty-eight (70%) of the nutritional supplement product labels had no indication 
or evidence that the product was “Contaminant Free”. This can be interpreted as 
either expressing confidence that the quality of the products are good and there is 
no concern for possible contamination, or that the manufacturer is not aware of 
possible contaminants in their products. This suggests that it is important to do 
screen testing of products to verify nutritional supplements for contaminants, with 
specific reference to steroids and stimulants that are investigated in this thesis. 
Even if “Contaminant Free” information is present on labels, this does not 
guarantee that the products are indeed free of contaminants, particularly   
considering that these products are produced in an environment without 
manufacturing regulations. Although the label may state that the product is 
stimulant free, there is no legislation which controls the accuracy of this statement. 
Furthermore, the word stimulant(s) may also be used in a generic way. Thus 
certain stimulants may be absent, whilst others may be present, either 
unintentionally or deliberately due to the manufacturing process [76, 86].  
 
Of the nutritional supplements assessed 38 (95%) had warning statements. There 
were on average five warnings per supplement, with one supplement having as 
many as 14 warnings. These statement(s) often had a small font size, and were not 
immediately noticeable. The two most frequently used warning statements on the 
product labels assessed were, “keeping product out of reach of children” 27 
(68%), and “the importance of adherence to storage details” 23 (57%). Both these 
warnings in particular alert the consumer of potential harm. The “children” alert 
often did not give a specific age.  The warning statements that were present at 
lower frequency, but may in fact be of greater importance are, “exclusion of use, 
and not a cure for disease states  1 (2%)” and the “presence of banned substances 
in the supplements 2 (5%)”. For the former there may be “contaminants” in 
products that could directly or indirectly contribute to, or exacerbate specific 
disease states. The latter affects professional athletes who may test “positive” for a 
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banned substance after ingesting a supplement. For the general consumer the 
potential implication is the impact on long term health consequences, due to 
harmful, continuous intermittent use effects, or the accumulative effects over time.  
 
In Australia and New Zealand new labelling initiatives pertaining to food 
standards, requires mandatory nutrition information panels. Substances that may 
cause adverse reactions have to be highlighted on the label. In context, this 
approach to labelling could also have similar application to nutritional supplement 
products [115]. 
Incorrect storage of the nutritional supplement product (eg. temperature) has the 
potential of “active” chemical compound(s) converting to other active or inactive 
chemical moieties, or completely harmful unknown compound(s) [76]. The 
consequence of consumption of such nutritional supplement products could lead 
to adverse events. The same logic applies to the consumption of gender specific 
products if not labelled adequately for a specific sex. Unintended consequences 
that impact on the physiological hormonal balance of a specific sex may occur if 
compounds present in the supplements are not declared on the label [8,116,117].  
 
Further, consumers who fail to comply with the directions for use, could also 
predispose themselves to long term effects of elevated accumulative doses. This 
could cause adverse effects, due to abnormal physiological and, or normal cell 
biological disruptive activity.  
 
Having an industry sector standardised batch number coding on nutritional 
supplement products with a trail of data from the manufacturing process to the 
consumer environment should be useful. Such an approach would serve as a 
reference to monitor good manufacturing practice (GMP) processes and also 
identify possible entry points of potential contaminants.  
 
Although “Best before” and expiry date information is valuable information, in 
many cases it was not clearly visible on the label. In the context of warning 
statements, a recent study designed to determine nutrition knowledge, and 
understanding of nutritional information, concluded that only 27% of respondents 
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looked at package information before making a decision [118]. Another study 
suggested that older, compared to younger consumers detect information changes 
less readily [119]. Thus newly added information does not necessary reach all 
consumers, posing a potential problem to policy makers and scientists [119].  
 
A study designed to determine the factors which draw the attention of the 
consumer to nutritional labels showed that the display size, colour scheme, 
familiarity with label, logo and its location on the front of the pack are key 
determinants [120]. The study showed that when the consumer had a better 
understanding of nutrition information and provided attention to label content, this 
impacted nutritional supplement choice [120]. 
 
Further, an off-label promotion study concluded that the media helps shape public 
perceptions and increases support for regulatory actions [121]. Off–label may be 
defined as drug or product used for indications not approved by the Food and 
Drug administration (FDA). This study concluded that the primary concerns about 
label content, included legal concerns, the lack of safety/efficacy data, and having 
no ethical, or clinical content. Having this type of information on the label would 
ensure that policy and decision makers, health care professionals, patients, and 
general public gather sufficient knowledge to make informed choices [121]. The 
findings in this study are supported by a study that suggests that nutrition 
education can be instrumental in encouraging, stimulating, motivating and 
providing technical help for the consumer [122]. Technical messages should 
include teaching consumers simple rules to interpret label information and to 
incorporate the information into planning [122]. Other alternative preventative 
approaches and improved label design in providing nutritional information, should 
be researched and implemented, if the results show it to be more effective [123]. 
It may be concluded from this study that “screen testing” nutritional supplement 
products on an ongoing basis is important. In particular the products would need 
to be tested via batch-to-batch analysis for contaminants, including steroids and 
stimulants. Also the presence and quantity of the ingredients on the label need to 
be verified. Peer-review scientific evidence would also ensure relevant 
engagement with the social media networks, and provide education and awareness 
to the consumer in an informed way. It also emphasizes the importance of relevant 
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screening of the “knowns” as per the number of ingredients on the label 
information (both qualitatively and quantitatively), and “unknowns” that may be 
determined or discovered, but are not reflected on the label information. 
Whilst this study highlighted concerns about claims and labelling, the concerns are 
compounded by the lack of structures of governance and policy development that 
need to ensure the transition from self-regulation to regulation of nutritional 
supplement sector in an improved way. Thus the importance of screen testing for 
contaminants and adulterants, and that of steroids and stimulants, as intended in 
this thesis, should be apparent.  
3.5 Conclusion and Recommendations 
The following information needs to be regulated and enforced as part of the label 
to ensure that the consumer can make an informed choice; 
• Highlighting the potential for adverse events needs to be presented on the 
label. 
• Warning statements such as, “keeping product out of reach of children”, 
and “the importance of adherence to storage details” should be maintained 
on the labels appropriately with acceptable font and visibility.  
• Warning statements, such as, (i) “exclusion of use, and not a cure for 
disease states” and (ii) the, “presence of banned substances in the 
supplements”, should be encouraged. These statements should be based on 
standardised laboratory screen methods. 
• A nutritional supplement sector specific system and guideline with regards 
to the best before and expiry date information, batch numbers, and good  
(GMP), that will also facilitate batch-to-batch laboratory screen testing, 
and provision to ensure accurate content detail, should  be determined and 
established. 
• Future work in this area to assess claims and labelling could also include 
other specific supplements such those used in pregnancy (eg. Folates). 
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• Future studies, to distinguish claims and labelling comparatively for 
locally assembled or manufactured products, and international imported 
products into South Africa.   
•  An alternative label design, that would be beneficial to providing relevant 
information to the consumer, needs to be scientifically explored and 
researched. 
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Section 2 
Labelling and other information that influences consumer 
purchasing decisions  
 
3.6 Introduction 
 
This section in Chapter 3 links to the content as presented in Chapter 2 of the 
thesis, and research work published by Gabriels et al. (2011 and 2012), which 
specifically dealt with Regulation and Legislation, and Labelling and Claims, 
pertaining to the nutritional supplement sector. A summary of observations made 
in the introduction of Chapter 2, stated that the nutritional supplement at present is 
generally laden between statutory laws in two extremes;  (i) laws that govern 
medicines,  and (ii) those that govern food at present. As discussed in Chapter 2 
medicine and food production is a multifaceted industry often governed by several 
laws, regulations, codes of practice and guidance, in different countries. For the 
nutritional supplement sector, the resultant “grey” area, and the widening 
divergence wedged between medicine and food, that has been created due to the 
lack of specific laws and regulation for the nutritional supplement industry, makes 
this a convoluted subject. 
 
In the United States of America (USA),  and in more recent years in South Africa, 
sports  supplements makes up a considerable proportion of the annual  retail sales 
of  nutritional supplement industry. In the USA in particular, the nutritional 
supplement sector has increased by $10 billion over a decade, amounting to $18.8 
billion in 2003 [31, 55]. In South Africa, the local turnover was estimated at R1.5 
billion per year (Health Product Association survey 1998-2000) and has grown 
swiftly, if not exponentially since. There is, however, no tangible and reliable 
information on annual retail sales in South Africa at present. The increase in retail 
sales is likely, not due to more effective nutritional supplements, but instead due 
to determined marketing by manufacturers [17]. 
 
Due to the complex legislation governing supplements in most countries, 
including South Africa, together with the aggressive marketing, companies can 
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make unproven claims about the effectiveness of the supplement [83]. 
Furthermore, the truthfulness of the labelling often goes uncontested, therefore 
any effects of the supplement may be due to contaminants or adulterants in these 
products not reflected on the label [76,78, 86, 87].  
 
To provide an evidence-based solution to the problem it is important to determine 
how consumers of nutritional supplement products gather information to assist 
their purchasing decisions. Therefore, the approach for this study was to ask a 
range of people to complete a self-administered questionnaire which enquired 
about which container label information and information other than container 
labelling sources influenced their purchasing decisions for nutritional 
supplements. 
 
3.7 Methodology 
The self-administered questionnaire was approved by the University of Cape 
Town, Health Science Faculty Human Research Ethics Committee (HREC REF 
346/2012) (Appendix 5b). Subjects who were present at the recruitment sites and 
gave informed consent were selected for the study.  There was no exclusion 
criteria for participation. Subjects who were physically challenged, visually 
impaired or deaf, were assisted by the principal investigator or by professional 
support to ensure appropriate communication.   
 
 
The questionnaire consisted of seven, closed and open-ended questions from a 
defined list of statements (Appendix 11). Question statements provided to the 
participants were basic and had the option of yes or no answers. From statements 
with defined options, participants could choose the respective categories ranging 
from, strongly influenced to no influence.  
 
The questionnaire covered  the following  specific areas, (i) general information 
about participants such as gender, age and the level of physical activity, (ii) had 
participants purchased  nutritional supplement in the last 12 months, (iii) what 
information on the container label influenced the purchase of  nutritional 
supplements, and (vi)  what had influenced  the purchase of  nutritional 
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supplements if it was not the information on the label. The participants were asked 
to complete the questionnaire as accurately as possible (truthfully and honestly), 
and to the best of their ability. The questionnaire took approximately  2-5 minutes  
to complete, and was administered in various similar  classroom settings,  over the 
period July to September 2012.  
Written approval was obtained from the various institutions or organisation where  
target and convenient samples/groups were identified and followed up as part of 
the recruitment process.  The specific sites were the University of Cape Town 
(UCT), the Cape Peninsula University of Technology (CPUT), and the University 
of the Western Cape (UWC) sport halls, and at the holding camps for the 2012 
South Africa Olympic (Pretoria) and Paralympic (Johannesburg) teams, 
respectively, prior to their departure to the 2012 London Olympic Games. 
 
The recruitment process, management, data capture and analysis of the 
questionnaire  was done  by the principal investigator. The compliance rate was 
100% with 259 participants completing and returning questionnaires. 
 
The data and processing of the returned questionnaires was captured using 
Windows-based Microsoft ® Office Excel 2003 SP 1 (Excel © 1985-2003 
Microsoft Corporation). Statistica Version 10 (copyright © Stat Soft, Inc. 1984-
2011) was used to calculate the descriptive statistics. Data are expressed as the 
mean ± standard deviation (SD). 
3.8 Results 
3.8.1 Level of physical activity and age of participants 
Seventy-seven participants described their physical activity as moderate, whilst 
181 of the participants stated that they are competitively active. Only one 
participant indicated that he was inactive and was therefore excluded from further 
analysis. The average age and standard deviation (SD) for the participants whose 
physical activity was classified as either moderate or competitive is presented in 
Table 6. 
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Table 6. Level of physical activity and age participants  
Level of 
Physical Activity 
No. of 
Participants 
Participants’Age (years)  
Moderate 77 29.5 ± 9.9  
Competitive 181 27.6 ± 8.1 
Total Group 258 28.2 ± 8.7 
  SD = standard deviation 
3.8.2 Physical activity and gender comparison 
Of the overall cohort (n=258), 159 were male and 99 were female participants. 
Fifty males indicated they were moderately active and 109 were competitively 
active. For the females 27 were moderately active and 72 were competitively 
active, respectively. The ages of the respective male and female groups based on 
level of physical activity are presented in Table 7. 
 
Table 7. Physical activity and gender comparison 
Level of 
Physical Activity 
No. of 
Participants 
Participants’ Age (years) 
 
Male (total) 159 29.5 ± 9.4 
    Moderate 50 31.0 ± 10.1 
    Competitive 109 28.8 ± 9.0 
Females (total) 99 26.1 ± 6.9 
    Moderate 27 26.9 ± 8.7 
    Competitive 72 25.8 ± 6.1 
All Groups (total) 258 28.2 ± 8.7 
 
3.8.3 Purchase of nutritional supplements  
The responses of the competitively physically active group indicated that 139 
(74%) had purchased nutritional supplements in the previous 12 month, whilst 48 
(26%) had not purchased nutritional supplements in this period. For the 
moderately physical active group, 61 (77%) indicated that they had purchased 
nutritional supplements, whilst 79 (23%) indicated that they had not purchased 
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nutritional supplements in the previous 12 months. These data are shown in Figure 
2.  
 
 
Figure 2. Purchase of nutritional supplements in last 12 months  
 
3.8.4 Information on container label 
When the data of  the whole group (n=195) that had  purchased nutritional 
supplement products were analysed,  132 (68%)  indicated  that  they were  
influenced  by information on the  container  label, and 63 (32%) indicated that 
their purchase of a nutritional supplement product  was not based on information 
on the  product  label.  
 
The results were similar (i.e. whether the information on the label of the 
supplement product influenced their purchase) when the moderately and 
competitively physically active groups were compared (Table 8).  
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Table 8. Influence of container label in purchase  
Level of 
Physical Activity 
No. of 
Participants 
Yes 
 
No 
 
Whole Group 195 (100%) 132 (68%)  63 (32%) 
Moderate 58 (100%) 37 (64%) 21 (36%) 
Competitive 135 (100%) 93 (69%) 42 (31%) 
Percentage (%) of respective groups in brackets 
 
3.8.5 Information on the container label that influenced purchase of 
nutritional supplements 
 The self-administered questionnaire (Appendix 11) provides the five defined 
categories, (i) absolutely no influence, (ii) partially no influence, (iii) uncertain, 
(iv) moderately influenced and (v) strongly influenced that could be selected by 
participants for the respective container label information. The results are 
presented  for, (a) brand name, (b) ingredients, (c) recommended dosage and 
directions for use, (d) claims, (e) disclaimers and warnings, (f) quality of product, 
and (g) free of banned substances. 
 
3.8.5.1 Brand name 
132 Respondents stated that brand name information on the container label 
influenced the purchase of nutritional supplement products. Thirteen % (n=17) 
stated the brand name had no influence on choice of purchase, whilst an increase 
of respondents in the defined respective categories, partially no influence 8% 
(n=10), uncertain 21% (n=27), moderately influenced 25% (n=31) and 36% 
(n=47), stated that the brand name had a strong influence on their purchase 
(Figure 3). 
 
3.8.5.2 Ingredients 
129 Respondents stated that ingredient information on the container label 
influenced the purchase of nutritional supplement products. Seven % (n=9) 
indicated the ingredient information had absolutely no influence and 7% (n=9) 
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stated partially no influence on choice of purchase, whilst an increase number of 
respondents in the other respective categories, being, uncertain 15% (n=19), 
moderately influenced 31% (n=40), and 40% (n=52), stated that the ingredient 
information had a strong influence on their purchase (Figure 3). 
 
3.8.5.3 Recommended dosage and directions for use 
132 Respondents stated that information about dosage and directions for use on 
the container label, contributed to their decision to purchase nutritional 
supplement products. The categories of influence were, 14% (n=18) who indicated 
that dosage and directions for use information had no influence, 13% (n=17) stated 
partially no influence on choice of purchase, whilst an increased number of 
respondents in the other respective categories, being, 25% (n=33) being uncertain, 
27% (n=36) being moderately influenced, and 21% (n=28), stated that the dosage 
and directions for use information had a strong influence on their purchase (Figure 
3). 
 
3.8.5.4 Claims 
127 Respondents stated that claims information on the container label influenced 
the purchase of nutritional supplement products. Twenty % (n=25) indicated that 
dosage and directions for use information had no influence, 21% (n=26) stated 
partially no influence on choice of purchase, 30% (n=38) being uncertain of this 
form of information, 22% (n=28) being moderately influenced, and 8% (n=10), 
stated that the dosage and directions for use information had a strong influence on 
their purchase (Figure 3). 
 
3.8.5.5 Disclaimers and warnings 
123 Respondents stated that disclaimers and warnings information on the 
container label influenced the purchase of nutritional supplement products. This 
ranged from 14% (n=17) stating that the disclaimers and warnings information 
had no influence on choice of purchase, whilst an increase number of respondents 
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in the defined respective categories stated, partially no influence 11% (n=14), 
uncertain 17% (n=21), moderately influenced 30% (n=35) and 29% (n=36) stated 
that disclaimers and warnings information had a strong influence on their purchase 
(Figure 3). 
 
3.8.5.6 Quality of product 
129 Respondents stated that the quality of product information on the container 
label influenced the purchase of nutritional supplement products. Six % (n=6) 
stated the quality of product information had no influence on their choice of 
purchase. The frequency of response tended to across the choices; partially no 
influence 2% (n=3), uncertain 11% (n=14), moderately influenced 30% (n=39) 
and 52% (n=67) stated that the quality of product information had a strong 
influence on their purchase (Figure 3). 
 
3.8.5.7 Free of banned substance(s) 
129 Respondents stated that information declaring the supplement was free of 
banned substance(s) on the container label influenced the purchase of nutritional 
supplement products. Seven % (n=9) stated free of banned substance(s) 
information had no influence on the choice of purchase, whilst an increased 
number of respondents in the defined respective categories, partially no influence 
4% (n=5), uncertain 9% (n=12), moderately influenced 11% (n=14), and 69% 
(n=89) stated that the free of banned substance(s) information had a strong 
influence on their purchase (Figure 3). 
 
3.8.6 Information not on container label  
The results are presented  for, (a) coach, gym and/or fitness trainer, and fellow 
athletes, (b) supplement representatives, (c) pharmacist, dietician, nutritionist and  
doctors, (d) print media, (e) electronic media, and (f) social media and the internet. 
The categories were scored as previously described. 
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3.8.6.1 Coach, gym and/or fitness trainer, and fellow athletes 
67 Respondents stated that information from coaches, gym and/or fitness trainer, 
fellow athletes influenced their purchase of nutritional supplement products. 30% 
(n=20) stated information from coaches, gym and/or fitness trainer, fellow athletes 
had no influence on the choice of purchase, whilst an increase number of 
respondents in the defined respective categories, partially no influence 10% (n=7), 
uncertain 15% (n=10), moderately influenced 21% (n=14), and 24% (n=16) stated 
that the information from coaches, gym and/or fitness trainer, fellow athletes had a 
strong influence on their purchase (Figure 3). 
 
3.8.6.2 Supplement representatives 
63 Respondents stated that information from supplement representatives 
influenced their purchase of nutritional supplement products. 60% (n=28) stated 
information from supplement representatives had no influence on the choice of 
purchase, whilst a decrease number of respondents in the defined respective 
categories, partially no influence 14% (n=9), uncertain 13% (n=8), moderately 
influenced 11% (n=7), and 2% (n=1) stated that the information from supplement 
representatives had a strong influence on their purchase (Figure 3). 
 
3.8.6.3 Pharmacist, Dietician, Nutritionist and Doctors 
60 Respondents stated that information from Pharmacist, Dietician, Nutritionist, 
and Doctor influenced their purchase of nutritional supplement products. 43% 
(n=26) stated information from Pharmacist, Dietician, Nutritionist, and Doctors 
had no influence on the choice of purchase, whilst a decrease number of 
respondents in the defined respective categories, partially no influence 23% 
(n=14), uncertain 12 % (n=7), moderately influenced 12 % (n=7), and 10% (n=6), 
stated that the information from Pharmacist, Dietician, Nutritionist, and Doctors 
had a strong influence on their purchase (Figure 3). 
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3.8.6.4 Print media   
67 Respondents stated that information in the print media (eg. magazines, 
newspapers) influenced their purchase of nutritional supplement products. 39% 
(n=26) stated information in the print media had no influence on the choice of 
purchase, 13% (n=9), stated partially no influence on choice of purchase, 21% 
(n=14) being uncertain, 15% (n=10) being moderately influenced, and 12% (n=8), 
stated that the information in the print media had a strong influence on their 
purchase (Figure 3). 
 
3.8.6.5 Electronic media  
66 Respondents stated that information in the electronic media (eg. television, 
radio) influenced their purchase of nutritional supplement products. 36% (n=24) 
stated information in the electronic media had no influence on the choice of 
purchase, 17% (n=11), stated partially no influence on choice of purchase, 21% 
(n=14) being uncertain, 12 % (n=8) being moderately influenced, and 14% (n=9), 
stated that the information in the electronic media had a strong influence on their 
purchase (Figure 3). 
 
3.8.6.6 Social media and the internet  
65 Respondents stated that information from social media and the internet (eg. 
website, twitter, Facebook) influenced their purchase of nutritional supplement 
products. 46% (n=30) stated information from social media and the internet had 
no influence on the choice of purchase, 14% (n=9), stated partially no influence 
on choice of purchase, 19% (n=12) being uncertain, 12% (n=8) being moderately 
influenced, and 9% (n=6), stated that the information from social media and the 
internet had a strong influence on their purchase (Figure 3). 
These data are summarized in Figure 3. The bar-charts on the left-hand side, 
illustrates the information on the container label that influenced the purchase of 
nutritional supplements. The bar-charts on the right-hand side illustrates other 
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factors that contributed to the purchase of nutritional supplements, rather than the 
information on the container label. 
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1- Absolutely no influence, 2- partially no influence, 3- uncertain, 4-moderately influenced              
5- strongly influenced  
Figure 3. Information influencing purchasing choice 
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3.9 Discussion  
The main finding of this study was that close to 70% of the respondents who 
purchased supplements were strongly influenced by container label information 
that stipulated that the nutritional supplement product is free of banned 
substances. The second finding is that just over 50% of the respondents attach 
importance to the quality of the nutritional supplement product information on the 
container label. The third finding is that about 40% of the respondents were 
strongly influenced by the ingredients on the labels when they purchased 
nutritional supplements.  Brand name (36%), disclaimers and warnings (29%), 
recommended dosage and directions for use (21%), and claims (8%) accounted for 
the other reasons influencing the purchase.  
 
These findings are important as its shows the information that is pertinent to 
people who purchase nutritional supplements, and who base their purchasing 
decision(s) on container label information. The absence intentionally or 
unintentionally of specific information with specific reference to “free of banned 
substances” is an important determinant in the purchase of nutritional supplement 
products.  Not  presenting  this information on the label, when  in fact a product 
may contain a prohibited  substance(s) may have  dire consequence(s)  to the 
health and wellness of the consumer  of  such products, or result in a competitive  
athlete  testing “positive” for a prohibited substance by anti-doping  agencies.   
 
This information points to the level and degree of concern that consumers of 
nutritional supplements would have if not all product content is declared on the 
container label. Furthermore, concealing information about a nutritional 
supplement product being adulterated or contaminated either unintentionally or 
intentionally would impact the consumers decision to purchase a product. These 
findings therefore also point to the importance of independent laboratory screen 
testing of all nutritional supplement products for contaminants and/or adulterants 
on a regular, and batch-to- batch basis. 
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A recent paper showed that for the consumer to make informed choice there was a 
need to alert those consuming nutritional supplements of the potential for banned 
substances being present in products [222]. Of the products labels assessed in that 
particular study, only 5% had information on “The presence of banned substances 
in the supplements”.  
 
The findings other than the container label information raise awareness of the 
factors that strongly influences the purchasing of nutritional supplement products. 
An important finding was that coaches, gym and/or fitness trainers, and fellow 
athletes (24%) have a greater influence on the choice of nutritional supplement 
products than that of a Pharmacist, Dietician, Nutritionist and Doctors (10%). This 
is contrary to the recommendations of Meltzer et al [226], which provided a 
practical guide to the use of nutritional supplements in South Africa (2004), 
specifically stating that fitness coaches and conditioning staff should not prescribe 
supplements. It is important to note that supplement representatives (2%) did not 
have much influence with regards to the purchase of supplements.  
 
The findings show that 46% of the respondents indicated that social media and the 
internet had absolutely no influence on their purchases. Print media and electronic 
media had absolutely no influence on their purchases, for 39% and 36% of the 
respondents, respectively. 
 
The findings further show that for 14% of the respondents, electronic media had a 
strong influence on their purchase of nutritional supplement products. For print 
media and social media and the internet the number of respondents that were 
strongly influenced on their purchases were 12% and 9% of respondents, 
respectively. 
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These respective information areas could provide the opportunity for consumer 
education and awareness that will ensure informed choice, through improved 
knowledge.  
 
In the context of this study, less than 15% of the study participants were 
influenced by the categories of electronic media, print media, social media and the 
internet to provide information on nutritional supplement products. What it does 
imply is that these are potential areas of growth to provide peer-reviewed 
evidenced based information.  
 
3.10 Conclusion and Recommendations 
The findings in this study (trends and/or emerging trends) thus provides;  
• A mechanism, and/or requirements, that may be needed for practical 
intervention, policy development, and/or regulation.  
• Facilitation, direction and guidelines of how nutritional products may be 
marketed in future. 
• Ensures that the consumer makes informed choices with complete 
knowledge and understanding of all product content linked to container 
label content.  
The evidence in assessing the labelling and claims information on nutritional 
supplement products, and assessing the impact of container labelling and other 
sources of information on consumer purchasing decisions highlights matters that 
require attention in the interest of both the nutritional supplement sector and the 
consumer. The evidence points to; 
• Short-comings in current labelling information practices. 
• It provides opportunities to improve label and non-label information and 
communication. 
• The requirement for quality assurance laboratory “screening testing” for 
trace element and heavy metal consistency and safety.  
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• The requirement for quality assurance laboratory “screening testing” to 
detect for the presence of undeclared steroids, stimulants and other 
compounds of interest that could have negative consequences to the 
consumer. 
 
The findings in chapter 3 with reference to the two specific study sections 1 and 2, 
thus forms the basis for the research gaps identified, and the laboratory 
experimental chapters that follow.   
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 Chapter 4 
Trace Elements and Heavy Metal Analysis  
Experimental Study 
 
4.1 Introduction 
The composition of nutritional supplements also comprises trace elements and 
heavy metals. Trace element and heavy metals could therefore be implicit in 
causing or contributing to adverse reaction events [127].  Both trace elements and 
heavy metals would not necessarily be declared on the product label, and 
consequently becomes an important consideration for this study. The importance 
of measuring heavy metals and trace metals in particular, is presented in a Herbal 
Supplement book [227], which points to the contamination of herbal supplements 
from metals, pharmaceuticals and plant poisoning. One of the most serious 
concerns associated with using herbal supplements is the potential exposure to 
toxic substances, whether as an expected component of the formulation or as an 
unintended contaminant.  
The  presence of  heavy metals is an excellent example of this concern as case 
reports  have described  adverse  effects  or death  secondary  to metal  toxicity 
from supposedly safe, “all natural” products [227]. The detrimental health 
outcomes  in the longer-term might arise as is illustrated by the following 
examples; (i) Cadmium (Cd) has a long biological half-life and ingestion over a 
lifetime results  in substantial  body burden due  to storage  in the liver and 
kidneys, (ii) Lead (Pb) replaces Calcium (Ca) leading to osteoporosis and may 
potentiate other genotoxins to induce cancer, (iii) Mercury (Hg)  crosses the blood  
brain barrier and the placenta, inducing neurological  damage, and (iv) Nickel (Ni) 
is a known carcinogen and shows wide variability to induce tumors [227]. 
There is no reason to suspect an offending herbal supplement for a risk of over 
exposure to heavy metals until the consumer shows signs of toxicity. Therefore, 
measuring the presence of these metals in nutritional supplement product could be 
used to verify their quality [227] and reduce the risk associated with unintentional 
or intentional metal exposure.  
Further, the profiling of consumer products (nutritional supplement) for trace 
elements and heavy metals could have the potential to determine intra-and-inter 
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product batch consistency or inconsistency, or identifying a contaminant via 
quantitative bar charts or visual radar plots. In this context, the definition of a 
contaminant is any substance (element) that is either present in an environment 
where it does not belong, or is present at levels that might cause harmful effects to 
humans or the environment.  
The World Health Organization (WHO) estimates that 60-80% of people in 
developing countries use traditional medicines [128]. Moreover, the use of over-
the-counter (OTC) herbal and other forms of drugs derived from plants products 
has increased dramatically over the past decade, both in developing and developed 
countries [129]. This upsurge in the use of natural products was driven by many 
factors, including availability and cost effectiveness, perceived safety and lack of 
side effects and deteriorated belief in the efficacy and safety of conventional 
drugs. Furthermore, public tendency towards self-medication, and increased 
publicity and sensational journalism has also increased the public interest in the 
products [130]. In addition, many of the aforementioned products have intensively 
been marketed as nutritional supplements.  
The next section will describe the experimental approach to the problem to extend 
the understanding of whether trace elements and heavy metals can be used to 
determine inter-and-intra product batch consistency or inconsistency. Following 
the review of the literature there will be a description of trace element and heavy 
metal analysis done. To serve as examples, Ginseng and Hypoxis products were 
used as sample products to do the trace element and heavy metal investigation. 
These products were selected because they are popular in complementary and 
alternative medicine practices [131]. However, this principle of trace element and 
heavy metal profiling as a measure of quality, could be applied to nutritional 
supplements in general, including multivitamins.  
 
4.2 The Scientific Literature 
4.2.1 Herbal-Botanical Synergistic Interactions 
It is essential to recognize the potential risks that nutritional supplements and/or 
herbal-botanical preparations pose to consumers, especially those consumers on 
medication and who may be further exposed to adverse drug-herb interactions. 
Nutritional supplements that are either contaminated with trace elements and 
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heavy metals or do not have the concentrations of the ingredients declared on the 
label, could result in undesirable interactions with other drugs the person may be 
ingesting at the time. The adverse effects of drug-herb combinations may 
invariably be related to synergistic or additive interactions [4,128,132,133]. 
Synergy or additively is defined as interactions among biologically active agents, 
including chemicals, drugs, pharmaceuticals, supplements, carcinogens, 
environmental pollutants, toxins, and plant or herbal extracts (phytochemicals), 
such that their combination produces a greater intensity of response than the 
individual components [129]. A synergistic response is regarded as beneficial 
when the desired therapeutic effects outweigh the unwanted side effects. The 
same assumption also applies when consumers concomitantly use complementary 
or alternative medicines [129, 130,134-137]. 
4.2.2 Phytochemicals and Traditional Medicines 
Plants have developed an array of antioxidant defences to protect themselves from 
environmental stress. Antioxidants, active substances, and trace element and 
heavy metal composition of plant-derived products also vary with the location or 
source [131,138-141]. It therefore follows that if these plants are ingested as food 
that the composition of the food will also vary. The use of traditional medicines or 
herbal preparations is commonplace in many societies and cultures. In South 
Africa, traditional medicines and herbs have multiple applications in various 
aspects of popular culture, including traditional healing practices related to 
ethnobotanical and ethnopharmacological folklore and knowledge, self-
medication, and as new medicines and supplements in an ever-growing industry 
[110, 142-144]. The lack of public confidence in traditional medicines and herbal 
products is generally due to misidentification of plants, lack of standardization, 
poor manufacturing practices, botanical substitution, adulteration, and 
contamination. The therapeutic effects of plant-derived medicines are thought to 
be enhanced by essential trace elements [142]. However, some products may also 
contain excessive amounts of trace elements and heavy metals that may 
precipitate adverse effects in consumers. Consequently, chemical compositional 
analysis of active ingredients and substances in phytochemical mixtures has 
become increasingly important and relevant in view of the revival of interest in 
the development and discovery of new plant-based medicines, as well as their 
varying composition and unidentified toxicity spectrum [143]. 
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4.2.3 Metal Content and Contamination in Supplements  
A study on the composition of  trace element and heavy metals of Ephedra  
containing  nutritional  supplements  showed   that  the lowest  concentration of 
metal  were mostly  found in single-ingredient supplements compared to multiple 
component  supplements  that generally had  higher metal concentrations [127].   
According to these data the multiple-component supplement products would have 
a greater probability of contributing to adverse effects [127]. Furthermore, this 
study showed that significant lot-to-lot variations were also observed in some of 
the supplement products [127].  
Trace elements and heavy metals are also included in multivitamin and mineral 
supplements products. People use these products for many reasons, including to 
compensate for nutritional deficiencies, to promote and maintain health, as  
protection against the functional declines associated with aging, to reduce the risk 
of developing chronic disease such as cancer, heart disease, and to manage or treat 
diseases [145,146]. A review on herbal product contamination identified concerns 
that contribute to toxicity. These concerns were a lack of child-resistant 
packaging, contamination, proliferation of multiple ingredient products, excessive 
concentration, and discovery of new drug-herb interactions [129]. FDA analyses 
showed that the greatest contamination associated with metals has been observed 
in the course of inspection of herbal products imported from Asia [147]. In 
summary, quality assurance and batch-to-batch consistency of these products 
could theoretically b  determined by using the trace elements and heavy metal 
profile markers. 
4.2.4 Bioactive Properties of Plants 
Although the effects and mechanisms of substances (compounds) in certain plant 
species may not be clearly understood, the plants often form an integral part of 
supplement products. The reason for their inclusion is often based on anecdotal 
evidence and observations of the plants eaten by wild animals such as 
chimpanzees, with the assumption that curative properties for disease in the plants 
eaten by these animals also applies to humans [156].   
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4.3 Literature from other Sources 
The book, “The Coming of China Wars” by Peter Navarro highlights the origins 
of China’s flood of contaminated, defective, and carcinogenic products on world 
markets [35]. The Chinese government’s own reports expressed apprehension that 
many rivers in the region are so contaminated with heavy metals from industrial 
waste, by-products and pesticides, including DDT, that they are too dangerous to 
touch, and unsuitable for aquaculture or commercial fish farming (Washington 
Post) [35]. It follows that nutritional supplements, such as herbal and botanical 
products, may be constituted, grown or processed using contaminated water 
supplies and this will obviously affect the quality of the supplement. Stock 
farming processes may also be impeded by water contaminated with heavy metals 
through a chain of events, with potential adverse concentration-dependent effects 
at the human consumption stage [35].  The Aristolochia plant, with main bioactive 
ingredients such as aristolochic acids, is an example of a popular plant grown in 
China. These plants are used to manufacture nutritional supplements, slimming 
pills and Traditional Chinese Medicines [148,149]. 
4.4 Ginseng and Hypoxis  
Commercial Ginseng and Hypoxis supplement products are regarded as herbal or 
plant-derived medicines used in primary healthcare, self-medication, and 
complementary and alternative medicine practices. Ginseng (prepared from the 
roots of the plant family Araliaceae, viz., Panax quinquefolium and P. Schinseng) 
is a popular traditional Chinese medicine used for its adaptogenic and restorative 
properties (an adaptogen is defined as a substance that balances the body, 
particularly during stress, generating mental arousal by either stimulating or 
relaxing mechanisms). Hypoxis (a member of the plant family Hypoxidaceae, 
Hypoxis hemerocallidea), also called the African potato, is used as a herbal 
supplement or in conjunction with conventional therapies. Hypoxis is acclaimed 
for its immune-boosting properties and beneficial effects against several diseases, 
including prostate cancer, rheumatoid arthritis, psoriasis, hypertension and, 
somewhat controversially, in terms of public debate, HIV/AIDS. The sterols and 
sterolins in extracts of Hypoxis have been implicated in their effects, but many 
other ingredients that are yet to be determined may also be involved.  
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“Finger print” profiling of the trace and heavy metal composition of supplements 
as will  be used  in this study, has the potential to be used as a reference standard 
against which subsequent manufactured batches can be validated. This should also 
be able to assist in the identification of trace element or heavy metal 
contamination. Radar plots could also be used as an additional visual tool to 
observe batch-to-batch discrepancies, insufficiencies or contaminations 
immediately after processing collective results. The proposed approach has the 
potential to contribute to standardising the production and quality of nutritional 
supplements and traditional herbal medicines.  The trace elements and heavy 
metal respective concentration should be consistent for every brand type.   
 
However, before the proposed system can be adopted, it needs to undergo 
evaluation to detect whether it is implementable. In accordance ith this, the two 
products Ginseng and Hypoxis will be systemically analysed to determine trace 
element and heavy metal collective profiles. 
 
This study will examine the repeatability of the trace element and heavy metal 
composition of the same and different batches of Ginseng and Hypoxis to 
determine whether their profiles can be used in operational quality control 
approaches applied to other nutritional supplements. The overall goal is to 
determine whether the trace element and heavy metal profiling of supplement 
product samples can determine the batch-to-batch consistency in a specific brand.  
4.5 Methodology 
4.5.1 Supplement Product Acquisition 
Ginseng and Hypoxis (African potato) commercial product brands were purchased 
from various pharmacies and health stores in Cape Town, South Africa with the 
strategy where possible, of having different batch numbers of the same product. A 
total of 11 products, (Ginseng n= 6 and Hypoxis n = 5) were purchased. The 
definition used for trace element and heavy metals in this study was generic in 
contrast to the specific definitions used in analytical chemistry, biochemistry and 
geochemistry. There was no prior knowledge of the concentrations to be expected 
for the respective trace elements and heavy metals. The selection of these products 
allowed for inter-and-intra batch analysis of the trace elements and heavy metal 
composition. 
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4.5.2 Trace Element and Heavy Metals Investigated 
The following trace elements and heavy metals were investigated: 
 
 
 
 
 
 
4.5.3 Inductively Coupled Plasma – Mass Spectrometry Methodology 
The trace element and heavy metal content in the supplements was determined, 
using the analytical combination tandem system technique of ICP-MS 
(Inductively Coupled Plasma - Mass Spectrometry). ICP-MS is a powerful, 
accurate, fast and sensitive analytical technique. The Perkin-Elmer 6000 ICP-MS 
instrument and analytical sample preparation procedures were used for the above 
analysis (Courtesy: Department of Geochemistry, University of Cape Town) 
[150]. The ICP-MS comprises a sample aspiration system and spray chamber in 
the presence of argon (Figure 4). The inductively coupled plasma is attached to a 
radio frequency supply that results in the excitation of the metal ions under 
investigation being pumped through a selective plasma spectrometer interface, an 
ion lens into the mass filter quadropoles (quads) and a detector system (electron 
multiplier). All the experimental work and preparation, and data processing were 
done by the principal investigator.   
4.5.4 Sample Preparation for ICP-MS Analysis 
A 500 mg sample of each supplement was weighed. The digestion procedure was 
done in a wide mouth Erlenmeyer flask. All reagents were of analytical grade 
quality. The acid digestion was adapted from the Karbochem Research and 
Development Laboratory as follows: A 10 ml combination of HCL/HF (1:4) was 
added to the sample and the mixture heated to boiling point on a heating mantle in 
a fume hood. Then 10 ml nitric acid was added to the flask, allowed to boil until 
the sample volume was approximately 2 ml and then 5 ml perchloric acid added, 
followed by boiling until the sample volume reached 2 ml. The contents in the 
Element Abbreviation Element Abbreviation 
Magnesium Mg Cobalt Co 
Potassium K Nickel Ni 
Calcium Ca Copper Cu 
Iron Fe Zinc Zn 
Manganese Mn Strontium Sr 
Lithium Li Cadmium Cd 
Sodium Na Mercury Hg 
Chromium Cr Lead Pb 
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Erlenmeyer flask was then transferred quantitatively to a 100 ml volumetric flask 
and filtered through Whatman No. 1 into a sample bottle.  
Prior to analysis each sample was diluted with a solution of 5% nitric acid  
containing 4 internal standards consisting of  Bi, Re, Rh and In, each at a 
concentration of 10 ppb, respectively. The analysis protocol consisted of running a 
blank and 3 calibration standards, made from artificial solutions of 10, 20 and 30 
ppb for each of the respective trace elements and heavy metals as defined in the 
study. The instrument was recalibrated after the analysis of every 10 samples by 
re-running the blank and the 3 standards. Replicate analyses typically gave an 
overall procedural error of  less than 3% relative standard deviation measured at 
ppm  level, and total procedural blank measured at ppb level [150]. The duplicate 
samples were then submitted in a blind randomised (coded) way to the analyst for 
ICP-MS analysis. The content of trace elements and heavy metals in the samples 
was determined quantitatively from calibration curves, and the results decoded for 
the respective duplicate samples. 
 
 
Figure 4. Schematic diagram of an ICP-MS instrument (Source: Hewlett- 
Packard Journal) 
4.5.5 Statistical Analysis  
Upon completion of data capturing and analysis of the respective investigations, 
the following computer-based programmes were used for statistical analysis and 
graphic representation: Windows-based Microsoft® Office Excel 2003 SP1 
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(Excel© 1985-2003 Microsoft Corporation), WinNonlin Standard Edition Version 
1.5 (WinNonlin© 1984-1997, Scientific Consulting, Inc.), and GraphPad Prism® 
Version 2.01 (GraphPad Software© 1994, 1995, 1996 GraphPad Software, Inc.). 
Descriptive data were calculated as means and standard deviations and the 
coefficient of variation. Statistical significance was determined where the p value 
was ≤ 0.05. Consistency was accepted where both duplicate sample determination 
were ≤ 20% CV for each trace and heavy metal investigated. The % CV was 
based on the upper limit of acceptable analytical precision, and within the 
permissible statistical window for bioequivalence assessment [151, 152, 153].  
4.6 Results and Discussion 
4.6.1 Products Investigated 
Table 9 reflects the Ginseng and Hypoxis (African potato) samples investigated. 
The tables shows the product name, and batch number/date of purchase. There is 
also a column in the table clarifying whether the comparisons will be inter or intra 
batch comparisons. The products were evaluated for content validity and 
contamination for the following trace elements and heavy metals: Mg, K, Ca, Fe, 
Mn, Li, Na, Cr, Co, Ni, Cu, Zn, Sr, Cd, Hg and Pb (see section 4.5.2 for full 
names of elements). 
Table 9. Ginseng and Hypoxis products investigated 
Code Product Batch 
number/date 
Comparison 
 Ginseng   
G1 Aspen Formule Naturelle Ginseng B/N 403966 Inter 
G2 Aspen Formule Naturelle Ginseng B/N 403746 Inter 
G3 Natrodale Formule Naturelle Ginseng MNF 20 Dec04 E1 Intra 
G4 Natrodale Formule Naturelle Ginseng MNF 20 Dec04 E1 Intra 
G5 Bettaway Ginseng  534521 Inter 
G6 Bettaway Ginseng 539702 Inter 
 Hypoxis products   
H1 Inkomfe Hypoxis  5092 Inter 
H2 Inkomfe Hypoxis 5478 Inter/intra 
H3 Inkomfe Hypoxis 5478 Inter/intra 
H4 Trazure African Potato Hypoxis  B/N 303 Intra 
H5 Trazure African Potato Hypoxis B/N 303 Intra 
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4.6.2 Statistical Evaluation of Ginseng and Hypoxis Formulas 
Samples of Ginseng and Hypoxis formulas (10 tablets or capsules) were randomly 
selected and evaluated for their mass (in mg) consistency. The unpaired-t-test was 
used to determine statistical significance for the comparison of mass. These data 
are shown in Table 10. 
Table 10. Comparison of mass for the Ginseng and Hypoxis samples (n = 10 in 
each).  
Code Mass ± SD (mg) Minimum 
(mg) 
Maximum 
(mg) 
CV (%) Comparison   
(p value) 
G1 619.2 ± 14.6 587.6 630.3 2.4 0.903 
G2 620.0 ± 15.8 586.5 631.5 2.6  
G3 650.6 ± 21.2 608.2 612.8 3.3 0.394 
G4 642.7 ± 19.3 612.8 663.9 3.0  
G5 438.3 ± 5.8 429.4 446.6 1.3 0.042* 
G6 432.6 ± 6.4 423.8 443.7 1.5  
H1 578.0 ± 13.7 547.6 598.2 2.5 0.017* 
H2 546.8 ± 34.8 497.2 594.1 6.4  
H4 513.8 ± 33.8 479.8 580.2 6.6 0.894 
H5 516.0 ± 37.3 476.0 592.1 7.2  
The coding and details of each sample are shown in Table 9  
The p-value comparison is for G1and G2, G3and G4, G5 and G6, H1 and H2, and H4 and H5  
The coefficient of variation ranged from 1.3 to 7.2%. There was a significant 
difference between the average mass of G5 and G6 (Bettaway Ginseng different 
batches) (p = 0.042) and H1 and H2 (Inkomfe Hypoxis different batches) (p = 
0.017). The samples from the same batches (Ginseng and Hypoxis) were not 
statistically significantly different. 
4.6.3 Trace Element and Heavy Metals in Ginseng and Hypoxis 
Tables 11 (a, b, c) and 12 (a, b) show the, (i) concentrations and (ii) mean total 
and percentage coefficient of variation (% CV) of replicate samples of trace 
element and heavy metals for Ginseng and Hypoxis products. These 
measurements indicate the inter-batch consistency. Tables 11 (a, b, c) and 12 (a, b, 
c) also show the (iii) mean and % CV of each duplicate sample of trace element 
and heavy metals. This gives an indication of the intra-sample batch consistency.  
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Table 11a, G1a and G1b are duplicate independent samples of the same batch of 
Ginseng formulas Naturelle product, and G2a and G2b are duplicate independent 
samples of a different batch of Ginseng formulas Naturelle product. 
Table 11a. Trace element and heavy metal concentration of Aspen Formule 
Naturelle Ginseng   B/N403966 (G1) and 403746 (G2)  
 
Values are expressed in mg/g for Mg, K, Ca and Fe and in µg/g for Mn, Li, Na, Cr, Co, Ni, Cu, Zn, Sr, Cd, Hg, Pb 
(*)  % CV is ≤ 20% for the trace and heavy metal in each of Sample 1 and 2, respectively 
In Table 11b, G3a and G3b are duplicate independent samples of the same batch 
of Ginseng formulas Naturelle product, and G4a and G4b are duplicate 
independent samples of the same batch of Ginseng formulas Natrodale product, 
both purchased at different geographical locations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
Sample 1 
(duplicates) 
Mean 
  
%CV 
 
Sample 2 
(duplicates) 
Mean 
 
%CV 
 
Mean 
 
%CV 
 
G1a 
 
G1b 
 
(G1a and G1b) 
 
G2a 
 
G2b 
 
(G2a and G2b) 
 
Samples 1 and 2 
(combined) 
Mg* 5.28 4.54 4.91 10.7 7.20 7.04 7.12 1.6 6.01 21.8 
K* 11.74 11.67 11.71 0.4 6.12 6.39 6.25 3.1 8.98 35.1 
Ca* 79.11 75.56 77.33 3.2 68.84 68.61 68.72 0.2 73.03 7.1 
Fe 3.71 7.14 5.43 44.7 4.81 0.00 2.40 141.4 3.92 76.0 
Mn 59.57 63.80 61.69 4.8 92.13 45.44 68.79 48.0 65.24 30.0 
Li 3.54 0.00 1.77 141.4 14.88 20.88 17.88 23.7 9.82 99.0 
Na 0.00 0.00 0.00 - 113.98 0.00 56.99 141.4 28.50 200.0 
Cr 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 - 
Co 1.00 2.26 1.63 54.4 1.44 1.38 1.41 2.7 1.52 34.8 
Ni 1.88 0.00 0.94 141.4 4.47 0.00 2.23 - 1.59 133.3 
Cu 2.11 0.00 1.06 141.4 3.99 2.03 3.01 46.0 2.03 80.1 
Zn 7.00 0.00 3.50 141.4 11.04 5.18 8.11 51.1 5.81 78.9 
Sr 45.54 38.89 42.22 11.1 57.25 99.29 78.27 38.0 60.24 45.0 
Cd 0.02 0.06 0.04 61.2 0.12 0.40 0.26 76.7 0.15 111.9 
Hg 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 - 
Pb 1.42 2.10 1.76 27.4 3.22 0.00 1.61 141.4 1.69 79.9 
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Table 11b. Trace element and heavy metal concentration in Ginseng product 
Natrodale B/N MNF 20 Dec04 E1 (G3 and G4) 
 
Values are expressed in mg/g for Mg, K, Ca and Fe and in µg/g for Mn, Li, Na, Cr, Co, Ni, Cu, Zn, Sr, Cd, Hg, Pb 
(*)  % CV is ≤ 20% for the trace and heavy metal in each of Sample 1 and 2, respectively 
In Table 11c, G5a and G5b are duplicate independent samples of the same batch 
of Ginseng formulas Naturelle product, and G6a and G6b are duplicate 
independent samples of a different batch of Ginseng Betterway product, 
respectively. 
Table 11c. Trace element and heavy metal concentration in Ginseng product 
Bettaway B/N 534521 (G5) and 539702 (G6) 
 
   
Sample 1 
(duplicates) 
Mean 
  
%CV 
 
Sample 2 
(duplicates) 
Mean 
 
%CV 
 
Mean 
 
%CV 
 
G5a 
 
G5b 
 
(G5a and G5b) 
 
G6a 
 
G6b 
 
(G6a and G6b) 
 
Samples 1 and 2 
(combined) 
Mg 1.78 0.91 1.35 45.6 1.40 0.96 1.18 26.5 1.26 32.4 
K 3.03 9.89 6.46 75.2 3.23 8.26 5.74 61.9 6.10 57.3 
Ca 4.00 2.51 3.26 32.4 4.71 3.25 3.98 25.9 3.62 26.2 
Fe 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 - 
Mn 3.74 6.61 5.17 39.2 6.52 7.93 7.22 13.8 6.20 28.4 
Li 0.00 2.47 1.24 141.4 0.00 0.00 0.00 - 0.62 200.0 
Na 115.74 0.00 57.87 141.4 207.03 0.00 103.51 141.4 80.69 124.4 
Cr 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 - 
Co 0.15 0.02 0.08 112.2 0.00 0.00 0.00 - 0.04 173.5 
Ni 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 - 
Cu 0.00 0.00 0.00 - 1.16 0.00 0.58 141.4 0.29 200.0 
Zn 0.00 0.00 0.00 - 17.19 11.73 14.46 26.7 7.23 119.5 
Sr 57.11 26.49 41.80 51.8 54.36 22.93 38.64 57.5 40.22 44.8 
Cd 0.07 0.03 0.05 51.8 0.25 0.15 0.20 34.4 0.13 77.8 
Hg 4.14 0.00 2.07 - 1.90 0.00 0.95 - 1.51 130.3 
Pb* 10.72 12.54 11.63 11.1 17.07 15.71 16.39 5.9 14.01 20.7 
Values are expressed in mg/g for Mg, K, Ca and Fe and in µg/g for Mn, Li, Na, Cr, Co, Ni, Cu, Zn, Sr, Cd, Hg, Pb 
(*)  % CV is ≤ 20% for the trace and heavy metal in each of Sample 1 and 2, respectively 
   
Sample 1 
(duplicates) 
Mean 
  
%CV 
 
Sample 2 
(duplicates) 
Mean 
 
%CV 
 
Mean 
 
%CV 
 
G3a 
 
G3b 
 
(G3a and G3b) 
 
G4a 
 
G4b 
 
(G4a and G4b) 
 
Samples 1 and 2 
(combined) 
Mg 0.44 0.45 0.44 1.1 0.69 1.09 0.89 31.9 0.67 45.7 
K*  8.43 7.63 8.03 7.1 8.55 10.26 9.41 12.9 8.72 12.7 
Ca 0.31 0.53 0.42 36.9 1.08 2.02 1.55 42.8 0.99 77.3 
Fe* 1.37 1.29 1.33 4.0 1.44 1.30 1.37 7.2 1.35 5.1 
Mn* 30.55 28.92 29.73 3.9 28.83 29.29 29.06 1.1 29.39 2.7 
Li 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 - 
Na 0.00 0.00 0.00 - 0.00 30.62 15.31 141.4 7.65 200.0 
Cr 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 - 
Co 2.34 0.02 1.18 138.5 0.04 0.02 0.03 45.4 0.60 191.2 
Ni 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 - 
Cu 0.00 5.96 2.98 141.4 1.56 0.00 0.78 141.4 1.88 149.9 
Zn 0.00 0.00 0.00 - 0.21 0.00 0.11 141.4 0.05 200.0 
Sr 44.32 8.40 26.36 96.4 15.51 27.51 21.51 39.4 23.93 65.6 
Cd 0.37 0.01 0.19 130.7 0.03 0.01 0.02 73.2 0.11 168.5 
Hg 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 - 
Pb 33.89 2.56 18.22 121.6 5.69 5.03 5.36 8.7 11.79 125.4 
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In Table 12a, H1a and H1b are duplicate independent samples of the same batch 
of Hypoxis Inkomfe product. H2a and H2b, and H3a and H3b are duplicate 
independent samples, respectively of a different batches of Hypoxis Inkomfe 
products, respectively. All batches were purchased at different geographical 
locations. 
Table 12a. Trace element and heavy metal concentration in Hypoxis product 
Inkomfe B/N 5092(H1) and 5478 (H2 and H3) 
 
 
Sample 1 
(duplicates) 
Mean %CV Sample 2 
(duplicates) 
Mean %CV Sample 3 
(duplicates) 
Mean %CV Mean %CV 
 
H1a H1b (H1a  and H1b) H2a H2b (H2a  and H2b) H3a H3b (H3a  and H3b) Samples 1,2 & 3   
(combined) 
Mg* 1.51 1.79 1.65 12.0 1.42 1.40 1.41 1.1 1.45 1.38 1.41 3.8 1.49 10.3 
K* 11.31 11.67 11.49 2.2 11.36 10.83 11.10 3.4 4.67 4.14 4.41 8.5 9.00 39.7 
Ca 1.42 1.91 1.67 20.7 1.50 1.83 1.66 13.7 1.29 1.85 1.57 25.1 1.63 16.0 
Fe 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.15 0.07 141.4 0.02 244.9 
Mn* 255.45 251.13 253.29 1.2 247.28 245.18 246.23 0.6 257.74 248.19 252.96 2.7 250.83 2.0 
Li 0.00 5.82 2.91 141.4 0.00 0.00 0.00 - 48.87 15.79 32.33 72.4 11.75 163.5 
Na 0.00 0.00 0.00 0.0 0.00 0.00 0.00 0.0 93.52 13.37 53.45 106.0 17.82 210.3 
Cr 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 - 
Co 1.34 0.81 1.08 34.8 3.79 0.80 2.29 92.3 1.02 0.89 0.95 10.3 1.44 81.0 
Ni 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 2.33 1.17 141.4 0.39 244.9 
Cu 5.48 11.28 8.38 48.9 9.74 9.69 9.71 0.3 11.12 17.44 14.28 31.3 10.79 35.9 
Zn* 33.32 30.00 31.66 7.4 59.14 46.02 52.58 17.7 43.28 36.00 39.64 13.0 41.29 25.7 
Sr 27.34 34.19 30.76 15.7 77.34 63.98 70.66 13.4 96.77 26.40 61.58 80.8 54.33 54.2 
Cd 0.18 0.19 0.19 2.8 0.58 0.49 0.54 12.5 0.72 0.14 0.43 96.1 0.38 64.1 
Hg 0.00 0.18 0.09 141.4 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.03 244.9 
Pb 3.09 2.26 2.68 22.0 49.82 36.69 43.25 21.5 12.33 4.75 8.54 62.7 18.16 111.2 
Values in are expressed in mg/g for Mg, K, Ca and Fe and in µg/g for Mn, Li, Na, Cr, Co, Ni, Cu, Zn, Sr, Cd, Hg, Pb 
(*)  % CV is ≤ 20% for the trace and heavy metal in each of Sample 1,2and 3, respectively 
 
In Table 12b, H4a and H4b are duplicate independent samples of the same batch 
of Hypoxis product Trazure, and H5a and H5b are duplicate independent samples 
of the same batch of Hypoxis product Trazure, both purchased at different 
geographical locations. 
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Table 12b. Trace element and heavy metal concentration in Hypoxis product  
Trazure B/N 303 (H4 and H5) 
Values in are expressed in mg/g for Mg, K, Ca and Fe and in µg/g for Mn, Li, Na, Cr, Co, Ni, Cu, Zn, Sr, Cd, Hg, Pb 
(*)  % CV is ≤ 20% for the trace and heavy metal in each of Sample 1 and 2, respectively 
 
Table 13 summarises the trace element and heavy metals that show intra-sample 
batch consistency, intra-batch variability, and inter-batch consistency. These trace 
elements and heavy metals can be used as markers, as part of specific product 
assessment and quality. 
 
Table 13. Trace element and Heavy metal Inter-and-Intra batch consistency 
  Intra-sample 
batch 
consistency  
 
Intra-batch variability 
 
Inter-batch 
sample 
consistency 
Ginseng 
(G1,G2) 
Aspen 
 
Mg, K, Ca Fe, Mn, Li, Na, Cr, Co, Ni, Cu, 
Zn, Sr, Cd, Hg and Pb 
Only for  Ca 
Ginseng 
(G3,G4) 
Natrodale K, Fe, Mn Mg, Ca, Li, Na, Cr, Co, Ni, Cu, 
Zn, Sr, Cd, Hg and Pb 
Only for  K, 
Fe, Mn 
Ginseng 
(G5,G6) 
Bettaway Pb Mg, K, Ca, Fe, Mn, Li, Na, Cr, 
Co, Ni, Cu, Zn, Sr, Cd, and Hg  
No 
Hypoxis 
(H1,H2, H3) 
Inkomfe  Mg, K, Mn, Zn Ca, Fe, Li, Na, Cr, Co, Ni, Cu, , 
Sr, Cd, Hg and Pb 
Only  for Mg, 
Mn 
Hypoxis 
(H4,H5) 
Trazure Mg, K, Ca, Mn, 
Sr 
Fe, Li, Na, Cr, Co, Ni, Cu, Zn, 
Cd, Hg and Pb 
Only for Mg, 
K, Ca, Mn, Sr 
Assessment for consistency based on ≤ 20%CV values. 
4.6.4 Trace Elements and Heavy Metals in Ginseng and Hypoxis  
4.6.4.1 Ginseng Commercial Products 
The Ginseng commercial products assessed showed that in the case of Aspen 
Formula Naturelle Pharmacare Ginseng, the highest concentrations measured 
   
Sample 1 
(duplicates) 
Mean 
  
%CV 
 
Sample 2 
(duplicates) 
Mean 
 
%CV 
 
Mean 
 
%CV 
 
H4a 
 
H4b 
 
(H4a and H4b) 
 
H5a 
 
H5b 
 
(H5a and H5b) 
 
Samples 1 and 2 
(combined) 
Mg* 1.19 1.08 1.14 7.4 1.15 1.10 1.13 2.8 1.13 4.6 
K* 4.26 3.91 4.09 6.1 4.56 4.24 4.40 5.2 4.24 6.3 
Ca* 1.87 1.93 1.90 2.2 1.80 2.10 1.95 10.7 1.93 6.5 
Fe 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 - 
Mn* 466.10 417.88 441.99 7.7 383.59 369.75 376.67 2.6 409.33 10.5 
Li 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 - 
Na 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 - 
Cr 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 - 
Co 0.42 0.27 0.35 30.8 0.37 0.31 0.34 11.2 0.34 19.2 
Ni 0.14 0.00 0.07 - 0.00 0.00 0.00 - 0.04 - 
Cu 1.28 1.46 1.37 8.9 1.41 0.00 0.70 - 1.04 67.0 
Zn 30.08 12.38 21.23 58.9 21.04 10.60 15.82 46.7 18.52 48.3 
Sr* 26.34 22.90 24.62 9.9 32.58 28.54 30.56 9.3 27.59 14.7 
Cd 0.33 0.08 0.21 84.5 0.26 0.04 0.15 103.6 0.18 78.0 
Hg 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 - 
Pb 1.21 0.00 0.61 141.4 1.57 0.00 0.79 141.4 0.70 117.4 
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were: Mg (7.20 mg/g), K (11.74 mg/g), Ca (79.11 mg/g), Fe (7.14 mg/g), Mn 
(92.13 µg/g), Li (20.88 mg/g), Na (113.98 µg/g), Ni (4.47 µg/g), Sr (99.29 µg/g) 
and Cd (0.40 µg/g), whereas those for Natrodale Ginseng Vitality were Co (2.34 
µg/g), Cu (5.96 µg/g) and Pb (33.89 µg/g). Bettaway Ginseng had the highest 
concentration for Zn (17.19 µg/g) and Hg (4.14 µg/g). Chromium was not 
detected in any of the Ginseng commercial products analyzed. 
4.6.4.2 Hypoxis Commercial Products  
The Hypoxis commercial products assessed showed that in the case  of Hypoxis 
Inkomfe the highest concentrations measured were for Mg (1.79 mg/g), K (11.67 
mg/g), Fe (0.15 mg/g), Li (48.87 µg/g), Na (93.52 µg/g), Co (3.79 µg/g), Ni (2.33 
µg/g), Cu (17.44 µg/g), Zn (59.14 µg/g), Sr (96.77 µg/g), Cd (0.72 µg/g), Hg 
(0.18 µg/g) and Pb (49.82 µg/g). The highest concentrations for Ca (1.93 mg/g) 
and Mn 466 (µg/g) were present in Hypoxis Trazure. As for Ginseng, chromium 
was also not detected in any of the Hypoxis commercial products investigated. 
Table 14 is a tabulated assessment of the highest trace elements and heavy metals 
measured overall, for both Ginseng and Hypoxis products. 
 
Table 14. Assessment of highest element concentrations  
 Ginseng Product Cmax† Hypoxis Product Cmax† 
Mg Aspen Formula Naturelle 7.20   
K Aspen Formula Naturelle 11.74   
Ca Aspen Formula Naturelle 79.11   
Fe Aspen Formula Naturelle 7.14   
Mn   Trazure 466.10 
Li   Inkomfe 48.87 
Na Aspen Formula Naturelle 113.98 Inkomfe 3.79 
Cr     
Co Natrodale Vitality 2.34 Inkomfe 3.79 
Ni Aspen Formula Naturelle 4.47   
Cu   Inkomfe 17.44 
Zn Aspen Formula Naturelle 59.14   
Sr Aspen Formula Naturelle 99.29   
Cd   Inkomfe 0.72 
Hg Bettaway 4.14   
Pb   Inkomfe 49.82 
†Cmax are the highest concentrations in mg/g for Mg, K, Ca and Fe and in µg/g for Mn, Li, Na, Cr, Co, Ni, Cu, Zn, Sr, 
Cd, Hg, Pb measured for commercial Ginseng and Hypoxis products. 
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4.6.5 Phytopharmaceutical Enhancing Indications and Toxicity 
In the context of the recommended upper levels for selected trace elements and 
heavy metals presented in Table 14, the highest concentration in each product type 
were determined. 
Table 15 summarizes selected trace elements and heavy metals measured in 
Ginseng and Hypoxis commercial products, their phytopharmaceutical enhancing 
indications, recommended daily upper limits and potential toxic effects in humans 
due to elevated levels [154, 155]. 
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Table 15. Phytopharmaceutical enhancing indications and toxicity  
Element 
 
Phytopharmaceutical 
Enhancing Indication 
UL* Description and Toxicity 
Ca 
 
Ca relieves cough, chronic 
bronchitis, asthma, laxative, 
diuretic, cathartic, vermifuge.  
 
2.5 
g/day 
 
 
These trace metals (Ca, Na, K, Mg) are 
macronutrients and are required in relatively large 
amounts in the human diet. In high doses they may 
be toxic to the body or produce deficiencies in 
other trace metals. Excessive intake of Ca result in 
deposits in soft tissue e.g., kidneys.  
Na Na is involved in extracellular 
and intracellular fluid balance, 
and maintenance of blood 
viscosity. 
Na also relieves urinary diseases. 
2.3 
g/day Plasma Na levels above 152 mM may contribute 
to coma, paralysis of lung muscles and death. 
K K maintains homeostasis, 
influences cardiac muscle 
activity, relieves urinary 
diseases, fever, diarrhoea, cough, 
chronic bronchitis. 
4.0 
g/day Individuals suffering from kidney diseases may 
suffer adverse health effects from consuming large 
quantities of dietary potassium 
Mg Mg is essential for the 
maintenance of cells, relieves 
dropsy, piles and boils. It is a 
purgative and diuretic. 
0.350 
g/day Excessive intake of Mg leads to diarrhoea. 
Fe Immune-booster, diuretic, 
astringent, demulcent, 
antipyretic, relieves fever, 
chronic rheumatism and 
psoriasis. 
45 
mg/day Fe is an important constituent of many enzymes. Has an important role in regulating 
immunocompetence. Known symptoms of iron 
toxicity include fatigue, dizziness, nausea, 
shortness of breath, headache, vomiting weight 
loss, anorexia, and greyish skin colour. 
Cu Expectorant, gastric disorders 10 
mg/day 
Constituent of more than eleven important oxidase 
enzymes and facilitates various principle 
metabolic functions. Cu is a heavy metal and is 
toxic in its unbound form. Symptoms of toxicity 
include hyperactivity, nausea, vomiting, diarrhoea, 
fatigue and apathy. 
Zn Relieves fever, ulcer, cough, 
chronic bronchitis; increases 
biopotency towards infectious 
diseases. 
40 
mg/day 
Zn plays an important role as cofactor in several 
enzymatic reactions. High concentrations may 
precipitate stomach cramps, vomiting, nausea; skin 
irritations and anaemia may result. 
Mn Used as an astringent and to 
treat scabies, pneumonia, 
bronchitis, asthma, headache 
and spertamorrhea. 
11 
mg/day 
Mn is an essential metal. Symptoms of poisoning 
include forgetfulness and nerve damage. A 
syndrome due to Mn toxicity has symptoms 
similar to Schizophrenia, dullness, weak muscle, 
headaches and insomnia. 
*UL, upper limit 
Dietary Reference Intake (accessed 2012, July 2012). Available from http://en.wikipedia.org/wiki/Dietary_Reference_Intake  
 
4.6.6 Comparative Highest Concentration Assessment 
Table 16 illustrates the equivalent number of commercial Ginseng and Hypoxis 
product tablets or capsules that have to be consumed to achieve concentrations of 
Mg, K, Ca, Fe, Mn, Na, Cu and Zn that may potentially cause adverse events. The 
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equivalent number of tablets or capsules was derived from the highest 
concentration data summarized in Table 14 and the daily upper limit for trace 
elements and heavy metals defined in Table 15. It is particularly noteworthy from 
the results and in the context of Ginseng and Hypoxis commercial products 
investigated, for example, that at least 9 Ginseng tablets or capsules would need to 
be consumed to achieve the upper limit of 40 mg/day for iron (Fe). This is highly 
relevant since consumers can easily take higher dosages of product than 
recommended or prescribed. However, toxicity and adverse effects need to be 
carefully monitored and evaluated from the perspective of synergy among the 
product’s ingredients, i.e., their individual and combined effect(s). 
Table 16. Illustrative equivalent upper limit tablet or capsule determination 
 Highest 
concentration 
(g/g) 
Upper 
limit 
(g) 
Mean 
tablet/ 
capsule 
(g) 
Type Brand Factor Quantity 
to 
consume 
(g) 
Equivalent 
number of 
tablets or 
capsules 
Mg 0.0072 0.350 0.62 Aspen Ginseng 139 49 78 
K 0.01174 4.0 0.62 Aspen Ginseng 85 346 550 
Ca 0.07911 2.5 0.62 Aspen Ginseng 13 32 51 
Fe 0.00714 0.04 0.62 Aspen Ginseng 140 6 9 
Mn 0.0004661 0.011 0.52 Trazure Hypoxis 2145 24 46 
Na 0.00011398 2.3 0.62 Aspen Ginseng 8773 20179 32547 
Cu 0.00001744 0.01 0.58 Inkomfe Hypoxis 57339 573 992 
Zn 0.00005914 0.04 0.62 Aspen Ginseng 16909 676 1091 
4.7 Fingerprint Profiles of Ginseng and Hypoxis Products  
Using the trace element and heavy metal analysis data of the commercial Ginseng 
and Hypoxis products, comparative fingerprint plots were created using 
logarithmic concentration values. This allowed for comparative profiles of the 
complete data-set as well as an assessment of product and processing consistency.  
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All the trace elements and heavy metals assessed could be classified as 
contaminants, in the context that they were not described on the label content. 
However, certain trace elements and heavy metals, within given product sample 
batches showed consistency, being present in all replicate samples tested.  These 
elements could be used as “markers” for product and batch –to– batch consistency 
testing. 
4.7.1 Fingerprint Profile of Aspen Formula Naturelle Ginseng 
The fingerprint profile (Figure 5) was established from quadruplicate samples 
from two respective batches of Aspen Formula Naturelle Ginseng. Based on the 
criteria of ≤ 20% CV and Table 13, Mg, K, and Ca showed intra-sample 
consistency. Ca was the only trace element with acceptable inter-batch sample 
consistency. Intra-batch variability was observed for Fe, Mn, Li, Na, Co, Ni, Cu, 
Zn, Sr, Cd, and Pb. No Cr and Hg were not detected in any of the specific 
samples. 
 
Figure 5. Fingerprint profile of Aspen Formula Naturelle Ginseng 
 
4.7.2 Fingerprint Profile of Natrodale Ginseng Vitality 
The fingerprint profile (Figure 6) was established from quadruplicate samples 
from two respective batches of Natrodale Ginseng Vitality. K, Fe and Mn showed 
intra-sample consistency. K, Fe, Mn also showed inter-batch sample consistency. 
Intra-batch variability was observed for Mg, Ca, Li, Na, Cr, Co, Ni, Cu, Zn, Sr, 
Cd, Hg and Pb. No Cr and Hg were not detected in any of the specific samples. 
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Figure 6. Finger print profile of Natrodale Ginseng Vitality 
 
4.7.3 Fingerprint Profile of Bettaway Ginseng 
The fingerprint profile (Figure 7) was established from quadruplicate samples 
from two batches of Bettaway Ginseng. Pb showed intra-sample batch 
consistency. Intra-batch variability was observed for Mg, K, Ca, Mn, Li, Na, Co, 
Ni, Cu, Zn, Sr, and Cd. No Cr, Fe and Ni were detected in the specific samples. 
None of the trace elements and heavy metals assessed showed inter-batch sample 
consistency. 
 
Figure 7. Finger print profile of Bettaway Ginseng  
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4.7.4 Fingerprint Profile of Inkomfe Hypoxis 
The fingerprint profile (Figure 8) was established from six replicates from three 
respective batches of Inkomfe Hypoxis. Mg, K, Mn, Zn showed intra-sample 
batch consistency, and inter-batch sample consistency was observed for Mg and 
Mn. Intra-batch variability is observed for Ca, Fe, Li, Na, Co, Ni, Cu, Sr, and Cd. 
No Cr, Fe and Ni were detected in the specific samples.  
 
Figure 8. Fingerprint profile of Inkomfe Hypoxis 
4.7.5 Fingerprint Profile of Trazure African Potato Hypoxis 
The fingerprint profile (Figure 9) was established from quadruplicate samples 
from two respective batches of Trazure Hypoxis. Mg, K, Ca, Mn, Sr had intra-
sample batch consistency, and inter-batch sample consistency was observed for 
Mg, K, Ca, Mn and Sr. Intra-batch variability was observed for Co, Ni, Cu, Sr, 
and Cd. Li, Na, Cr, Fe and Hg were not detected in the specific samples tested.  
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Figure 9. Fingerprint profile of Trazure African Potato Hyp xis 
4.7.6 Summary of Commercial Ginseng and Hypoxis Fingerprint Plots  
None of the commercial Ginseng and Hypoxis products investigated contained Cr. 
Of the 3 Ginseng and 2 Hypoxis products, intra-batch consistency based on trace 
element and heavy metal assessment was determined for specific products. All the 
products, except the Ginseng Bettaway product, provided inter-batch sample 
consistency, based on the assessment of certain trace elements and metals. The 
trace elements and heavy metals identified for each product, could be used as 
specific markers of inter and intra batch-to-batch consistency for the specific 
products. 
4.8 Radar Plots of Ginseng and Hypoxis Commercial Products 
Using the trace element and heavy metal analysis data of the commercial Ginseng 
and Hypoxis products, comparative radar plots were constructed using logarithmic 
concentration values. Each of the batches investigated were done in duplicate. 
This allowed a visual comparative profile of the complete data set as well as a 
visual assessment of the samples (product). A reflection of the overall collective 
manufacturing process, being from starting materials to final product is also 
accomplished. The results are represented in logarithmic concentrations ranging 
from nanogram (ng) to milligram (mg) trace element or heavy metal, depicted as 
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concentric circles in the plots. Figure 10 is an enlarged sample illustration, with 
respect to Figure 11 to Figure 15 for easy reference. The inner concentric circle 
being the lower concentration, and the outer concentric circle being the higher 
concentration of respective elements. No line from the centre for a given trace 
element or heavy metal respectively implies that it was not present at detectable 
level in the product sample investigated. In the case of Figure 10 this is Li, Cr, Ni, 
and Hg. The resultant image hence represents the trace elements and heavy 
metals, that are present in the product investigated. 
 
Figure 10. Sample illustration of radar plot   
 
4.8.1 Radar Plots of Ginseng Aspen 
In Figure 11 (Aspen Formula Naturelle Ginseng), the top left graph represents a 
composite radar plot of the concentration (logarithmic scale) of the trace element 
and heavy metal analysis of all Ginseng Aspen samples tested. This plot therefore 
gives the outer limits (all inclusive) for consistency. G1a and G1b, and G2a and 
G2b are duplicate samples of different batches of the same product brand. The 
composite radar concentration maximum (Cmax) plot shows that there were no Hg 
and Cr present in the Ginseng Aspen samples tested. The duplicate representative 
radar plots of G1a and G1b, and G2a and G2b showed partial similarity, with 
respect to intra- and inter-sample batch association. There are, however, 
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indications of product inconsistency due to discrepancies in some of the samples 
for Na, Pb, Li, and Fe. This implies a lack of inter- and intra-sample homogeneity.  
 
Figure 11. Radar plots of Aspen Formula Naturelle Ginseng 
 
4.8.2 Radar Plots of Ginseng Vitality 
In Figure 12 (Ginseng Vitality), the top left graph represents a composite radar 
plot of the concentration (log scale) of the trace element and heavy metal analysis 
of all Ginseng Vitality samples tested. This plot consequently gives the outer 
limits (all inclusive) for consistency. G3a and G3b, and G4a and G4b are 
duplicate samples of different batches of the same product type. The composite 
radar concentration maximum (Cmax) plot suggests that there was no Hg, Cr, Li 
and Ni present in the Ginseng Vitality samples tested. The duplicate 
representative radar plots of G3a and G3b, and G4a and G4b showed excellent 
similarity, with respect to intra- and inter-sample batch association, except for Cu, 
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Zn and Na in some of the samples. This implies lack of inter- and intra-sample 
homogeneity.  
Figure 12. Radar plots of Ginseng Vitality 
 
4.8.3 Radar Plots of Ginseng Bettaway 
Figure 13 (Ginseng Bettaway) gives the outer limits (all inclusive) for 
consistency. G5a and G5b, and G6a and G6b are duplicate samples of different 
batches of the same product. The plot gives indicates that there was no Cr, Fe and 
Ni present in the Ginseng Bettaway samples tested. The duplicate representative 
radar plots of G5a and G5b, and G6a and G6b showed good similarity, with 
respect to intra- and inter-sample batch association, but not for some samples due 
to discrepancies in Co, Cu, Zn, Hg, Li and Na, pointing to lack of inter- and intra 
sample homogeneity.  
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Figure 13. Radar plots of Ginseng Bettaway 
 
4.8.4 Radar Plots of Hypoxis Inkomfe 
In Figure 14 (Hypoxis Inkomfe), H1a and H1b, H2a and H2b, and, H3a and H3b, 
are duplicate samples of different respective batches of the same product type. 
The plot shows that Hg and Cr were absent in the Hypoxis Inkomfe samples 
tested. The duplicate representative radar plots of H1a and H1b, and H2a and H2b 
showed excellent similarity with respect to intra- and inter-sample batch 
association. H3a and H3b showed excellent intra-sample association, and partial 
similarity to H1 and H2 samples. There are, however, sample (product) 
inconsistency with specific reference to Ni and Fe content in H3 samples. This 
points to lack of inter and intra-sample homogeneity. H1 and H2, and H3 are 
consistent in trace element and heavy metal consistency for the respective 
duplicate samples tested, yet H3 is clearly different to H1 and H2. This may be 
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indicative of potentially different raw materials and/or manufacturing processes or 
protocols, or advertent additions.  
Figure 14. Radar plots of Hypoxis Inkomfe 
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4.8.5 Radar Plots of Hypoxis Trazure 
In Figure 15 (Hypoxis Trazure), H4a and H4b, and H5a and H5b are duplicate 
samples of different batches of the same product type. The plot shows that no Hg, 
Cr, Li, Na and Fe were detected in the Hypoxis Trazure samples tested. The 
duplicate representative radar plots of H4a and H4b, and H5a and H5b showed 
excellent similarity, with respect to intra-and inter-sample batch association. Ni, 
Cu, and Pb results, point to lack of sample homogeneity.  
Figure 15. Radar plots of Hypoxis Trazure 
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4.8.6 Summary of Commercial Ginseng and Hypoxis Radar Plots  
None of the commercial Ginseng and Hypoxis products investigated in this study 
contained Cr. The deviation from pre-determined, established and maintained 
visual radar plots when investigating and/or evaluating commercial products using 
the range of trace elements and heavy metals studied, imply the following: 
variation of product raw material source, variation in manufacturing processes, 
advertent additions/deletions and/or non-compliance with established protocols 
and/or operating procedures. 
4.9 Summary of results 
The descriptive data (Table 10) for the Ginseng and Hypoxis tablet or capsule 
samples generally showed good consistency for mass, as there was no significant 
difference between samples. However, there were significant differences in mass 
in the Bettaway Ginseng product batches G5 and G6 (p= 0.042), and Inkomfe 
Hypoxis product batches H1 and H2 (p= 0.017) respectively.   
Table 11 (a, b, c) for Ginseng containing products, and Table 12 (a, b) for 
Hypoxis containing products, provide the results of two independent samples 
(Sample 1 and 2) each done in duplicate. The percentage coefficient of variation 
shows the extent of the inter-and-intra consistency for the respective trace element 
and heavy metals assessed. 
Table 13 provides a summary of Ginseng and Hypoxis products assessed with 
respect to the trace element and heavy metals that show intra-sample batch 
consistency, those that show intra-batch variability, and those that show inter-
batch sample consistency.  
Table 14 provides a comparative assessment of the highest overall element 
concentrations in the respective Ginseng and Hypoxis products. These findings  
were used  to establish Table 16, which illustrates the upper limit concentration of 
a given trace element or  heavy  metal individually that would  be accomplished 
when  consuming a given  number of tablets or capsules. These findings also 
suggest the importance of the individual effects of the elements investigated, but 
also the combined, synergistic effect that may arise. 
Further, the findings in this study show that;  (i) none of the commercial Ginseng 
and Hypoxis products investigated contained Cr, (ii) the trace elements and heavy 
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metals identified for each specific product, could be used as specific markers for 
inter and intra batch-to-batch consistency, (iii)  the Fingerprint and  Radar Plots 
can be utilized as important visual tools to assist the  process of establishing 
product quality and consistency on an ongoing basis, (iv) deviation from pre-
determined and established visual radar plots implies the following individually or 
collectively for subsequent sample batches; (a) the variation of product raw 
material source and manufacturing processes, (b) advertent additions/deletions, 
and (b) non-compliance w.r.t. protocols and/or operating procedures. 
4.10 Conclusion 
Plant-derived phytochemicals, trace elements and minerals may potentially boost 
the therapeutic efficacy of complimentary and traditional medicines in foods 
(CTMF). The large potential of the phytopharmaceutical industry in South Africa 
may be jeopardized by lack of quality control testing procedures and efficient 
product regulation. It is also important to recognize the individual or collective 
(combined or synergistic) impact of  various trace elements and heavy metals 
might have on human health and disease, particularly when use in conjunction 
with conventional drug treatment regimens.  
There are many organizations and regulatory bodies that monitor and control the 
phytopharmaceutical industry in South Africa to ensure consumer confidence and 
satisfaction, including the Direct Selling Association and Health Products 
Association. Validation processes that are key to ensuring the quality, safety and 
efficacy of natural products include Standard Operating Procedures (SOPs) for 
Good Agricultural Practice (GAP), Good Laboratory Practice (GLP), Good 
Supply Practice (GSP) and Good Manufacturing Practices (GMP). The 
aforementioned principles and fundamentals need to be established, implemented, 
regulated and monitored. The findings in this study reveal the need for such 
measures to be instituted.  
The social and methodological contexts of this study are based on what is 
currently relevant in terms of the commercialization of Ginseng and Hypoxis 
supplement products, based on African traditional belief, anecdotal claims and 
absence of scientific evidence, for use as adaptogens, the treatment of HIV/AIDS 
as well as “all cure” for common ailments and other serious diseases.  
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This study emphasizes that prudent and novel approaches are necessary to ensure 
that commercially available nutritional supplement products comply with standard 
safety and efficacy requirements.  
It further suggests that constituents such as trace elements and minerals, along 
with other constituents in supplement products, should have unique “fingerprints” 
and visual radar plot profiles to ensure GAP, GMP and GSP, in the interest of 
consumer safety and satisfaction. 
 It also emerged from this study that deviations from the initial pre-determined 
“fingerprint” levels and visual radar plots are reliable indicators to judge overall 
product quality and consistency, or lack thereof. Such analyses are imperative in 
the supplement industry.  
That radar plots might be more accepting to consumers than written text on labels 
to assess quality, and could provide a vehicle for education, awareness, advocacy, 
research and enforcement, and for the manufacture will help in the process of 
ensuring continuous quality. These two aspects, (i) consumer driven requirement, 
and (ii) manufacturer requirement, will see that label design and content 
presentation of supplement products, will be presented differently to how 
information is currently provided.       
 
4.11 Limitations and opportunities  
 
o The current trace metal and heavy metal assessment was developed as a 
proof of concept, using Ginseng and Hypoxis based products. 
o Further investigation for the presence of trace elements and heavy metals 
that were not consistently present in all of the Ginseng and Hypoxis, 
product requires replicate testing. 
o In future studies the trace element and heavy metal method and application 
needs to be applied to nutritional supplement products to determine and 
evaluate product batch-to-batch consistency. 
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Chapter 5 
Steroid and Stimulant Analysis 
Experimental Study 
 
5.1 Introduction 
This chapter will describe the experimental approach in the context of steroids, 
stimulants and other compounds (drugs) of interest that may also be present in 
nutritional supplement products. Drug abuse in sport is often called doping. There 
are several suggestions explaining the different origins of the term “doping”. For 
example, the term may be derived from; 
(i) the Dutch word “doop” which means “Christian baptism” [157],  
(ii)  the Dutch word "doop" as a thick dipping sauce that entered American 
slang to describe how robbers stupefied victims by mixing tobacco with 
the seeds of Datura stramonium [158],  
(iii)  from the Dutch word dop [159], 
(v)  a viscous opium juice, being the drug of choice of the ancient Greeks 
[160], 
(vi) the name of an alcoholic beverage made from grape skins used by Zulu 
warriors to enhance their prowess in battle [159], 
(v)  an alcoholic drink used as a stimulant in ceremonial dances in 18th century 
Southern Africa [158], 
(vi) the preparation of a thick viscous preparation of opium for smoking, and 
during the 1890s this extended to any stupefying narcotic drug [158],  
(vii)  dope, which was a word in the 1990’s to describe "a preparation of drugs 
designed to influence a racehorse's performance" [158]. 
 
The use of nutritional supplements by professional sportspersons, and serious and 
recreational participants in sport and physical activity is widespread [161]. This 
can partially be attributed to the ease with which supplements can be obtained. 
This has increased the temptation for the professional sportsperson, “weekend 
warriors”, and consumers to experiment with supplements [161].   
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“Supplement doping” may be rife at the local and international level based  on 
evidence in a study showing  the  presence of small amounts of 19-nor-4-
androstenedione, 4-androsten-3,17-dione, and another study showing  the presence 
of prohibited anabolic  androgenic steroids (prohormones) not declared on the 
label  [76,162].  This type of doping is defined as the process whereby the 
supplement, contains ergogenic substances in addition to those substances which 
are described on the label. The addition of the ergogenic substance to the 
supplement may be intentional or inadvertent. An example of intentional doping is 
where a manufacturer deliberately adds a given anabolic steroid or stimulant, that 
is banned by the World Anti-doping agency (WADA), to the nutritional 
supplement without declaring this on the label. A professional athlete, who 
consumes the contaminated nutritional supplement product, could thus test 
“positive” if tested by anti-doping agency controls [35]. 
 
 An example of inadvertent doping is where a manufacture is not aware of the 
steroid product contamination, due to lack of screen testing procedures and also 
specifically when ingredients of animal origin are used for the product, hormones, 
such as testosterone, may  be present [35]. This may occur when raw materials are 
sourced from alternative suppliers or, where there are no or inadequate quality 
control procedures [35].  Using such a supplement may result in a “positive” drug 
test for the athlete if the added substance is on the banned list as defined by 
WADA [163]. 
 
Therefore, as described previously (Chapter 4), it is important to have measures 
for  detection in place that will screen products for contaminants and consistency.  
Furthermore, to guard against “supplement doping” it is also important to screen 
nutritional supplements for prohibited steroids, stimulants and other compounds to 
ensure quality, clean and safe nutritional supplement products. The next section 
will present a review of the literature consisting of (i) drugs in supplements and 
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drug effects on performance and behaviour, (ii) analytical methods, and (iii) a 
summary of the experimental study. 
5.2 The Scientific Literature 
5.2.1 Drugs in supplements 
WADA publishes an annual list of substances and practices prohibited at all time, 
in and out of competition. The original aim was to only list doping agents (drugs) 
known or suspected of improving performance in sports. However, the list is now 
defined by other reasons, such as the substance affecting the safety of athletes, 
being socially unacceptable, or attempting to mask the presence of a banned 
substance [164-166]. Reviews on the use of doping agents in sport and society 
have concluded that these agents, particularly anabolic androgenic steroids (AAS), 
are used widely [78,164,167].  
 
There is evidence that in the USA, between 1 million and 3 million people have 
used AAS [167]. In Sweden the estimate is that 50 000-100 000 people among a 
population of 9 million have used AAS [164]. Further, a questionnaire 
investigation of 6000 Swedish people age 16-17 years revealed that 3.2% of males 
had used AAS [164].  A German study assessed the use of AAS among visitors to 
fitness centres by use of anonymous questionnaires. Fourteen percent reported that 
they had used AAS previously, of which four percent were women. Similar results 
for women were found in Great Britain and the USA [164].   
 
There is a strong likelihood that some of the positive doping tests that have been 
reported may be as a result of inadvertent doping due to the athlete ingesting a 
prohibited substance that was present, but not stated, in a nutritional supplement 
product. An example would be an athlete testing positive for the steroid 
nandrolone as a result of inadvertent intake via a contaminated supplement 
[168,169]. In addition to the anabolic steroids other steroid products have 
appeared on the market that have never been marketed as approved drugs. An 
example would be numerous xenobiotic compounds that have been derived from 
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testosterone with the aim that the modification reduces androgenic properties 
while maintaining the anabolic potential. These products have been withdrawn 
from the legal market, but have been found to have been added to otherwise 
inefficient nutritional supplements [170]. 
 
Further, scientific investigations and developments since 1980s have highlighted 
the need for a well-balanced and well-controlled diet to optimise sports 
performance [215].  Although nutritionists and dieticians usually recommend 
whole food solutions to these and other problems first, some are starting to accept 
the use of supplements as an adjunct to nutrition [172,215].  However the 
marketing strategies of nutritional supplement manufacturers ensure that 
supplements are frequently presented as ergogenic aids. This means that 
supplements are intended to improve, or at least support performance in several 
aspects of physical activity [173,215]. Thus some may argue that using nutritional 
supplements, and particularly if these are contaminated with banned substances, 
may create or stimulate a doping "attitude" among consumers of these products. 
 
5.2.2 Drug Effects on Performance and Behaviour 
Table 17 represents examples of some drugs which may be included in nutritional 
supplement products. These drugs may be on the WADA prohibited list and may 
result in a “positive” doping test. More detailed description of each drug can be 
found in the references provided. 
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Table 17. Illustration of drugs that could be included advertently or inadvertently 
in nutritional supplements 
Drug or Drug 
Combination 
Drug Indication and Effects Reference 
Caffeine • xanthine alkaloid that acts as a stimulant  
• increases lipolysis 
• no longer on WADA prohibited list.  
• the dose and frequency of consumption of products 
containing caffeine may have an effect on the metabolism 
and elimination of caffeine and other chemical moieties.  
117,174-177 
Anabolic-androgenic steroids 
(AAS) 
• has the potential to alter myocardial textural parameters. 
• have anti-catabolic effect, used to increase muscle mass 
and strength 
178,179 
Cocaine • is a stimulant of the central nervous system, an appetite 
suppressant. 
• use of such drugs on a daily basis can produce a clear, 
significant decrease in simple reaction times. 
• use is also associated with acute and chronic 
cardiovascular diseases. 
180-182 
Synephrine (Oxedrine), 
Octopamine, Tyramine, 
(sympathommimetic amines) 
and Caffeine, with  
 St John’s wort   
• is a drug combination with a traditional medicine 
supplement. 
• use has been associated with the cause of acute myocardial 
infarction. 
183 
Testosterone • is the principal male sex hormone biosynthesized from 
cholesterol.  
• phase 1 metabolism employs specific enzymes and 
pathways.  
• phase II metabolism and excretion follow more general 
patterns. 
• the effect is twofold: anabolic effect and androgenic 
(endogenous nature). 
184 
Amphetamines • used in sports, which are characterised by short duration 
high intensity exercise, with the goal of delaying the onset 
of fatigue.   
• is addictive, and chronic abuse causes behavioural change 
and sometimes psychosis. 
• the mechanism of action is believed to be the relaxation of 
smooth muscles via the inhibition of cyclic guanosine 
monophosphate (GMP). 
42,185,186 
Sidenafil • used for the treatment of erectile dysfunction. 
• at low dosage, the drug may be misconstrued to be safe 
hence the potential to be experimented with for improving 
sport or exercise performance. 
• it is believed the mechanism is the relaxation of smooth 
muscles via the inhibition of cyclic guanosine 
monophosphate (GMP). 
187 
Ephedrine and Ephedra • ephedrine is classified as a sympathomimetic drug, and 
central nervous system stimulant, 
• ability to act as agonist and increase thermogenesis and to 
reduce fatigue and increase alertness. 
• used for weight-management or enhanced athletic 
performance, 
• the efficacy and safety of these compounds are uncertain  
• enhanced effectiveness is also coupled with both caffeine 
and aspirin. Ephedrine stimulates the synthesis of 
prostaglandins and serves as a prostaglandin blocker, and 
thereby may prevent inhibition of norepinepherine release  
188-192 
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5.3 Analytical Methods 
Laboratory testing and/or screening methods for drugs require analytical 
techniques and methods that can accomplish the desired multiple chemical 
compound (drug) separation, selectivity, and sensitivity with appropriate detection 
capability. Studies where the established analytical techniques of High 
Performance Liquid Chromatography (HPLC), Gas Chromatography-Mass 
Spectrometry (GC-MS), and Liquid Chromatography-Tandem Mass Spectrometry 
(LC-MS/MS) have been utilized for drug analysis are presented below.  
 
5.3.1 High Performance Liquid Chromatography (HPLC) 
Various High Performance Liquid Chromatography methods have been 
developed, to measure, as examples, iron chelators, drugs and metabolites in 
serum, urine and skin. The measurement is through ultraviolet (UV), florescence, 
or electrochemical detection [193-199]. Other published methods have also been 
developed for the quantification of ephedrines, and antiretrovirals using High 
Performance Liquid Chromatography [22, 200-203]. Useful methods have also 
been developed using preparative techniques measuring drugs from dried blood 
spots, prior to analysis by liquid chromatography [204]. 
  
5.3.2 Gas Chromatography-Mass Spectrometry (GC-MS) 
Conventional testing for anabolic steroids has been done using the analytical 
method Gas Chromatography coupled with Mass Spectrometry [161]. For 
example, a review paper explaining the determination of Cannabinoids in 
biological samples, gave special attention to blood and alternative matrices like 
hair, saliva, sweat and meconium, using Gas Chromatography and Liquid 
Chromatographic procedures with mass spectrometry or dioarray detection [205]. 
Gas Chromatography with tandem mass spectrometry has also been used to detect 
and quantify strychnine in body fluids and tissues [206]. Other techniques in this 
category include isotope dilution tandem mass spectrometry to improve detection 
of compounds of interest [207-209, 228].  
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5.3.3 Liquid Chromatography-Tandem Mass Spectrometry (LC-
MS/MS) 
LC-MS/MS advancement has enabled a more sensitive assay. This has 
subsequently provided an alternative analytical method to measure low levels of 
testosterone (e.g. at the low concentrations in women and children), that could 
previously not be detected and measured reliably by immunoassays methods 
[210]. 
Recent proteomics in mass spectrometry has enabled systematic analysis of 
cellular components in the ubiquitin pathway [211]. Matrix effects should also be 
taken in consideration when developing screening or validated methods for LC-
MS/MS [212-214]. The analytical techniques  as presented (5.3.1-5.3.3) have 
evolved  from  the use of  HPLC  with various  drug  detection  systems, to more 
advanced  combination analytical  techniques of GC-MS and that  of  LC- 
MS/MS. In these  techniques  the mass  spectrophotometer (MS)  is  used  as  the  
drug  detection  tool on it’s own or to enhance specific drug detection  using 
tandem combination techniques as in MS/MS [167,213,228]. 
  
5.4 Summary  
The use of nutritional supplements has become widespread due to marketing and 
ease of availability of these products [161]. Supplements were initially used as an 
adjunct to nutrition, but more recently are being used to promote physical 
performance through their purported ergogenic properties [173,215]. Nutritional 
supplements may also contain steroids and stimulants. These may be included 
intentionally by the manufacturers, without any claims on the label, or 
inadvertently as a result of contamination. Concern about the efficacy and safety 
has been raised by the medical fraternity about the misuse of anabolic androgenic 
steroids (AAS) [78,164,167]. 
 
It is thus important to have detectable measures that can test nutritional 
supplements with specific reference to prohibited steroids and stimulants. 
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Analytical assay methods, which could serve this purpose, have evolved over 
time. Such analytical methods include HPLC, GC-MS, LC-MS to LC-MS/MS for 
various specific applications to achieve desired drug compound separation, 
selectivity, sensitivity and detection that require investigation [161,200,204, 207, 
210, 216]. The analytical instrument technique used for this study was the 
analytical tool of LC-MS/MS [214].  
 
5.5 Methodology  
The analytical technique of Liquid Chromatography-Mass Spectrometry (LC-
MS/MS) was used in this study to achieve the aim and objectives described in 
Chapter 1.This technique was selected because it offers the desired multiple 
chemical compound (drug) separation, selectivity, and sensitivity with appropriate 
detection capability. The methodology described below covers, (i) the steroids, 
stimulants, other compounds investigated in this study, and (ii) the analytical assay 
methodology for steroids, stimulants, and other selected compounds, using Liquid 
Chromatography-Mass Spectrometry (LC-MS/MS), and (iii) Nutritional 
supplement products purchase process.  
 
The first consideration for the selection of compounds investigated in the study 
(Table 18, 19, 20) was whether they were discussed in the literature and deemed 
important. Thereafter compounds were considered if the reference compounds 
required for their analysis could be purchased and imported into South Africa, 
with the required inter-goverment written permission.  
 
5.5.1 Steroid, Stimulants, and Other Compounds Investigated  
Table 18 reflects the name, molecular formula, molecular weight, and chemical 
structure of steroids which fulfilled the selection criteria and which were 
investigated in this study.  
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Table 18. Steroids investigated 
Code Steroids Molecular 
Formula 
Molecular 
Weight 
(g/mol) 
Chemical 
Structure 
S1 17α-19 Nor testosterone C18H26O2 274.3 
 
S2 Nandrolone C18H26O2 274.3 
 
S3 17α-Testosterone C19H28O2 288.4 
 
S4 17β-Testosterone C19H28O2 288.4 
 
S5 19-Nor-4-androstene-3β, 17β- diol C18H28O2 276.4 Similar to S2 
S6 19-Nor-5-androstene-3β, 17β- diol C18H28O2 276.4 Similar to S2 
S7 19-Nor-5-androstene-3,17 dione C18H28O2 272.4 Similar to S2 
S8 4- Androstene-3β,17β- diol C19H30O2 290.4 
 
S9 5- Androstene-3β,17β- diol 19H30O2 290.4 
 
S10 4- Androstene-3,17-dione (AED) C19H26O2 286.4 Similar to S4 
S11 1,4-androstediendione (ADD) C19H24O2 284.4 Similar to S2 
S12 1-Androstedione C19H26O2 286.4 Similar to S2 
S13 1-Testosterone C19H28O2 288.4 
 
S14 DHEA- Dehydroepiandrosterone C19H28O2 288.4 
 
S15 Epiandrosterone C19H30O2 290.4 
 
S16 Methyl- Boldenone C20H28O2 300.4 
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Table 19 reflects the name, molecular formula, molecular weight, and chemical 
structure of the stimulants investigated.  
 
 
 
Table 19. Stimulants investigated 
 
Code Stimulants Molecular 
Formula 
Molecular 
Weight 
(g/mol) 
Chemical 
Structure 
T2 Methyl – amphetamine 
Commonly known as 
methamphetamine 
IUPAC 
N-methyl-1-phenyl-propan-2-
amine 
C10H15N 
 
149.2 
 
 
 
T5 Ephedrine  
IUPAC 
2-methylamino-1-phenyl-
propan-1-ol 
 
C10H15NO 
 
165.2  
 
T10 Caffeine  
IUPAC 
1,3,7-trimethylpurine-2,6-dione 
C8H10N4O2 
 
194.2  
 
T13 Fenfluramine  
IUPAC 
N-ethyl-1-[3-
(trifluoromethyl)phenyl]-
propan-2-amine 
 
C12H16F3N 
 
231.2 
 
T14 
 
 
 
 
 
 
 
 
Synephrine  
IUPAC 
4-(1-hydroxy-2-methylamino-
ethyl)phenol 
C9H13NO2
 
167.2 
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Table 20 reflects the name, molecular formula, molecular weight, and chemical 
structure of other compounds of interest investigated in this study. 
 
Table 20. Other compounds of interest investigated 
Code Other compounds of 
interest 
Formula Molecular 
Weight 
(g/mol) 
Chemical 
Structure 
O2. Melamine 
IUPAC 
1,3,5-triazine-2,4,6-triamine 
C3H6N6 126.1  
 
O3. Methaqualone 
IUPAC 
'2-methyl-3-o-tolyl-4(3H)-
quinazolinone; 
3,4-dihydro-2-methyl-4-oxo-3-
o-tolylquinazoline; 
2-methyl-3-(2-methylphenyl)-
4-(3H)-quinazolinone 
C16H14N2O 250.30  
 
O4. Prozac (Fluoxetine) 
IUPAC 
N-methyl-3-phenyl-3-[4-
(trifluoromethyl)phenoxy]propa
n-1-amine 
 
C17H18F3NO 309.3  
 
 
 
5.6 Acquisition of Reference Standards and Permits 
Steroid reference standards were purchased from Steraloids Incorporated, United 
States of America, after gaining the necessary import permit authorisation from 
the South African Government Department of Health (Appendix 6). Stimulants 
and other reference compounds were purchased from Sigma-Aldrich (Germany).  
 
5.7 Chemical Reference Standard Preparations 
Primary standards of the respective steroids, stimulants, and other compounds of 
interest, were prepared by recording the required weight (to 5 decimal positions) 
on a Sartorius analytical research electronic balance (R200D). The respective 
weighed samples were then reconstituted in ethanol for a concentration of 1000 
µg/ml, for each of the compounds.  
 
These primary standards were used to prepare secondary standards which were 
required to optimize the LC-MS/MS assay methodology. The concentration used 
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for the infusion optimization, through the mass spectrometer source was 
approximately 300 ng/ml of each of the respective steroids, stimulants and other 
compounds investigated, individually. 
5.8 Liquid Chromatography-Mass Spectrometry Methodology 
The South African National Accreditation System (SANAS) accredited laboratory 
and research support infrastructure in the Division of Clinical Pharmacology – 
University of Cape Town was used for the investigation of the steroids, stimulants 
and other compounds of interest in the nutritional supplements.  The analytical 
instrumentation technique of Liquid Chromatography-Mass Spectrometers (LC-
MS/MS) was used for the steroid, stimulant, and other compounds of interest 
investigated. All the experimental work and instrument data capture processing 
and integration was done by the principal investigator.   
 
In the schematic below (Figure 16) the LC-MS/MS is comprised of a Liquid 
Chromatography component starting on the far left. This is interfaced into the 
source component of the Mass Spectrometer that is assembled alongside Quad 1, 
Quad 2 and Quad 3, with addi ional components in between, and a detector system 
to the far right.  The quadropoles (quads) consist of four parallel rods (poles)   that 
are equally spaced around a central axis.  The principle of operation is that ions 
are introduced along the axis of the poles. By applying precisely controlled 
voltages (radio frequency and direct current to opposing sets of poles) a “mass 
filter” is created. Further, by ramping the voltage on each set of poles a complete   
range of masses can be passed to the detector.  Only ions with a particular mass-
to-charge ratio will pass through the filter to be detected at a particular applied 
voltage.  
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Figure 16. Schematic diagram of a triple-quad LC-MS/MS instrument (Source 
Applied Biosystems - www.appliedbiosystems.com) 
  
5.9 Mass Spectrometry 
A sensitive and selective LC- MS/MS assay method was developed to analyze for 
each of the respective steroids, stimulants, and other compounds of interest as 
stated in Tables 18, 19 and 20. The approach was to optimize (via infusion) the 
analytical   instrumentation to detect on the Applied   Biosystems Sciex API 3200 
mass spectrometer for the respective steroids, stimulants and other compounds of 
interest. 
 
The settings  on the Agilent  LC 1200 Binary Pump Method were; the minimum 
pressure (psi) 0.0, maximum pressure (psi) 5801.0, the dead volume (µl) 40.0, 
maximum flow ramp (ml/min2) 100.0, maximum pressure  ramp (psi/s) 290.0.  
 
The settings on the MS/MS component of the instrument is summarized in Table 
21, 23, and 24, and a representative Q1 (MS) and Q3 (MS/MS) spectra are 
presented in Figure 17-27.  
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Table 21. Electronspray ionization settings 
 
 
Steroids Stimulants Other  
Compounds 
Curtain Gas (CUR) 20 20 20 
Collision  Gas (CAD) 5 5 5 
Ion spray  voltage (IS) 5500 5500 5500 
Source temperature (TEMP) 400 475 475 
Gas 1 (psi) (GS1) 50 50 50 
Gas 2 (psi) (GS2) 60 60 60 
Inter Heater (ihe) On On On 
 
For the MS/MS the scan type for steroids, stimulants, and other compounds was 
MRM, the polarity was in the positive mode, and the pause time was 5 
milliseconds (ms) for the steroids, and 5 ms for stimulants, with a total run time of 
3.0 minutes for steroids and 8 minutes for stimulants. The MS/MS 
instrumentation parameters for the steroids are reflected in Table 22, for 
stimulants in Table 23 and for other compounds of interest Table 24. 
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Table 22. MS/MS instrumentation parameters for the steroids 
Co
de
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n
tia
l (C
XP
)  (
Vo
lts
) 
S1 17α-19 Nor testosterone 275.2 109.1 50 56 4.5 16 39 4.0 
S2 Nandrolone 275.2 81.0 50 56 4.5 14 39 4.0 
S3 17α-Testosterone 289.2 109.1 50 61 4.5 20 35 4.0 
S4 17β-Testosterone 289.2 109.2 50 66 4.5 16 37 4.0 
S5 19-Nor-4-androstene-3β, 17β- diol 277.0 216.8 50 51 4.0 14 21 4.0 
S6 19-Nor-5-androstene-3β, 17β- diol 277.0 217.0 50 51 4.5 14 21 2.0 
S7 19-Nor-5-androstene-3,17 dione 273.2 109.0 50 41 7.0 24 35 4.0 
S8 4- Androstene-3β,17β- diol 293.0 137.0 50 41 5.0 18 35 4.0 
S9 5- Androstene-3β,17β- diol 293.0 137.0 50 46 7.0 16 35 4.0 
S10 4- Androstene-3,17-dione (AED) 287.2 97.1 50 51 7.0 16 31 4.0 
S11 1,4-androstediendione (ADD) 285.2 121.1 50 41 11.0 20 29 4.0 
S12 1-Androstedione 287.2 121.1 50 41 4.5 14 29 4.0 
S13 1-Testosterone 289.2 109.1 50 51 4.0 24 35 4.0 
S14 DHEA- Dehydroepiandrosterone 289.2 253.1 50 31 9.0 16 17 6.0 
S15 Epiandrosterone 273.2 161.1 50 56 4.5 16 25 4.0 
S16 Methyl- Boldenone 301.3 121.1 50 36 4.5 18 33 4.0 
* an explanation of the coding is shown in Table 18 
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Table 23. MS/MS instrumentation parameters for the stimulants 
Co
de
 
 St
im
u
la
n
ts
 
Q1
 
m
a
ss
 
 
[M
 
+
H
]+  
Q3
 
m
a
ss
 
D
we
ll 
tim
e 
(m
s) 
D
ec
lu
st
e
rin
g 
 
po
te
n
tia
l (D
P)
 
(V
o
lts
) 
En
tra
n
ce
 
po
te
n
tia
l (E
P)
 
(V
o
lts
) 
Co
llis
io
n
 
ce
ll 
en
tra
n
ce
 
 
po
te
n
tia
l  
(C
EP
) (
Vo
lts
) 
Co
llis
io
n
 
en
er
gy
 
(C
E)
 
 
(V
o
lts
) 
Co
llis
io
n
 
 
ce
ll 
ex
it 
 
po
te
n
tia
l (C
XP
)  (
Vo
lts
) 
T5 Ephedrine 166.2 133.1 150 21 3.5 12 29 4 
T6 Ephedrine 166.2 133.1 150 21 5.0 12 27 4 
T10 Caffeine 195.1 138.1 150 51 5.0 12 27 4 
T14 Synephrine 168.2 135.0 150 16 3.0 10 27 4 
T2 Methyl – amphetamine 150.2 91.1 150 26 4.0 10 27 4 
T2 Methyl – amphetamine 150.2 119.0 150 26 4.0 10 15 4 
T13 Fenfluramine 232.2 159.1 150 36 5.5 14 31 4 
T13 Fenfluramine 232.2 109.1 150 36 5.5 14 55 4 
* an explanation of the coding is shown in Table 19 
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Table 24. Other compounds of interest 
Co
de
 
  Q1
 
m
a
ss
 
 
[M
 
+
H
]+  
Q3
 
m
a
ss
 
D
we
ll 
tim
e 
(m
s) 
D
ec
lu
st
e
rin
g 
 
po
te
n
tia
l (D
P)
 
(V
o
lts
) 
En
tra
n
ce
 
po
te
n
tia
l (E
P)
 
(V
o
lts
) 
Co
llis
io
n
 
ce
ll 
en
tra
n
ce
 
 
po
te
n
tia
l  
(C
EP
) (
Vo
lts
) 
Co
llis
io
n
 
en
er
gy
 
(C
E)
 
 
(V
o
lts
) 
Co
llis
io
n
 
 
ce
ll 
ex
it 
 
po
te
n
tia
l (C
XP
)  (
Vo
lts
) 
O2 Melamine 127.1 68.1 150 41 9.5 10 37 4 
O3 Methaqualone 251.2 132.1 150 61 5.5 16 37 4 
O3 Methaqualone 251.2 91.0 150 61 6.5 16 53 4 
O4 Prozac (Fluoxetine) 310.2 148.0 150 26 6.5 14 13 4 
O4 Prozac (Fluoxetine) 310.2 117.2 150 26 6.5 14 69 4 
* an explanation of the coding is shown in Table 20 
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Figures 17–22 below represents Q1 and Q3   MS/MS spectra of selected   steroids 
Nandrolone, Testosterone, Androstene, DHEA, Epiandrosterone and Methyl- 
Boldenone.  For figures 17-27 the vertical (Y) axis has the measure of intensity 
(cps), and the horizontal (X) axis the m/z (amu). The display is to provide an 
illustration of MS/MS specific Q1 and Q3, respectively. 
 
Figure 17. Representative Q1 and Q3 Spectra of steroid Nandrolone 
 
 
Figure 18. Representative Q1 and Q3 Spectra of steroid 17 ß - Testosterone 
 
 
Figure 19. Representative Q1 and Q3 Spectra of steroid 5 Androstene-3ß,17 ß – 
diol 
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Figure 20. Representative Q1 and Q3 Spectra of steroid DHEA  
 
 
 
Figure 21. Representative Q1 and Q3 Spectra of steroid Epiandrosterone 
 
 
 
Figure 22. Representative Q1 and Q3 Spectra of steroid Methyl- Boldenone 
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Figures 23-27 below are representative Q1 and Q3 MS/MS spectra of selected   
stimulants, Ephedrine, Caffeine, Synephrine, Nor-ephedrine, pseudo-ephedrine. 
 
 
Figure 23. Representative Q1 and Q3 Spectra of stimulant Ephedrine  
  
 
Figure 24. Representative Q1 and Q3 Spectra of stimulant Caffeine  
 
 
Figure 25. Representative Q1 and Q3 Spectra of stimulant Synephrine 
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 +MS2 (166.18) CE (50): 26 MCA scans from Sample 1 (TuneSampleName) of S5_InitProduct_Pos.wiff (Turbo Spray) Max. 3.7e5 cps.
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Q
 +Q1: 0.235 min from Sample 1 (TuneSampleID) of MT20081203145650.wiff (Turbo Spray) Max. 1.1e6 cps.
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 +MS2 (195.13) CE (50): 26 MCA scans from Sample 1 (TuneSampleName) of S10_InitProduct_Pos.wiff (Turbo Spray) Max. 1.6e6 cps.
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194.2 g/mol 
 +Q1: 0.687 min from Sample 1 (TuneSampleID) of MT20081203150327.wiff (Turbo Spray) Max. 7.7e5 cps.
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 +MS2 (168.19) CE (50): 26 MCA scans from Sample 1 (TuneSampleName) of S14_InitProduct_Pos.wiff (Turbo Spray) Max. 7.5e5 cps.
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Figure 26. Representative Q1 and Q3 Spectra of stimulant Nor-ephedrine 
 
 
 
Figure 27. Representative Q1 and Q3 Spectra of stimulant Pseudo-ephedrine 
 
The Chromatography method utilized prior to MS/MS detection, was performed   
using an Agilent 1200 series HPLC with a Phenomenex Gemini C18 NX (5µm, 
110A, 50x2 mm) analytical column. The mobile phase consisted of Acetonitrile: 
0.1% Formic acid (1:1, v/v) and was delivered at a constant flow rate of 0.5 
ml/min.  The column was kept in a column compartment at 35 °C [19, 78].   
 
An autosampler injected 5 µl of sample onto the HPLC column.  The injection 
needle was rinsed with mobile phase before each injection for 10 seconds using 
the flush port wash station.  The samples were cooled to 5 °C while awaiting 
injection.  
 
 
 
 
 
 +Q1: 0.101 min from Sample 1 (TuneSampleID) of MT20081212153047.wiff (Turbo Spray) Max. 9.6e5 cps.
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 +MS2 (152.16) CE (50): 26 MCA scans from Sample 1 (TuneSampleName) of 3_InitProduct_Pos.wiff (Turbo Spray) Max. 5.8e5 cps.
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151.2 g/mol 
 +Q1: 0.587 min from Sample 1 (TuneSampleID) of MT20081203145046.wiff (Turbo Spray) Max. 1.8e6 cps.
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 +MS2 (166.18) CE (50): 26 MCA scans from Sample 1 (TuneSampleName) of S6_InitProduct_Pos.wiff (Turbo Spray) Max. 1.9e6 cps.
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5.10 Chromatographs 
Figures 28-31 below are representative chromatographs of selected steroids, 
stimulants and other compounds of interest at 125 ng/ml, and 5 µl and 20 µl 
injection volumes respectively.  The vertical axis represents the arbitrary intensity 
values and the horizontal axis the retention time in minutes of respective 
chromatographic compounds. 
Figure 28. Steroid chromatograph at 125 ng/ml (5µl injection) 
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Figure 29. Steroid chromatograph at 125 ng/ml (20 µl injection) 
 
Figure 30. Stimulants, (and other) chromatograph at 125 ng/ml (5 µl injection) 
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Figure 31. Stimulants, (and other) chromatograph at 125 ng/ml (20 µl injection) 
 
5.11 Serial Dilution to Establish Calibration Curves  
Figures 32-35 below are representative calibration curves of selected steroids, 
stimulants and other compounds of interest.  The calibration range was established 
as a combined mixture of the investigated steroids and stimulants and other 
compounds of interest. Serial dilution using a  prepared mixture of 
acetonitrile:0.1% formic acid (1:1) t  establish concentrations starting from 1000 
ng/ml to 1.953 ng/ml  to establish  the ng/ml range 1000, 500, 250, 125, 62.5, 
31.25, 15.63, 7.81, 3.91, 1.95. 
 
The calibration  analysis (primary  and secondary stocks) was verified  by repeat 
analysis in  three  cycles at  both  5 µl and 20 µl, respectively  to determine  which  
volume would  provide  best results for the  HPLC column  configuration.     
 
These primary and secondary stocks were stored in freezers at – 80 oC, and used in 
the sample batch analysis to serve as a system test, and establish calibration curves 
to determine estimation concentration in nutritional supplements.  
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24032010 A_1st peak.rdb (A): "Quadratic" Regression ("1 / x" weighting): y = -0.0968 x 2^ + 522 x + -131 (r = 0.9998)
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Figure 32. Calibration curve of steroid Testosterone 275.2/109.1 amu (n=3) 
 
18032010.rdb (150): "Quadratic" Regression ("1 / x" weighting): y = -2.2 x^ 2 + 7.82e+003 x + 1.11e+004 (r = 0.9947)
0 50 100 150 200 250 300 350 400 450 500 550 600 650 700 750 800 850 900 950 1000
Concentration, ng/mL
0.0
5.0e5
1.0e6
1.5e6
2.0e6
2.5e6
3.0e6
3.5e6
4.0e6
4.5e6
5.0e6
5.5e6
6.0e6
6.5e6
 
Figure 33. Calibration curve of stimulant Fenfluramine 232.2/159.1 amu (n=3) 
 
r = 0.9998 
r = 0.9947 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 5 Steroid and Stimulant Analysis  
 
106
106
18032010.rdb (127): "Quadratic" Regression ("1 / x" weighting): y = -0.00424 x^2 + 18.3 x + 256 (r = 0.9881)
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Figure 34. Calibration curve of Melamine 127.1/68.1 amu (n=3) 
 
18032010.rdb (251): "Quadratic" Regression ("1 / x" weighting): y = -1.71 x^2 + 8.15e+003 x + -612 (r = 0.9991)
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Figure 35. Calibration curve of Methaqualone 251.2/132.1 amu (n=3) 
 
5.12 Nutritional Supplement Product Acquisition and Processing  
The sample consisted of 138 nutritional supplements obtained from; 
1. The returned questionnaire survey information based on 128 returned 
questionnaires from elite athletes (independent to this thesis) (unpublished 
research). Popular  nutritional  supplement brands  that were consumed  by 
r = 0.9881 
r = 0.9991 
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the study cohort  assisted  the  process of sample acquisition as presented  
in  point 2 below.  
2. Direct purchases from shops, pharmacies and outlets which sold nutritional 
supplements. These supplements were either manufactured or assembled 
locally or were internationally imported brands.  (n = 82) 
3. The users of nutritional supplements. The samples were solicited through 
an active marketing campaign.  (n = 41) 
4. Suppliers, manufacturers and distributors of nutritional supplement 
products, and who were willing to supply nutritional supplement sample 
products for the research study. (n =15) 
 
5.13 Nutritional Supplement Sample Storage and Management 
 
Samples (n = 138) were stored in the dark, at ambient temperature in glass vials or 
as provided in the original product container, and appropriately labelled. For  the  
nutritional supplement database register the  following  information  was  captured 
for record keeping and  management of samples for laboratory  analysis; (i) date 
when product/sample  was obtained, (ii) provider of  product/sample, (iii)  contact 
details, (iv) product  name, (v) product  batch number,  if  available, (vi) other 
information that would  be relevant to the product, and (vii) product study code. 
 
5.14 Supplement sample formulation  
 
Table 25 provides the breakdown of the 138 supplement samples tested. 
Supplements in the form of powders were the most common samples (39%).  
 
 
Table 25. Nutritional supplement formulation types 
Code Type n % 
P Powder 54 39 
P/T Tablet ground to powder 42 30 
P/C Powder in capsule 30 22 
L/C Liquid in capsule   8 6 
L Liquid   4 3 
Total   138 100 
 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 5 Steroid and Stimulant Analysis  
 
108
108
 
5.15 Sample Preparation for Assay Analysis for Steroids,  
        Stimulants and Other Compounds 
The sample preparation was in accordance with the requirements for the different 
formulations (Table 25). Depending on the formulation the required weight or 
volume (weighed) of sample was obtained using a Sartorius (R200D) analytical 
balance (Sartorius - Germany). The sample was then subjected to the necessary 
extraction procedure (see below).  All reagent solvents used for extraction were 
Analytical Grade or LiChrosolv© quality.  
 
5.16 Calibration standards and sample extraction methodology 
5.16.1 Steroids 
Figure 36 represents the extraction efficiency for triplicate samples (n=3) for the 
organic solvents Tertiary Butyl Methyl Ether (TBME), Diethyl Ether and 1- 
Chlorobutane respectively.  The best extraction recovery was 74% for 1-
Chlorobutane, 70% for TBME and 67% Diethyl Ether. Diethyl Ether gave the 
overall best solvent extraction recovery for the respective steroids that was 
investigated in this study.  
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Figure 36. Organic solvent tested for extraction recovery of steroids 
 
The specific extraction methodology for calibration curve standards and samples 
prior to analysis was thus as follows; 
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The extraction procedure for standards and samples were prepared on ice. 
Duplicate standards at each specific concentration were equally dispersed across 
the required concentration range.    
• 200 µl of each prepared standard was pipetted and transferred into a 5 ml 
polypropylene tube. For the samples that were being tested, the accurately 
weighed amount of sample was mixed with 5 ml of Methanol in a 15 ml 
polypropylene tube. The samples were then vortexed vigorously for 1 
minute. Then 200 µl of this mixture was used for the extraction procedure. 
• 1 ml of the Diethyl Ether was added to all standards and samples, and 
vortexed vigorously for 1 minute. 
• The standards and samples were then centrifuged at 5°C at a high speed 
(2500 rpm) for 5 minutes. Separation in the sample tube consisted of two 
phases, (i) organic layer (Diethyl Ether) as the upper layer, and (ii) the non-
organic layer located below the organic content in the tube. 
• Liquid nitrogen was used to freeze the bottom non-organic layer (standards 
and samples), thereby allowing quantitatively the transfer of the organic 
layer into clean 5 ml polypropylene tubes. 
• The standards and sample were then evaporated in a nitrogen purge 
concentrator (Stuart sample concentrator –SBH CONC/1) at ambient 
temperature for 1 hour.  
• The dried  standards and samples were then reconstituted with 200 µl 
mobile phase (1:1)  Acetonitrile and 0.1% Formic Acid  
• Standards and samples were then vortexed for 30 seconds and then 
subjected to pipette transfer to 96 well polypropylene plates. 
• The 96 well plate containing the standards and samples was then 
centrifuged at 5°C at 2500 rpm for 5 minutes. 
• 20 µl was injected onto the HPLC column for analysis. 
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5.16.2 Stimulants and other drugs 
Figure 37 represents the extraction efficiency for triplicate samples (n=3) for the 
organic solvents TBME, Diethyl Ether and 1- Chlorobutane respectively.  The best 
extraction recovery was 108% for TBME, 102% for Diethyl Ether and 76% for 1-
Chlorobutane. TBME gave the overall best solvent extraction recovery for the 
respective stimulants and other drugs that were investigated in this study.  
 
Percentage stimulant extraction recovery at pH 11(n=3)
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Figure 37. Organic solvent tested for extraction recovery of stimulants 
• 200 µl of each prepared standards was pipetted and transferred into a 5 ml 
polypropylene tube. Each sample that tested was accurately weighed and 
was mixed with 5 ml of Methanol in a 15 ml polypropylene tube. The 
samples were then vortexed vigorously for 1 minute and then 200 µl of 
this mixture was used for the extraction procedure. 
• 200 µl of Britton Robinson universal buffer (0.1 M, pH 11) was added to 
all standards and samples. 
• 1 ml of the TBME was added to all standards and samples, and vortexed 
for 1 minute, vigorously. 
• The standards and samples were then centrifuged at 5° C at a high speed 
(2500 rpm) for 5 minutes. This ensured good separation of the organic 
layer TBME. Separation in the sample tube consisted of two phases, (i) 
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organic layer (TBME) as the upper layer, and (ii) the non-organic layer 
located below the organic content in the tube. 
• Liquid nitrogen was used to freeze the bottom non-organic layer (standards 
and samples).  This allowed the organic layer to be transferred to clean 5ml 
polypropylene tubes. 
• The standards and sample were then evaporated in a nitrogen purge 
concentrator (Stuart sample concentrator –SBH CONC/1) at ambient 
temperature for 1 hour.  
• The dried standards and samples were then reconstituted with 200 µl (1:1) 
mobile phase Acetonitrile and 0.1% Formic Acid. 
• Standards and samples were then vortexed  for 30 seconds and then 
subjected to pipette transfer to 96 well polypropylene plates 
• The 96 well plate containing the standards and samples was then 
centrifuged at 5° C at 2500 rpm for 5 minutes. 
• 20 µl was injected onto the HPLC column for analysis. 
 
5.17 Assay analysis approach methodology 
The analysis of samples for the respective three categories (i.e. steroid, stimulants 
and other compounds), followed the steps below;  
(1) Complete screen using LC-MS/MS detection for the assessment of the 
defined steroids and stimulants and other compounds of interest 
investigated. 
(2) “Positive” tested supplements were then identified through the initial 
screen. 
(3) The concentration (of contamination/ adulterant) was then estimated via 
calibration curve standards that formed part of the extraction and analysis 
run.  
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5.18 Statistical analysis and evaluation methodology 
Upon completion of data capture and analysis the following computer-based 
programmes were used for the statistical analysis and graphic representation; 
Windows-based Microsoft ® Office Excel 2003 SP 1 (Excel © 1985-2003 
Microsoft Corporation) and GraphPad Prism® Version 2.01 (GraphPad 
Software© 1994, 1995, 1996 GraphPad Software, Inc).  Descriptive data were 
calculated as percentage positive samples, and the estimated concentration, 
median concentration, lowest limit of quantification (LLOQ) were determined.  
 
5.19 Results and Discussion  
Figure 38 is a representative illustration (eg. Steroid 1= 17α-19 Nor 
testosterone) of a bar plot overview of nutritional supplement samples 
investigated that tested positive for a given steroid, with estimate 
concentration in ng/g of sample. The tested sample was defined as positive 
when the result was greater than the lower limit of quantification (LLOQ) as 
presented in Table 26. 
 
 
Figure 38. Plot of samples that tested “positive” for steroids  
 
Figure 39 is a representative illustration (Stimulant 3 = Caffeine) of a bar 
plot overview of nutritional supplements samples investigated that tested 
positive for a given stimulant, with estimate concentration in ng/g of 
sample. 
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Figure 39. Plot of samples that tested “positive” for stimulants  
5.20 Steroids 
5.20.1 General overview of samples tested for steroids 
Table 26, 27, 28 for steroids and Table 29, 30, 31 for stimulants and other 
compounds should be read and viewed as follows. The structure from left to right 
of each table consist of (first line of Table 26 used as example), (a) the steroid or 
stimulant (other compound) eg. S1/S2, (b) the MS/MS compound transition eg. 
275.2/109.1, (c) Retention time in minutes of compound(s) eg. 1.02, (d) Total 
number of “positives” eg. 74, (e) Percentage of “positives” of the total 138 
samples eg. 54%, (f) Lower limit of quantification (LLOQ) in ng/ml and ng/g 
equivalent in sample, (g) the percentage “positives” above and below LLOQ eg. 
61 and 39 respectively, (h) the estimate concentration range ≥LLOQ eg. 19.65-
630.41 ng/g, and the median concentration of the specific “positives” eg 31.01 
ng/g. The two examples cited in the narrative describing each of the tables 26, 27, 
28, 29, 30, and 31 are highlighted in blue in the steroid, and stimulant code 
column. 
 
Table 26 provides a qualitative summary of all the samples (Table 25; n = 138) 
Steroid S7, 22 samples (16%) and (ii) Steroids S10/S12 118 samples (86%) based 
on overall qualitative assessment. 
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When sub-grouping the qualitative results (Table 26) in the examples (S7 and 
S10/S12) into “positive” tested  samples greater than and equal to the lower limit 
of quantification (≥LLOQ) for S7, 55% (12) of the “positive” tested samples were 
≥LLOQ and 45% (10) < LLOQ. For S7 the estimate concentration range was 
19.42-149.37 ng/g with a median value of 55.04 ng/g. For S10/S12 this was 
≥LLOQ 40% (47) and < LLOQ 60% (71). The S10/S12 estimate concentration 
range was 19.60-636.81 ng/g, with a median value of 34.38 ng/g. 
 
 
Table 26. Summary of Nutritional Supplement products investigated for steroids  
Qualitative Assessment Screen Estimate Concentration Range
Steroid Compound RT No. % LLOQ LLOQ No. (%) No. (%) ≥ LLOQ Median 
Code Transition min. Total Positive (ng/ml) (ng/g) ≥ LLOQ < LLOQ (ng/g) (ng/g)
S1/S2 275.2/109.1 1.02 74 54 1.95 19 45 61 29 39 19.65 - 630.41 31.01
S1/S2 275.2/109.1 1.36 42 30 1.95 19 21 50 21 50 19.13 - 579.28 25.85
S3/S4/S13/S14 289.2/109.1 1.27 31 22 1.95 19 13 42 18 58 19.60 - 584.80 43.09
S3/S4/S13/S14 289.2/109.1 1.76 85 62 1.95 19 32 38 53 62 19.34 - 88.92 25.79
S5/S6 277.0/216.8 0.30 44 32 3.91 39 40 91 4 9 53.18 - 316788.87 299.28
S7 273.2/109.0 1.33 22 16 1.95 19 12 55 10 45 19.42 - 149.37 55.04
S8/S9/S15 293.0/137.0 0.35 48 35 15.63 156 21 44 27 56 174.67 - 6603.40 504.73
S10/S12 287.2/97.1 1.71 53 38 1.95 19 7 13 46 87 28.17 - 655.09 125.10
S11 285.2/121.1 1.19 62 45 1.95 19 10 16 52 84 22.92 - 24331.91 166.46
S10/S12 287.2/121.1 0.92 118 86 1.95 19 47 40 71 60 19.60 - 636.81 34.38
S3/S4/S13/S14 289.2/109.1 1.27 34 25 1.95 19 16 47 18 53 20.92 - 689.62 28.19
S3/S4/S13/S14 289.2/109.1 1.77 68 49 1.95 19 5 7 63 93 20.20 - 700.65 21.54
S7 273.2/161.1 1.14 48 35 1.95 19 42 88 6 13 19.07 - 10682.16 190.39
S7 273.2/161.1 1.33 47 34 7.81 78 35 74 12 26 82.03 - 7842.95 246.68
S7 273.2/161.1 2.01 71 51 7.81 78 60 85 11 15 80.48 - 5453.52 192.00
S16 301.3/121.1 1.11 33 24 1.95 19 6 18 27 82 24.44 - 142.98 57.43
 
* Examples (a) = S7 and (b) =S10/S12 
 
5.20.2 South African Produced Nutritional Supplements 
Table 27 provides a qualitative summary of the samples which were locally 
produced or assembled (n=27).  Two examples are used to make the illustration 
(*), (i) for Steroids S3/S4/S13/S14, 4 samples (15%) and (ii) Steroids S10/S12 24 
samples (89%).  
 
When sub-grouping the qualitative results (Table 27) into “positive” tested  
samples greater than and equal to the lower limit of quantification (≥LLOQ) for 
S3/S4/S13/S14, 25% (1) “positive” tested  sample was ≥LLOQ and 75% (3) < 
LLOQ. For S3/S4/S13/S14 the estimate concentration was 49.81 ng/g with a 
median value of 49.81 ng/g. For S10/S12 this was ≥LLOQ 42% (10) and < LLOQ 
58% (14). The S10/S12 estimate concentration range was 20.20-315.19 ng/g, with 
a median value of 47.94 ng/g. 
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Table 27. South African nutritional supplements investigated for steroids  
Qualitative Assessment Screen Estimate Concentration Range
Steroid Compound RT No. % LLOQ LLOQ No. (%) No. (%) ≥ LLOQ Median 
Code Transition min. Positive (ng/ml) (ng/g) ≥ LLOQ < LLOQ (ng/g) (ng/g)
S1/S2 275.2/109.1 1.02 17 63 1.95 19 13 76 4 24 19.65 - 630.41 32.54
S1/S2 275.2/109.1 1.36 12 44 1.95 19 8 67 4 33 19.20 - 82.39 23.50
S3/S4/S13/S14 289.2/109.1 1.27 4 15 1.95 19 1 25 3 75 49.81 - 49.81 49.81
S3/S4/S13/S14 289.2/109.1 1.76 18 67 1.95 19 11 61 7 39 19.34 - 64.96 27.35
S5/S6 277.0/216.8 0.30 4 15 3.91 39 4 100 0 0 191.97 - 316788.87 672.71
S7 273.2/109.0 1.33 8 30 1.95 19 6 75 2 25 30.59 - 149.37 74.88
S8/S9/S15 293.0/137.0 0.35 10 37 15.63 156 5 50 5 50 174.67 - 1171.47 374.48
S10/S12 287.2/97.1 1.71 9 33 1.95 19 1 11 8 89 125.10 - 125.10 125.10
S11 285.2/121.1 1.19 11 41 1.95 19 2 18 9 82 252.06 - 1377.25 814.66
S10/S12 287.2/121.1 0.92 24 89 1.95 19 10 42 14 58 20.20 - 315.19 47.94
S3/S4/S13/S14 289.2/109.1 1.27 11 41 1.95 19 4 36 7 64 20.92 - 48.84 26.58
S3/S4/S13/S14 289.2/109.1 1.77 16 59 1.95 19 2 13 14 88 21.14 - 21.57 21.35
S7 273.2/161.1 1.14 9 33 1.95 19 8 89 1 11 163.32 - 10682.16 1218.53
S7 273.2/161.1 1.33 10 37 7.81 78 7 70 3 30 390.21 - 7842.95 2001.15
S7 273.2/161.1 2.01 16 59 7.81 78 15 94 1 6 95.48 - 5453.52 256.61
S16 301.3/121.1 1.11 6 22 1.95 19 1 17 5 83 48.63 - 48.63 48.63
 
* Examples (a) = S7 and (b) =S10/S12 
 
5.20.3 South African Purchased Imported Nutritional Supplements  
Table 28 provides a qualitative summary of all the samples tested for steroids 
(n=50) that were imported into South Africa. Two examples are used to make the 
illustration (*), (i) for Steroid S7, 6 samples (12%) and (ii) Steroids S10/S12 45 
samples (90%). When sub-grouping the qualitative results (Table 28)  into 
“positive” tested  samples greater than and equal to the lower limit of 
quantification (≥LLOQ) for S7, 50% (3) of the “positive” tested samples were 
≥LLOQ and 50% (3) < LLOQ. For S7 the estimate concentration range was 20.16-
78.06 ng/g with a median value of 50.07 ng/g. For S10/S12 this was ≥LLOQ 44% 
(20) and < LLOQ 56% (25). The S10/S12 estimate concentration range was 19.67-
509.64 ng/g, with a median value of 19.88 ng/g. 
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Table 28. Imported nutritional supplement products investigated for steroids 
 
* Examples (a) = S7 and (b) =S10/S12 
 
5.21 Stimulants 
5.21.1 General overview of samples tested for stimulants   
Table 29 provides a summary of all the samples tested for stimulants (n=138). 
Two examples are used to make the illustration (*); (i) for Stimulant T5, 18 
samples (13%) and Stimulant T14 62 samples (45%). When sub-grouping the 
qualitative results (Table 29) into “positive” tested  samples greater than and equal 
to the lower limit of quantification (≥LLOQ) for T5 72% (13) of the “positive” 
tested samples were ≥LLOQ and 28% (5) < LLOQ. For T5 the estimate 
concentration range was 19.35-2789.30 ng/g with a median value of 56.82 ng/g. 
For T14 this was ≥LLOQ 76% (47) and <LLOQ 24% (15). The T14 estimate 
concentration ranged from 161.00 ng/g to 19.53 mg/g, with a median value of 
1025.55 ng/g. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Qualitative Assessment Screen Estimate Concentration Range
Steroid Compound RT No. % LLOQ LLOQ No. (%) No. (%) ≥ LLOQ Median 
Code Transition min. Positive (ng/ml) (ng/g) ≥ LLOQ < LLOQ (ng/g) (ng/g)
S1/S2 275.2/109.1 1.02 26 52 1.95 19 17 65 9 35 19.67 - 178.33 25.99
S1/S2 275.2/109.1 1.36 18 36 1.95 19 9 50 9 50 22.14 - 579.28 31.06
S3/S4/S13/S14 289.2/109.1 1.27 15 30 1.95 19 10 67 5 33 20.51 - 584.80 38.13
S3/S4/S13/S14 289.2/109.1 1.76 27 54 1.95 19 18 67 9 33 19.40 - 88.92 24.43
S5/S6 277.0/216.8 0.30 27 54 3.91 39 24 89 3 11 53.18 - 6922.95 212.57
S7 273.2/109.0 1.33 6 12 1.95 19 3 50 3 50 20.16 - 78.06 50.07
S8/S9/S15 293.0/137.0 0.35 11 22 15.63 156 4 36 7 64 175.21 - 907.25 410.25
S10/S12 287.2/97.1 1.71 27 54 1.95 19 6 22 21 78 28.17 - 655.09 85.17
S11 285.2/121.1 1.19 30 60 1.95 19 7 23 23 77 24.61 - 24331.91 44.35
S10/S12 287.2/121.1 0.92 45 90 1.95 19 20 44 25 56 19.67 - 509.64 19.88
S3/S4/S13/S14 289.2/109.1 1.27 13 26 1.95 19 7 54 6 46 23.88 - 689.62 49.30
S3/S4/S13/S14 289.2/109.1 1.77 17 34 1.95 19 3 18 14 82 20.20 - 700.65 21.54
S7 273.2/161.1 1.14 20 40 1.95 19 19 95 1 5 25.48 - 1150.53 187.29
S7 273.2/161.1 1.33 21 42 7.81 78 17 81 4 19 82.03 - 2025.40 178.48
S7 273.2/161.1 2.01 21 42 7.81 78 19 90 2 10 80.48 - 1136.91 192.00
S16 301.3/121.1 1.11 16 32 1.95 19 4 25 12 75 45.86 - 142.98 66.62
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Table 29. Summary of Nutritional Supplement products investigated for 
stimulants  
Qualitative Assessment Screen Estimate Concentration Range
Stimulant Compound RT No. % LLOQ LLOQ No. (%) No. (%) ≥ LLOQ Median 
Code Transition min. Total Positive (ng/ml) (ng/g) ≥ LLOQ < LLOQ (ng/g) (ng/g)
T5 166.2/133.1 0.74 18 13 1.95 19 13 72 5 28 19.35 - 2789.30 56.82
T10 195.1/138.1 2.68 126 91 1.95 19 121 96 5 4 67.45 - 10369090.24 1637.76
T14 168.2/135.0 0.31 62 45 1.95 19 47 76 15 24 161.00 - 19532746.07 1025.55
T2 150.2/91.1 1.39 10 7 1.95 19 9 90 1 10 19.75 - 1104.82 54.96
T13 232.2/159 3.45 3 2 3.91 39 1 33 2 67 42.26 - 42.26 42.26
O2 127.1/68.1 0.26 67 49 1.95 19 66 99 1 1 513.44 - 127029.61 5992.55
O3 251.2/132.1 4.46 6 4 15.63 156 3 50 3 50 30.37 - 1685.27 442.97
O4 310.2/148.0 4.53 75 54 1.95 19 72 96 3 4 360.96 - 525638.49 3889.99
 
* Examples (a) =T5 and (b) =T14 
 
5.21.2 South African Produced Nutritional Supplements 
Table 30 provides a summary of all the samples tested for stimulants (n=27) that 
were locally produced or assembled. Two examples are used to make the 
illustration (*), (i) Stimulant T5, 5 samples (19%) and (ii) Stimulant T14, 17 
samples (63%).  
 
When sub-grouping the qualitative results into “positive” tested  samples greater 
than and equal to the lower limit of quantification (≥LLOQ) for T5, 100% (5) of 
the “positive” tested  samples were ≥LLOQ and 0% (0) < LLOQ. For T5 the 
estimate concentration range was 19.35-282.34 ng/g with a median value of 41.17 
ng/g. For T14 this was ≥LLOQ 88% (15) and < LLOQ 12% (2). The T14 estimate 
concentration range was 200.92 ng/g to19.53 mg/g, with a median value of 
3516.67 ng/g. 
 
Table 30. South African nutritional supplements investigated for stimulants  
Qualitative Assessment Screen Estimate Concentration Range
Stimulant Compound RT No. % LLOQ LLOQ No. (%) No. (%) ≥ LLOQ Median 
Code Transition min. Total Positive (ng/ml) (ng/g) ≥ LLOQ < LLOQ (ng/g) (ng/g)
T5 166.2/133.1 0.74 5 19 1.95 19 5 100 0 0 19.35 - 282.34 41.17
T10 195.1/138.1 2.68 25 93 1.95 19 23 92 2 8 73.38 - 9766373.04 3430.73
T14 168.2/135.0 0.31 17 63 1.95 19 15 88 2 12 200.92 - 19532746.07 3516.67
T2 150.2/91.1 1.39 3 11 1.95 19 2 67 1 33 24.17 - 717.32 370.74
T13 232.2/159 3.45 - - 3.91 39 - - - - - - - -
O2 127.1/68.1 0.26 16 59 1.95 19 16 100 0 0 543.22 - 127029.61 10488.85
O3 251.2/132.1 4.46 1 4 15.63 156 1 100 0 0 1685.27 - 1685.27 1685.27
O4 310.2/148.0 4.53 18 67 1.95 19 17 94 1 6 554.22 - 431709.65 5193.39
 
*Examples (a) =T5 and (b) =T14 
 
5.21.3 South African Purchased Imported Nutritional Supplements 
Table 31 provides a summary of all the imported nutritional supplement samples 
purchased in South Africa and tested for stimulants (n=50). Two examples are 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 5 Steroid and Stimulant Analysis  
 
118
118
used to make the illustration (*); (i) Stimulant T5, 9 samples (18%) and Stimulant 
T14 22 samples (44%). When sub-grouping the qualitative results into “positive” 
tested  samples greater than and equal to the lower limit of quantification 
(≥LLOQ) for T5, 89% (8) of the “positive” tested samples were ≥LLOQ and 11% 
(1)  < LLOQ. For T5 the estimate concentration range being, 24.96-2789.30 ng/g 
with a median value of 411.33 ng/g. For T14 this was ≥LLOQ 73% (16) and < 
LLOQ 27% (6). The T14 estimate concentration range was 161 ng/g to 342 µg/g, 
with a median value of 23.56 µg/g. 
 
Table 31. Imported nutritional supplement products investigated for stimulants 
Qualitative Assessment Screen Estimate Concentration Range
Stimulant Compound RT No. % LLOQ LLOQ No. (%) No. (%) ≥ LLOQ Median 
Code Transition min. Total Positive (ng/ml) (ng/g) ≥ LLOQ < LLOQ (ng/g) (ng/g)
T5 166.2/133.1 0.74 9 18 1.95 19 8 89 1 11 24.96 - 2789.30 411.33
T10 195.1/138.1 2.68 45 90 1.95 19 45 100 0 0 136.30 - 10369090.24 693313.37
T14 168.2/135.0 0.31 22 44 1.95 19 16 73 6 27 161.00 - 342649.61 23557.25
T2 150.2/91.1 1.39 2 4 1.95 19 2 100 0 0 54.96 - 1104.82 579.89
T13 232.2/159 3.45 - - 3.91 39 - - - - - - - -
O2 127.1/68.1 0.26 23 46 1.95 19 22 96 1 4 1089.04 - 76419.21 12265.22
O3 251.2/132.1 4.46 - - 15.63 156 - - - - - - - -
O4 310.2/148.0 4.53 28 56 1.95 19 28 100 0 0 551.93 - 104308.11 20051.35
 
* Examples (a) =T5 and (b) =T14 
 
5.22 Conclusion 
This study described the percentage “positive” results of steroid and stimulant 
analysis in nutritional supplement products, based on the qualitative assessment 
screen results. The concentration range and the median values are presented as an 
estimate and not as an absolute quantitative assessment. It would be important for 
a subsequent study to verify the current findings by re-extraction and analysis. 
  
Isomeric forms of steroids may not be able to be separated chromatographically 
(having similar retention time and similar molecular weight and similar 
fragmentation (transition) patterns. Hence results reflect steroid S3, S4, S13 and 
S14 individually or a combination of different proportions of S3, S4, S13, and S14 
respectively. The results would therefore indicate a “positive” steroid sample, but 
the estimate concentration could be of individual steroid S3, S4, S13, S14 or 
collective proportional sum of S3, S4, S13, and S14.    
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The frequency of “positive” tested samples for the respective steroids assessed in 
the overall cohort ranged from 16-86%, for South African produced nutritional 
supplements 15-89%, and for imported products, bought in South Africa, 12-90%. 
 
The  frequency of  “ positives” tested samples for  respective  stimulants and other 
drugs  assessed, in the overall cohort ranged from 2-91%, for South African 
produced  nutritional  supplements 4-93%, and  for imported  products, purchased  
in  South Africa, 4-90%. 
 
For the specific steroids investigated  there was a notable  high frequency  in the 
overall sample cohort, of the nutritional supplements produced in South Africa for 
steroids,  S10/S12, and the combination of  S3, S4, S13, S14, and S1/S2. For the 
imported  products, purchased in South Africa, it was the frequency of steroids 
S10/S12, S11, the  combination of  S3, S4, S13, S14, and S5/S6 compounds that 
was high  in the overall sample cohort. 
 
For the stimulants and other drugs investigated there was a notable high frequency 
of “positives” for T10 (Caffeine) 90-93%, T14 (Synephrine) 44-63%, and O4 
(Fluoxetine) 54-67%, presented in the nutritional supplements categories assessed.  
For the specific stimulants and other drugs investigated there was a notable high 
frequency “positives” in the overall sample cohort. For imported products, 
purchased in South African this was T10, O4, and 02, and for South African 
produced products it was T10, O4 and T14. 
 
The findings of the steroid and stimulant “positive” tested samples provide 
sufficient evidence for implementing a system for regulating, monitoring and 
enforcing the quality control of nutritional supplements.  
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5.23 Limitations and opportunities of current Steroid and 
Stimulant Screen 
The current method was developed as a “Steroid and Stimulant Screen” 
respectively and thus results and data should be interpreted from a qualitative 
perspective. The quantitative assessment is only an estimate concentration and not 
absolute, due to potential matrix effects from the respective nutritional supplement 
products. 
o Ion suppression or enhancement may/or would also contribute to varied 
concentration and hence the concentration should be viewed as an estimate 
and not in absolute terms. 
o An improved method to the current “Screen Method” would be to use an 
appropriate Internal Standard (IS) to improve on the “estimate 
concentration approach”, as done in this study. 
o Another option to improve quantitative results and data is to use labelled 
isotopic compounds of interest. 
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Chapter 6 
Discussion, Conclusion, Perspectives 
 
6.1 Purpose of Research Study 
The main purpose of the study was to evaluate commercially available, (i) 
traditional supplements for trace element and heavy metal consistency and safety 
(Chapter 4) and, (ii) in nutritional supplements to detect the presence of steroids, 
stimulants and other compounds of interest using qualitatively and semi-
qualitative techniques (Chapter 5). 
 
Prior to these experimental sections (Chapter 4 and 5) of the study the following 
studies were done;  
• a comparative assessment of current Regulations, Legislation, Labelling 
and Claims applied in both South Africa and globally (as presented in 
Chapter 2),  
• a study to assess the labelling and claims information on imported into/and 
South African manufactured or assembled nutritional supplements 
products (as presented in Chapter 3), 
• a study to assess the impact of container labelling and other sources of 
information that currently assist consumers of nutritional supplement 
products in their purchasing decisions (as presented in Chapter 3). 
 
The key questions of the overall study were;   
• What information is presented on the container labels of nutritional 
and traditional supplement products?  
• What container labelling and other sources of information assist the 
consumers of nutritional supplement products in their purchasing 
decisions? 
• How consistent is the batch-to-batch trace element and heavy metal 
composition of commercial traditional supplement products?  
• Do nutritional and traditional supplement products contain 
undeclared contaminants and/or adulterants, such as steroids and 
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stimulants that could compromise nutritional and traditional 
supplement usage and safety? 
 
6.2 Discussion and Conclusion 
 
Based on the literature review and personal global assessment of the nutritional 
supplement sector the gaps and “grey” areas in the industry were identified. These 
points formed the  basis for  the integrated  approach to the thesis and covered the 
following; (i)  regulations and legislation, and labelling and claims associated with 
nutritional supplement products in the USA, European Union and South Africa, 
(ii) assessing the labelling and claims information on nutritional supplement 
products imported into/and manufactured or assembled in South African, (iii) 
assessing how consumers were influenced when they purchased supplements 
information; the focus was on the labelling on the container and other sources of 
information (iv) assessing traditional commercial supplements for contamination 
and consistency of trace elements and heavy metals using Inductively Coupled 
Plasma-Mass Spectrometry, and  (v) assessing the content of nutritional 
commercial supplements for steroids, stimulants and other compounds of interest 
using Tandem Liquid Chromatography-Mass Spectrometry.  
 
The study thus makes an important contribution in assessing the current 
regulations and legislation (or lack thereof). This is the  basic  framework  where 
fundamental changes  should  occur  to ensure improved  regulation  and  
legislation of the nutritional  supplement sector globally.  Having scientific insight 
into the type and categories of information on the container of nutritional 
supplement will assist in determining what may be more appropriate, relevant and 
important. This will help to guide changes in label content in the best interest of 
the consumer.  
 
The laboratory experimental work with respect to trace element and heavy metal   
profiling using Ginseng and African Potatoe products introduced a novel proof of 
concept. This method has the potential to ensure quality and consistency, and also 
contamination of nutritional supplement products from batch-to-batch.  The 
laboratory experimental work with respect to assessing the content of nutritional 
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commercial supplements for steroids, stimulants and other compounds, exposed 
content  that was  not  disclosed  (intentionally or unintentionally) on the  
container  label  of nutritional  supplement products. These could potentially be 
harmful to the consumer or have negative consequence if such banned substances 
or compounds are embedded in nutritional supplements. 
 
The main findings and assessment for the respective chapters in the thesis are, 
 
In Chapter 1 the literature review identified the increased use of nutritional 
supplements by athletes in competitive and recreational sport. There has been an 
increase in media and public scrutiny because of the increase in positive doping 
tests worldwide in recent years [1].   Many athletes have blamed nutritional 
supplements as the primary cause of their positive doping test [2, 5, 6]. 
 
Chapter 1 further covered the history of Performance-Enhancing Substances, with 
evidence for their use going as far back as 300BC. Steroids and amphetamines 
became popular ergogenic aids more recently. When these substances where 
banned by WADA, the quest began for legal ergogenic substances that would 
provide the competitive edge [7-10]. This resulted in more interest in nutrition 
with the nutritional supplement industry growing at an exponential rate [14, 15]. 
 
Global sporting organizations and anti-doping agencies often advise athletes to 
abstain from using supplements because of the risk of ingesting a contaminated 
product that would result in a positive doping test [150,165,217]. However, this 
message has not had much impact, mainly due to athletes’ belief that nutritional 
supplements boost their physical and psychological abilities [40]. This leads to the 
motivation for having a screening protocol for testing nutritional supplements for 
purity before they are available for commercial distribution [19, 20]. 
 
Chapter 1 also discussed the concern among sports scientists and nutritionists that 
athletes and consumers make uninformed choices about supplements. The concern 
that nutritional supplements may exert their effect by undeclared embedded 
contaminants such as steroids and stimulants was also highlighted [76, 78, 86].  
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The role of nutritional supplements in malnutrition, obesity, patient care and anti-
aging was also presented and the consequences that may manifest due to 
contamination of consumed products was also discussed [45, 68, 72].   
 
The literature review in Chapter 1 also presented a synopsis of current matters 
relating to regulation, de-regulation, re-regulation, law enforcement and consumer 
protection agencies [87, 93, 94].  An outline was also provided explaining how 
nutritional supplement product contamination may occur, including the conduit of 
counterfeiting and piracy [35].  The importance of laboratory screen testing of 
nutritional supplements, harmonization of interpretation of questionnaire surveys, 
and genetic pre-disposition profile of supplement users was given emphasis [79, 
218-220].     
 
Chapter 2 covered the global and local regulations, legislation, labelling and 
claims made for nutritional supplements. The chapter focussed on current laws in 
general, and then discussed the specific laws pertaining to the USA, the European 
Union (UK, Germany, Belgium, The Netherlands, and Austria in particular) and 
South Africa.  This legal framework provided a reference to current practice and 
future potential development of relevant and appropriate policy.   
    
In Chapter 2, a synopsis of the Current Laws and Regulation pertaining to 
nutritional supplements identified that infringes can only be interpreted or applied 
implicitly and not necessary stated specifically. The divergence of the laws 
between Food and Drug Law has created an increasingly “grey” area, which makes 
it difficult to institute appropriate law enforcement. This is particularly relevant to 
the “voluntary” declaration of “all” content in a specific nutritional supplement 
product.  The need for basic research information and investigation is therefore 
important to maintain ongoing quality of nutritional supplement products. 
 
Chapter 2 also identified the Consumer Forums and Councils of importance 
within specific regions. There was specific focus on Consumer International, The 
Council for Responsible Nutrition, The European Consumer Centres Network, 
The South African National Consumer Forum, and The South African National 
Consumer Union. The observations from this section provided supporting 
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evidence for the study, and shows additional requirements and guidelines to 
improve on the mandate and intention of consumer forums. 
 
Chapter 3 discussed the assessment of specific knowledge and understanding on 
the claims and labelling on nutritional supplements products used by general, and 
more specifically sports consumers. The point was made of the importance for 
studying this information for practical intervention, policy development, and 
possible appropriate legislation and regulation. The information also provides 
guidelines on how nutritional supplement products may be marketed in future to 
ensure informed choice for the consumer.  Secondly, Chapter 3 dealt with  
determining how consumers of nutritional supplement products gather information 
to assist their purchasing decisions. This was accomplished by administering a 
self-administered questionnaire to test which container label information, and 
information other than container labelling sources assist the consumer in making 
purchasing decisions.  
 
The main finding in Chapter 3 showed that seventy percent of the nutritional 
supplement product labels had no indication or evidence that the product was 
“Contaminant Free”. Chapter 3 further shows the importance of screen testing of 
products to verify nutritional supplements for contaminants, with specific 
reference to steroids and stimulants and other compounds that were investigated in 
this thesis. The three main findings with specific reference to the self-administered  
questionnaire were, (i) that close to 70% of  the respondents were  strongly  
influenced by  container label information that stipulated  that the  nutritional  
supplement product  is free of banned substances, (ii) 50% of the respondents 
attach importance to the quality, and (iii) 40% of the  respondents where  strongly 
influenced in their purchase of  nutritional supplements based on  ingredients. The 
specific finding in this thesis study related  to “free of  banned substances”  
information requirement, and  the lack of  information on product labels that the  
product is  “contaminant free” should  be of major concern to both consumer and 
government enforcement. Not presenting this information on the label, when in 
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fact a product may contain a prohibited substance(s), may have dire 
consequence(s) to both general consumer and competitive athletes, respectively. 
The main findings of the self-administered questionnaire study emphasises  the 
importance of independent laboratory screen testing of all nutritional supplement 
products for contaminants and/or adulterants on a regular, and batch-to-batch 
basis.   
 
These findings are further supported and extended by the published work from this 
thesis by Gabriels et al [222]. This study showed that in order for the consumer to 
make informed choice that there was a need to alert those consuming nutritional 
supplements of the potential for banned substances being present in products.  Of 
the product labels assessed in that particular study, only 5% had information on 
“The presence of banned substances in the supplements”. Brownell et al [223] 
conducted research work on the Food Industry (which is similar to the nutritional 
supplement sector). They describe the free-for-all approach different companies 
use and in many cases self-serving symbols to communicate how healthy their 
products are. The authors also point to the importance and evaluation of various 
classification models for front-of packaging labelling w.r.t to food packaging. 
They state that the effectiveness of any given system may vary with the 
population’s nationality, culture, level of health literacy and socioeconomic status. 
A pertinent point, because of undeclared content on the labels, is that the industry 
may have proven itself untrustworthy [223].   
 
At the legislative and regulatory level the published work of Gabriels et al [224] 
concluded  that  in South Africa, the new  Consumer Protection Act 68 of 2008 
(CPA) should  promote  greater  levels  of policy  development, regular 
enforcement, and  consumer education  with respect  to the supplement industry 
[122,224]. This work is supported by work published by Cohen et al that assessed 
supplement safety, stating specifically, if the FDA succumbs to industry pressure 
that the public health consequences will be significant, as hundreds of thousands 
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of Americans continue to turn to new supplements to sustain their health and treat 
their ailments [118, 225]. The importance of information on the container label 
linked to ingredient content is hereby emphasised.  
 
The main finding in the category, other than the container label information 
showed that coaches, gym and/or fitness trainers, and fellow athletes (24%) have 
a greater influence to the consumer of nutritional supplement products than that of 
a Pharmacist, Dietician, Nutritionist and Doctors (10%), and nutritional 
supplement representatives (2%), respectively.  A second finding is that 
electronic, print and social media and the internet, all showed an influence on 
respondents in the purchase of nutritional supplements, to less than 15%.  
 
The findings supports the paper on practical guidelines to the use of nutritional 
supplement in South Africa (2004) [226]. These guidelines stated specifically that 
fitness coaches and conditioning staff should not prescribe supplements. The 
findings in this thesis (2012), shows that coaches, gym and/or fitness trainers, and 
fellow athletes have an influence on the consumer of nutritional supplement 
products. This influence may be construed as providing indirect-prescription for 
usage, and thus highlights an area where important focus with relevant peer-
reviewed information should be directed to ensure educated and informed choice 
is provided to the athletes. 
 
Further, work published by Berning et al showed that by identifying  consumer 
preferences for nutrition information, the authors raise the  possibility that 
alternative  formats (platforms)  of  communication may become more effective 
[119,123].  In the context of this thesis, the findings show that less than 15% of 
the study participants were influenced by categories such as electronic, print, and 
social media and the internet. This finding suggests that these are potential areas 
of growth to provide peer-reviewed evidenced based information. This is in 
accordance with the work of Joshi et al which states that the news media helps 
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shape the public understanding of promotional practices of companies and their 
potential benefits and harms [121].    
  
In conclusion, the findings in Chapter 3 provide a mechanism, and/or 
requirements, that may be needed for practical intervention, policy, regulation, and 
legislation development in South Africa. It may further provide and facilitate the 
direction and improved guidelines, and permissible marketing practices. This will 
ensure that the consumer can make informed choices about product content linked 
to container label content.  
 
Chapter 4 described an Experimental Study of Trace Elements and Heavy Metal 
analysis in the natural commercially products Ginseng and Hypoxis. The World 
Health Organization (WHO) estimates, that 60-80% of people in developing 
countries use traditional medicines. This has resulted in over-the-counter plant 
drugs increasing dramatically over the past decade, in both developing and 
developed countries. The upsurge in the use of natural products has lead to these 
products being packaged in a similar way to nutritional supplement products in the 
market. This gives reason to scrutinize the quality content of natural products 
incorporated into the nutritional supplements for trace element and heavy metals. 
 
Chapter 4 further highlights the importance of recognising the potential risk where 
consumers of nutritional  supplements  and/or Herbal- Botanicals  who are 
receiving medical drug treatment,  may  be exposed to adverse drug-herb 
interaction that is synergistically  induced [4,128,132,133]. The same reasoning 
may apply to the use of complementary/alternative medicine 
[129,130,134,135,221].  
 
The findings of Chapter 4 includes the assessment of the trace elements and heavy 
metals, magnesium (Mg), potassium (K), calcium (Ca), Iron (Fe), manganese 
(Mn), Lithium (Li), sodium (Na), chromium (Cr), cobalt (Co), nickel (Ni), copper 
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(Cu), zinc (Zn), strontium (Sr), cadmium (Cd), mercury (Hg) and lead (Pb) using 
the analytical instrument methodology Inductively Coupled Plasma - Mass 
Spectrometry (ICP-MS).  
 
The presence of these trace elements and heavy metals that would often not be 
declared on supplement product label, could have an impact when conventional 
medicine practice, is taken in conjunction with complementary or alternative 
medicine.  Work published by Sirven et al [130], points to commonly tried 
botanical supplements as being garlic, gingko, soy, melatonin and kava. Linked to 
this Grippo et al, states  that  the lowest metal concentration  were  most single–
ingredient  botanical  supplements, while  multiple–component, ephedra 
containing  dietary  supplements generally  had  higher  metal  concentrations 
[127]. The presence of these metals could synergistically contribute to toxicity 
[4,132]. Work  published  by  Singh and Dhananjay et al, points to the need for 
detailed investigations (screening) to identify clinically significant interactions 
that may cause adverse effects in herbal/botanical supplements [129,134,135,221].     
       
The findings in this study also point to the important requirement for qualitative 
and quantitative assessment of these products, to minimize risk to health and 
wellness, and as suggested by Dasgupta et.al [227].   Herbal products are often 
exported to high-consumption markets, thus spreading the risk of heavy metal 
toxicity [227]. Whilst findings in this study, based on the Ginseng and Hypoxis 
products investigated is not cause for alarm, but allow for a marker of quality, this 
does not imply that other similar products may not present higher concentration 
levels as contaminants. The study described in Chapter 4, using Ginseng and 
Hypoxis supplements as examples shows the trace element and heavy metal 
content were not declared on label. This may have negative consequences as the 
metals accumulate in the same target organs (e.g. liver and kidney), suggesting 
that their respective toxicities may be additive. The number of case reports 
describing toxicity linked to the use of herbal products provides strong evidence 
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that the presence of heavy metals in alternative medicine is a matter of serious 
concern [227].  
 
Further, the findings in Chapter 4 of this thesis established a proof of concept for 
measuring intra-sample consistency, intra-batch variability, and inter-batch sample 
consistency for the trace elements and heavy metal. Fingerprint profiles and novel 
Radar plots were established for each of the Ginseng and Hypoxis products 
investigated. The fingerprint profiles showed a reliable marker to evaluate overall 
product quality and consistency, and radar plot provided a concise visual analysis 
of the collective trace element and heavy metals. This novel approach has the 
potential to firstly determine the quality of products indirectly, secondly to assist 
in determining metal associated - drug interactions as required and concluded by 
other researchers [128].   
 
Chapter 5 described an Experimental Study that laboratory screened for 16 
steroids, 5 stimulants and 3 other compounds of interest. The requisite reference 
compounds were used for calibration in the analytical methodology Liquid 
Chromatography-Tandem Mass Spectrometry (LC-MS/MS). The study 
established a method with analytical detectable measures that has the potential to 
“screen test” supplements in the laboratory. In this study a total of 138 nutritional 
products were screened as part of the experimental study.  
 
Findings in this thesis has illuminated the presence and extent of banned 
substances and stimulants in nutritional supplement products. The number of 
“positives” in the nutritional supplement products assessed ranged from 12-90% 
for the respective steroids. For stimulants and other drugs respectively, this was 
“positive” in 2-93% of the nutritional supplement products assessed.  It was 
concluded that if this method was implemented on a larger scale it could be 
assured that the quality of the nutritional supplement could be verified to be 
“clean” and safe. 
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These results and findings contribute a substantial knowledge and insight about 
nutritional supplement products. The data confirms the requirement and 
importance of laboratory screen testing of nutritional supplements and 
harmonization of terminology. This will improve the quality of the supplement 
and also provide informed choice to consumers of nutritional supplement products 
through improved information provision. 
 
Poor regulations contribute to contamination and/or adulteration of products such 
as metals, animal parts and conventional drugs [76,78,208,215,227]. The data 
from this thesis point to the need for expanded laboratory “screen testing”, with 
continuous vigilance.  
 
6.3 Perspectives – Future research work and recommendations   
Chapter 2 suggests, that (i) there needs to be further work to achieve common 
international regulations and guidance policies for the nutritional supplement 
sector, (ii) greater awareness of concern needs to be created about nutritional 
supplements with  respect  to  the  potential problems, addressing  enforcement 
difficulties and obstacles, (iii) there is the  need  to develop common global 
centres for  laboratory screening  for contaminants  and maintaining research  
vigilance, with appropriate accountability, reporting and awareness measures, and 
(iv) there should be a global harmonization of protocols,  including synergy  in the 
use of  terminology. 
 
Chapter 3 suggests, (i) the importance  of  highlighting the potential for adverse 
events that may occur, should be presented on the nutritional supplement product 
label, (ii) that warning statements such as, “keeping product out of reach of 
children”, and “the importance of adherence to  storage details” should be 
maintained on the labels appropriately, with acceptable  font and visibility, (iii) 
warning statements, such as; (a) “exclusion of use, and not a cure for disease 
states” and  (b) the  “presence of banned substances in the supplements”, should 
be encouraged based on standardised laboratory screen methods as presented  in 
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this  study, (iv) the  requirement to determine and establish a nutritional 
supplement sector specific system and guideline with regards to the best before 
and expiry date information, batch numbers, and Good  Manufacturing  Practices   
(GMP), that should also facilitate batch-to-batch laboratory screen testing, and (v) 
the need for scientifically explored and researched alternative label designs, that 
would be beneficial to providing relevant information to the consumer.  
Chapter 4 suggests; (i) that trace  elements and heavy  metals are  a good 
assessment tool  to determine the consistency and a measure of quality for 
nutritional  and  traditional  supplement products, (ii) that “finger print” profile of 
determined  trace metals and heavy  metals  can  be  used  as a reference standard 
to measure subsequent  manufactured batches against, as well as identification of 
trace element or  heavy metal contamination, (iii) that radar plots could be used as 
an additional visual tool, to observe discrepancies, deficiency and/or  
contaminants in replicate samples and respective batches, (iv) that the safety, 
quality and efficacy of these  natural  products need to be established according to 
the principles of  Standard Operating Procedures (SOP), Good  Agricultural  
Practice (GAP), Good  Laboratory Practice (GLP), Good Supply Practice (GSP) 
and Good  Manufacturing  Practices (GMP), (v) the “finger print” profile and 
radar plot approach applied in this study,  would have similar application for 
nutritional  supplement  products  in general, and (vi) deviation from the initial  
pre-determined  “fingerprint” levels and visual radar plot, would be a reliable 
measure of overall product quality and consistency. 
 
Chapter 5 suggests; (i) that the current findings provide sufficient evidence that 
the nutritional supplement sector should be regulated and monitored on an 
ongoing basis, (ii) that “screen testing” should be applicable to existing  products, 
when “new” products are developed and batch-to-batch testing of all nutritional 
supplement  products in the market place, (iii) that the current “screen test” 
developed in this thesis has limitations and needs to be refined, as it is currently 
only able to provide a qualitative  assessment  with an  estimate concentration  
component and not absolute concentration, (iv) the current study presents the 
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opportunity as a separate project to improve the current method by using ion-trap 
instrument technology to provide absolute quantitative determination for steroids 
and stimulants, (v) to expand the current “screen test” developed with additional 
chemical compound reference standard acquisition, and/or via LC-MS/MS 
software  libraries, and (vi) that a further study should be  conducted  where the 
“positive” tested  products could be consumed by subjects to test if the  urine 
concentration would yield a “positive” doping result. 
 
It is clear that a change in approach needs to occur in the nutritional supplement 
sector. There should be a requirement for “all” content in a specific product to be 
declared, rather than “voluntary” declaration of content only. The findings also 
suggest the need for enhanced capacity requirement, which will facilitate in part, 
the mandate of consumer forums and specific agencies, in South Africa. This 
requirement will ensure the relevant vigilance and continuous monitoring of the 
nutritional supplement sector. The data provides practical intervention for policy 
development, and possible appropriate legislation and regulation.  
The laboratory screen testing for contamination and/or adulteration of steroids, 
stimulants and other drugs in nutritional supplement in this thesis highlights the 
extent of the problem. The study and the analytical guidelines provided, 
emphasises the importance and expansion for laboratory screen testing protocols. 
These processes and procedures will ensure informed choice to consumer of 
nutritional supplement products through improved peer-reviewed information 
provision. 
 
In conclusion this thesis has shown that there should be concern about the quality 
of nutritional supplement products in the South African market place, based on the 
various aspects covered. Specific legislation and regulation needs to be drafted 
and enforced in the best interest for the wellness and health of the consumer of 
nutritional supplement products.  
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Appendices  
Appendix 1 
Action Plan 1 
To accomplish  objective 1  in scope of  study with content in Chapter 2 
 
 
Global Regional  
Framework for  
Nutritional  Supplements 
Regulations 
Legislations 
Labelling 
Claims 
Regions 
USA 
European Union 
South Africa 
Requirements 
Current Laws 
Regulations 
Discretionary  Policies 
Consumer Forums  
and  
Councils 
Governance issues 
Medicine -  Food 
Unregulated  
Terrain 
Current and Recent Issues 
in Nutritional Supplement 
and Related  Sectors 
Labelling of products 
Labelling  Laws 
Misleading  claims 
USA  European Union  South Africa  
Comparative summary  
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Appendix 2 
Action Plan  2 
To accomplish  objective 2  in scope of  study with content in Chapter 3  
 
 
 
 
Nutritional  
Supplements 
Products 
Assessment 
Imported 
Locally Manufactured 
Locally Assembled  
 
Product types 
powder 
powder capsule 
powder tablet 
liquid capsule 
  
Product Label 
Categories Examples 
Claims, Disclaimers, Contaminant 
Free, Stimulant Free, Warnings 
Data Capture Microsoft  Office Excel 
2007 
Yes/ No 
Other 
 Data Analysis 
Statistica Version  10 
Frequency analysis 
Results Conclusion 
Self- 
administered  
Questionaire 
Seven questions 
(close and open) 
  
Label Information and Non-Label Information 
Absolutely no influence, partially no influence, 
uncertain, moderately influenced and strongly 
influenced 
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Appendix 3 
Action Plan  3 
To accomplish  objective 3  in scope of  study with content in Chapter 4 
 
 
 
 
 
 
 
Trace Element and Heavy 
Metal Assessment of 
Nutritional Supplements  
 
Product  Consistency 
Product Contamination 
Samples 
Investigated 
 
Literature  Review 
Analytical Assay 
Methodology Tool 
Mg, K, Ca, Fe, Mn, Li, Na, Cr, 
Co, Ni, Cu, Zn, Sr, Cd, Hg and 
Pb 
Conclusion 
Statistical Analysis  
and 
Evaluation 
Methodology 
Commercial 
Ginseng and Hypoxis 
Sample Preparation 
Acid  Digestion 
Inductively Coupled Plasma - 
Mass Spectrometry 
(ICP-MS) 
Results 
Tablets/Capsules 
Concentration 
Maximum 
Estimations 
Fingerprint Profiles 
Radar Plot Profiles  
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Appendix 4 
Action Plan  4 
To accomplish  objective 4  in scope of  study with content in Chapter 5 
 
 
 
 
 
 
 
Assessment of Steroids, 
Stimulants and Other 
Compounds of Interest  
 
Nutritional Supplement 
Products   
Samples 
Investigated 
 
Literature  Review 
Analytical Assay 
Methodology Tool 
Conclusion 
Statistical Analysis  
and 
Evaluation 
Methodology 
Steroids  (16) 
Stimulants (17) 
Other Compounds (5)  
Sample Preparation 
Tandem Liquid 
Chromatography-Mass 
Spectrometry (LC-MS/MS) 
Results 
Screening  Elements 
 
Popular Local Brands (RSA) 
Popular International Brands (RSA) 
Open Request Campaign 
Anecdotal Indications 
Questionnaire Survey 
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Appendix 5a 
Research Ethics Approval 
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Appendix 5b 
Research Ethics Approval 
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Appendix 6 
Example of Import For Controlled Substances 
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Appendix 7 
Conference Poster Presentation  
2007 G.A. Gabriels, K. Govender, P.J. Smith, A.Spath. Assessment  of  
Commercial  Ginseng  and Hypoxis supplement products  for trace  element and 
heavy metal  contamination. South African Pharmacology and Toxicology 
Congress 2-5th October 2007, Rustenberg, South Africa 
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Appendix 8 
Conference Poster Presentation  
2008  G.Gabriels, P.Smith. Trace element and heavy metal analysis of  
Commercial  Ginseng  and Hypoxis supplement products. WOCMAP IV World  
Conference  on Medicinal and Aromatic Compounds 9th -14th November 2008, 
Cape Town, South Africa     
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Appendix 9a 
Peer-Reviewed Publication 
 
Gabriels, G., Lambert, M., Smith, P., Hiss, D. Will the new Consumer Protection 
Act prevent  nutritional  supplement users from harm? South African Medical 
Journal  2011; 101:543-545 
 
Go to the link below to see the article in electronic format ( and PDF) 
http://www.samj.org.za/index.php/samj/article/viewFile/4946/3309 
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Appendix 9b 
Peer-Reviewed Publication 
Gabriels, G., Lambert, M., Smith, P Information on labels of nutritional 
supplements – time for legislation? South African Journal of Clinical Nutrition 
2012; 25(1): 22-24 
 
Go to the link below to see the article in electronic format ( and PDF) 
http://www.sajcn.co.za/index.php/SAJCN/article/view/559/842 
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Appendix 10 
Questionnaire Survey (Unpuplished Research) 
The investigation and assessment of  Nutritional and 
Traditional  Supplement products.  
 
 
Survey Questionnaire  
 
 
 
 
 
 
 
 
Gary Gabriels 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
July 2008 
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Questionnaire 
 
Please complete  the questionnaire as accurately ( truthfully and honestly)  to 
the best of your ability and write /mark  legibly please. 
 
Section A - General Information (GI) 
1. Date  when  completing  questionnaire (dd:mm:yy) 
2. State  your  following  details. Your age (in years), estimated  height (m)  
and weight ( kg). 
Age 
(in  
years) 
 Height 
(m) 
 Weight 
(kg) 
 
 
3. State your  ethnicity.  ……………………. 
4. Educational Experience – Which category reflects your  highest  
educational experience. 
Informal  only  Primary School  High School  
Technical College    University Degree  Other  (state)  
 
5. City  of residence …………………………….. 
6.  Province ( in  South  Africa) 
Western 
Cape 
 Eastern 
Cape 
 Kwazulu- 
Natal 
 
Gauteng  Free 
State 
 Mpumalanga  
Northern 
Cape 
 North 
West 
 Limpopo  
 
7. Occupation ………………………………………. 
8. Exact name of  event where  this questionnaire is  being completed. 
………………………………………………………………………. 
 
9. What is  your  Nationality……………………………….. 
 
10. What is your country of origin…………………………….. 
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11. What is your marital  status: 
 
Single  Married  Divorced  
 
12.  Do you have any  children 
Yes  No  
 
Section B - Health Status (HS) 
13. How would you rate your  own health  at  this moment. (tick  the relevant  
box with )  
Very 
Poor 
 Poor  Reasonable  Good  Very 
good 
 
 
 
14. How would you rate the quality  of your  own diet overall( excluding  the 
use of supplements). (tick  the relevant  box with ) 
Very 
Poor 
 Poor  Reasonable  Good  Very 
good 
 
 
15. How  many hours per week  in total do you estimate  you engage in  some 
form of physical activity.  
 
2 hours  4 hours  6 hours  8 hours  More than 8 hours  
 
16. Do you  exercise  in a  gym. If yes, state  the name of the gym. 
Yes  No  Name of  gym ( state)  
 
17. Do you smoke cigarettes. If yes, state how many cigarettes you smoke per 
day. 
Yes  No  How many cigarettes per day  
 
18. What best describes your  alcohol consumption over a given week. (tick  the 
relevant  box with )  
  
 
Do  not consume alcohol at all  
Two glasses (2)  
Three glasses (3)  
More than three glasses  
Only  in moderation  on special  occasions  
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19. State  which  exercise(s)  you participate in, and frequency of  participation 
over the last  three( 3)  months. 
 
Type  of  Exercise No Yes If  yes, how many 
days per week 
If  yes, how many 
minutes per day 
Bodybuilding/ 
toning (eg. weights, 
circuits) 
    
Cardiovascular 
machines/ track (eg. 
running, cycling) 
    
Cardiovascular 
classes (eg. Taibo, 
V-box, spinning) 
    
Flexibility classes 
(eg. Yoga) 
    
 
 
20.  What are your goal(s) for  doing exercise  training?  (tick  the relevant  box 
with ) 
 
 
Strongly  
Disagree 
   
Strongly 
Agree 
Muscle building and  strength  1 2 3 4 5 
To stay healthy 1 2 3 4 5 
To lose weight 1 2 3 4 5 
To stay fit 1 2 3 4 5 
To look good 1 2 3 4 5 
To impress others 1 2 3 4 5 
Other (state)……………............ 1 2 3 4 5 
 
21. List  the organised sport types you  currently participate in competitively,  
in order of priority. 
 
1 ( most important)  
2  
3  
4  
5  
 
 
Section C - Supplement Use/ Non  Use (SU/NU) 
 
Please read the  DEFINTION  of dietary  supplement  before  proceeding  
further with the questionnaire. 
 
Dietary Supplement Health and Education Act of 1994 (DSHEA) defines a dietary 
supplement as a “product (other than tobacco) intended to supplement the diet that 
bears or contains one or more of the following dietary ingredients: (a) a vitamin; 
(b) a mineral; (c) a herb or other botanical; (d) an amino acid; (e) a dietary 
substance for use by man to supplement the diet by increasing the total dietary 
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intake; or (f) a concentrate, metabolite, constituent, extract, or combination of any 
ingredient described in clause (a), (b), (c), (d), or (e)”. 
 
Please proceed with the questionnaire - Thanks 
 
 
ONLY ANSWER THIS QUESTION IF YOU DO NOT USE ANY   
SUPPLEMENTS  
 
22. Why do  you NOT use  supplements? ( tick  the relevant  boxes with ) 
 
 
Strongly  
Disagree 
   
Strongly 
Agree 
Supplements are not  necessary 1 2 3 4 5 
Supplements do not  work 1 2 3 4 5 
I do not  know  enough  about 
supplements 
1 2 3 4 5 
Supplements are too expensive 1 2 3 4 5 
Supplements use can give you 
side effects 
1 2 3 4 5 
Supplements may contain  
banned  substances 
1 2 3 4 5 
Other (state)……………............ 1 2 3 4 5 
 
If you do not  use  supplements and  answered the above question  then you 
may proceed to the end of the questionnaire. (Section  F - Question 44) 
 
If  you use  supplements , then proceed further with the remaining  questions 
and sections of the questionnaire below. 
 
23. Which phase of the season do you use supplements in general. (tick  the 
relevant  box with ) 
 
Base phase -  (Pre- Season)  
Competition Phase  
Both-  (Base Phase and Competition Phase)  
 
 
24. When do you use supplements in general. ( tick  the relevant  box with ) 
 
Only on training days  
Unrelated to training days  
Competitions days  
Daily  
 
 
 
 
 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Appendices 
 
169
169
25. Supplements Group A - Mark  which of the  listed  supplement(s)  you  
used  during  the past  6 months and state the brand name in the column 
provided. ( tick  the relevant  boxes with ) 
 
Example  Brand / Name 
Eg. vital 
Multi vitamin and mineral   
Multi vitamin with  no  minerals   
Vitamin C   
Vitamin E   
Vitamin B complex   
Β-carotene/Vitamin A   
Effervescent tablets (eg. berroca)   
Energy tonic (eg. bioplus/vita-thion   
Immune support (eg. viral guard)   
Anti-oxidants    
Zinc   
Magnesium   
Calcium   
Iron   
Selenium   
Boron   
Vanadium   
Chromium   
Procydin   
Spirulina   
Echinacea   
Herbal mix   
Astragalus   
Chorella   
Bee Pollen   
Flaxseed oil   
Pycnogenol   
Probiotics/ Prebiotics    
Essential fatty acids    
Inosine    
Other supplement(s) 
(Name) 
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26. Supplements  Group B - Mark  which of the  listed  supplement(s)  you  
used  during  the past  6 months and state the brand name of the supplement 
in column provided. ( tick  the relevant  boxes with ) 
 
Example  Brand / Name 
Eg. Fast  Fuel 
Creatine   
Hydroxymethylbutyrate (HMB)   
Glutamine   
Arginine( eg alpha nitrox)   
Pretraining (arginine, creatine, 
caffeine) 
  
Lactic buffers/ bicarbonate   
Cramp attack/ cramp stop   
VO2max/ VO2peak/Rhodiola   
Endurox/Enduraid   
Carnitine   
Ribose   
Pyruvate   
ZMA   
Testosterone Enhancers   
DHEA- Dehydroepiandrosterone   
Fat burners (eg. phedracut)   
Glucosamine   
Condroitin Sulfate   
CLA- Conjugated linoleic acids   
Ornithine   
Androstenedione   
Ginseng    
Ginko biloba   
Green tea  extract (EGCG)   
Caffeine/Guarana   
Yohimbine   
Ephedra/ Ma Huang   
Tribulus Terrestris    
Chrysin   
Indole-3 Carbinol   
Gamma oryzanol   
Simlax    
Mummio   
Saw palmetto   
Any other supplement(s) you use 
that is not listed above 
(Name) 
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27. Supplements Group C - Mark  which of the  listed  supplement(s)  you  
used  during  the past  6 months and state the brand name in the column 
provided. ( tick  the relevant  boxes with ) 
 
Example  Brand / Name 
Eg. USN muscle fuel 
Energy drinks (eg. energade)   
Corn syrup   
Energy gels (eg. GU or Vooma)   
Carboloader   
Energy bars (eg. powerbar)   
Protein bars   
Protein powder (eg. whey/soy)   
Amino acid combo   
Weight gainer (eg. mega mass)   
Meal replacement ( nutrin active)   
Recovery drink (eg. recovery max)   
Any other supplement(s) you use 
that is not listed above 
(Name) 
 
  
 
28. Indicate by rating with    which statement(s) describes your general use of 
supplements. 
 
Strongly  
Disagree 
   
Strongly 
Agree 
Obtain energy 1 2 3 4 5 
Reduces  fatique/ tiredness 1 2 3 4 5 
Improve your performance 1 2 3 4 5 
Prevent/treat illness 1 2 3 4 5 
Improve general health 1 2 3 4 5 
To build  muscle 1 2 3 4 5 
Compensate for less optimal diet 1 2 3 4 5 
To meet  unusual  nutrient  
demands induced  by  exercise 
1 2 3 4 5 
Just like the taste  1 2 3 4 5 
For rehydration 1 2 3 4 5 
Enhance recovery 1 2 3 4 5 
My  diet  does not provide  what I 
need 
1 2 3 4 5 
To decrease body fat 1 2 3 4 5 
To improve  exercise  recovery 1 2 3 4 5 
To increase energy  levels 1 2 3 4 5 
To protect my joints 1 2 3 4 5 
To prevent  muscle cramps 1 2 3 4 5 
Do  not know 1 2 3 4 5 
Other (state)……………............ 1 2 3 4 5 
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29. What  monetary  estimate do you spend and/or  are sponsored  on 
nutritional  supplements on a monthly basis. (tick  the relevant  box with ) 
 
Less 
than 
R500 
 Greater 
than 
R500  
 Greater 
than  
R1500  
 
 
 
30. How  often do you purchase and/or  sponsored  most  of  your supplements 
products. ( tick  the relevant  boxes ) 
Weekly  Monthly   Quarterly  As  
may 
be 
needed 
 At 
Promotions  
 
 
 
Section D - Perceptions, information sources and knowledge (SR) 
 
31. How would you rate your knowledge  and understanding of  supplements. 
Very 
Poor 
 Poor  Reasonable  Good  Very 
good 
 
 
32. How do you gain your  sources of information to choose the supplements 
you use, or might intend  using?  ( tick  the relevant  boxes with or ) 
 
 
Strongly  
Disagree 
   
Strongly 
Agree 
Gym  trainer 1 2 3 4 5 
Fellow athletes 1 2 3 4 5 
Supplement representative 1 2 3 4 5 
Pharmacist 1 2 3 4 5 
Dietician/ nutritionist 1 2 3 4 5 
Doctor 1 2 3 4 5 
Family 1 2 3 4 5 
Friends 1 2 3 4 5 
Magazines 1 2 3 4 5 
Television 1 2 3 4 5 
Radio 1 2 3 4 5 
Internet 1 2 3 4 5 
Other 
(state)……………............ 
1 2 3 4 5 
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33. Where and from whom do you  usually  buy/get your supplements. ( tick  
the relevant  boxes with ) 
 
 
Strongly  
Disagree 
   
Strongly 
Agree 
Grocery store 1 2 3 4 5 
Pharmacy 1 2 3 4 5 
Health food store 1 2 3 4 5 
Provided free of charge 1 2 3 4 5 
Sport shop 1 2 3 4 5 
Gym 1 2 3 4 5 
Fitness Centre 1 2 3 4 5 
Expo 1 2 3 4 5 
Home based  business  1 2 3 4 5 
Nutritionist 1 2 3 4 5 
Trainer/Coach 1 2 3 4 5 
Mail Order 1 2 3 4 5 
Internet 1 2 3 4 5 
Other 
(state)……………............ 
1 2 3 4 5 
 
34. List any  negative  experiences/ adverse effects, you believe associated with 
using  supplements you have  indicated previously. ( tick  the relevant  
boxes with ) 
 
 
Strongly  
Disagree 
   
Strongly 
Agree 
Stomach  cramps 1 2 3 4 5 
Fever 1 2 3 4 5 
Headache 1 2 3 4 5 
Dehydration 1 2 3 4 5 
Pain 1 2 3 4 5 
Nervousness 1 2 3 4 5 
Insomnia 1 2 3 4 5 
Laxative effect 1 2 3 4 5 
Increased heart rate 1 2 3 4 5 
Loss of energy 1 2 3 4 5 
Water  retention 1 2 3 4 5 
Reduced aerobic  
capacity 
1 2 3 4 5 
Diarrhoea 1 2 3 4 5 
None 1 2 3 4 5 
Other  
(state)……………. 
1 2 3 4 5 
 
35. Do you consciously seek  more knowledge  and understanding  of 
supplement  products. 
 
Yes  NO  
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36. What are your overall perceptions of the quality and consistency of all the 
supplements you use. ( tick  the relevant  box with  ) 
 
Acceptable  Sometimes  
suspicious  
 Always 
suspicious 
 
 
37. Are you comfortable in general that all the supplement  products you use  
are of good quality  and not  contaminated in any form. ( tick  the relevant  
box with ) 
 
 
Strongly  
Disagree 
   
Strongly 
Agree 
I am confident 1 2 3 4 5 
 
 
Section E - Marketing and Labelling (ML) 
 
38. How do you read the labels/information on supplements products. ( tick  the 
relevant  boxes with ) 
 
 
Strongly  
Disagree 
   Strongly 
Agree 
I look at the  name 1 2 3 4 5 
I look at the ingredients 1 2 3 4 5 
I  look  at  the directions for 
use 
1 2 3 4 5 
I look  at the warnings  for 
side effects 
1 2 3 4 5 
I look at the recommended 
dosage 
1 2 3 4 5 
I look at the nutritional 
information/ RDA 
1 2 3 4 5 
Other 
(state)……………............ 
1 2 3 4 5 
 
 
39. Do  you  usually follow the dosage instructions on the supplement container 
label. ( tick  the relevant  box with ) 
 
I normally use less than  the dose the  label  states  
I normally use  the exact  dose as the label states  
I normally use  more  than the dose  the label states  
 
40. Do you  use supplement products  that  are often on promotion relative to 
your  supplement needs. 
 
Yes  NO  
 
 
41. Do you  use supplement products that  others have referred you to use. 
 
Yes  NO  
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42. Do you  use  any of these supplement  products  that  is promoted for joint 
health and protection against ageing and overuse. ( tick  the relevant  boxes 
with ) 
 
Antioxidants  
Essential fatty acids    
Vitamins: Niacin (B3)   
Pantothenate (B5),   
Minerals- boron, calcium   
Proteolytic enzymes   
Glucosamine   
Chondroitin   
Methyl sulphonylmethane ( MSM)   
S – Adenosyl methionine (SaMe)   
Type 2 Collagen    
Hyaluronic acid   
Soy isofalvones  
None of the above  
Any other supplement  for  this  
condition. (state) 
 
 
43. What  attracts you predominantly to the su plement products you use. 
 
 
Strongly  
Disagree 
   Strongly 
Agree 
Taste  1 2 3 4 5 
Product colour  1 2 3 4 5 
The packaging  1 2 3 4 5 
Friends and family referred  1 2 3 4 5 
Labelling colour 1 2 3 4 5 
Reputable and quality  brand   1 2 3 4 5 
Good  manufacturing  practice (GMP)   1 2 3 4 5 
Sufficient/ adequate information and 
support. 
1 2 3 4 5 
 
 
Section  F - General  Comments (GC) 
44. Any further comments on supplements  you wish to provide. 
 
 
 
 
 
Thank you  for your time and contribution in  completing  this survey  
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Appendix 11 
Questionnaire Survey (Unpuplished Research) 
Nutritional supplement use and knowledge of labelling 
information  
 
 
Questionnaire  
 
 
 
 
 
 
 
 
Gary Gabriels 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
June 2012 
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Questionnaire 
 
Please complete the questionnaire as accurately (truthfully and honestly) to the 
best of your ability and write /mark legibly. 
 
Question 1 
Have you purchased a nutritional supplement in the last 12 months (mark the 
relevant  box  with X) 
YES  NO  
 
Question 2 
If you answered YES to Question 1, did the information on the container label 
influence your purchase? (mark the relevant  box  with X) 
YES  NO  
 
Question 3       
If you answered YES in Question 2, please rate each type of information on the 
nutritional supplement product container label that influenced your choice:  (tick 
the relevant  box  with X)     
  
 
Absolutely 
no influence 
on my 
choice  
   
Strong 
influence 
on my 
choice 
agree 
Brand name  1 2 3 4 5 
Ingredients 1 2 3 4 5 
Recommended dosage and directions for  use 1 2 3 4 5 
Claims  1 2 3 4 5 
Disclaimers and warnings  1 2 3 4 5 
Quality of product 1 2 3 4 5 
That the product  is free of banned substance(s) 1 2 3 4 5 
Other 
(state)...................... 
1 2 3 4 5 
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Question 4       
If you answered NO in Question 2, state what information contributed to you 
purchasing a nutritional supplement product: (tick the relevant box with X)      
 
 
Absolutely 
no 
influence 
on my 
choice  
   
Strong 
influence 
on my 
choice 
agree 
Coach, gym and/or fitness trainer, fellow athletes 1 2 3 4 5 
Supplement representative 1 2 3 4 5 
Pharmacist, Dietician, Nutritionist, Doctor 1 2 3 4 5 
Information in print media – eg. magazine, 
newspaper 
1 2 3 4 5 
Information in electronic media – eg. television, 
radio 
1 2 3 4 5 
Information in internet and social media eg. 
website, twitter, facebook  
1 2 3 4 5 
Other 
(state).............. 
1 2 3 4 5 
 
Question 5 
       
What is your age? (in years) 
   
 
    
Question 6       
 
What is your gender? (eg. male/female)       
 
Male  Female  
 
 
Question 7 
 
Do you regard yourself as: 
 
Sedentary  Moderately 
physically 
active  
 Competitive 
sportsperson 
 
 
 
 
 
 
